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Abstract Tavish Barnes 
There is increasing evidence that mammalian endoribonucleases play a significant 
role in the degradation of messenger RNA (mRNA) and are key players in the regulation 
of gene expression particularly under conditions of cellular stress. 
The main goal of this thesis was to re-purify and conclusively identify the 
mammalian hepatic-derived endoribonuclease(s) and the proteins that co-purified with 
endonucleolytic activity against c-myc CRD RNA in vitro. The first aim of this 
investigation was to purify and identify enzyme(s) responsible for endoribonucleolytic 
activity. The second aim of this study was to further characterize the endoribonuclease(s) 
and to confirm the identity of the enzyme(s) by immunodepleting native 
endoribonuclease activity. The third aim of this study was to test the recombinant 35 kDa 
endoribonuclease (APEI) for endoribonuclease activity. This study demonstrated that 
recombinant APEI does possess endoribonuclease activity and cleaves specifically at 
dinucleotide UA 1751 of c-myc CRD RNA. 
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CHAPTER 1- INTRODUCTION 
CHAPTER 1 
Introduction 
1.1 Messenger RNA Regulation and Gene Expression- An Overview 
The many complexities involved in the processes required for gene expression 
necessitates an understanding of a diverse set of cellular pathways. One such gene 
regulatory pathway is the process of mRNA (messenger RNA) degradation. Identifying 
the mechanisms and players involved in the regulation of mRNA decay has become 
paramount in our understanding of gene expression. The control of gene expression 
occurs at various levels including: transcriptional, post-transcriptional and translational 
levels. Cytosolic levels of mRNA transcripts are generally believed to be an indicator of 
gene expression levels; moreover, the longer an mRNA persists in the cytosol, the higher 
the levels of protein expression (Dodson and Shapiro 2002). The stability of different 
mRNAs within a cell can vary by orders of magnitude and thus contribute greatly to 
differential gene product levels (Parker and Song 2004). The stability of individual 
mRNAs can be regulated in response to a variety of stimuli, allowing for rapid alterations 
in gene expression (Parker and Song 2004; Wilusz and Wilusz 2004; Khodursky and 
Bernstein 2003; Brewer 2002; Guhaniyogi and Brewer 2001). 
•7 
A number of elements contribute to the stability of a given mRNA. The m G 
(methyl guanosine) cap at the 5' termini of the mRNA and the poly (A) tail at the 3' 
termini of the transcript provide the basic level of transcript stability. Specific cis 
elements also contribute to mRNA transcript stability. Stability elements of many 
mRNAs are located within the 3'-untranslated region (3'-UTR) of the transcript. It has 
become increasingly clear that higher-order structures of RNA and trans-acting proteins, 
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such as RNA-binding proteins, ribonucleases and RNA helicases are the critical 
determinants of mRNA longevity; moreover, cw-determinants, trans-acting factors, and a 
variety of secondary structural features inherent in the transcript determine the 
accessibility for cleavage by cellular exonucleases and endoribonucleases (Dodson and 
Shapiro 2002; Coburn and Mackie 1999; Mackie 1998). The following review sections 
will examine the various pathways involved in the control and processes governing 
mRNA degradation. Specific emphasis will be given to the family of endoribonuclease 
proteins that initiate mRNA degradation from within the sequence. These review 
sections will serve as a framework for the investigations within this thesis. Specifically, 
this thesis aims at identifying and exploring the properties of a novel mammalian 
endoribonuclease that possesses the ability to degrade c-myc mRNA in vitro. 
1.2 Generalized Mechanisms and Pathways of Messenger RNA Decay 
The core mRNA degradation pathways and quality control mechanisms governing 
RNA decay and processing have been well-characterized in bacteria, lower eukaryotes 
(predominantly using Saccharomyces sereviciae) and higher eukaryotes-albeit to a lesser 
extent. Core mRNA degradation events can be classified into a defined number of 
pathways. Consequently, the mRNA regulatory functions involved in gene expression 
within the cell direct the initial events of mRNA degradation into one of these defined 
pathways (see Figure 1). The major degradation pathways appear to be as follows: 
deadenylation-dependent removal of the poly (A) tail at the 3' terminus of the mRNA 
transcript followed by 3'-5' exonucleolytic decay, deadenylation-dependent removal of 
the poly (A) tail followed by decapping and 5'-3' exonucleolytic decay, deadenylation-
independent 5' decapping and 5'-3' exonucleolytic degradation, nonsense-mediated 
2 
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decay, and endoribonucleolytic degradation (Figure 1) (Parker and Song 2004; 
Guhaniyogi and Brewer 2001). In addition, there exists several decay pathways in what 
are termed mRNA-surveillance mechanisms (Garneau et al. 2007) (Figure 2). A more 
detailed account of each of these pathways will be discussed shortly. 
The enzymes that are responsible for cleavage of mRNA in vivo and in vitro can 
be classified into two broad categories; the exoribonucleases and the endoribonucleases. 
The exoribonucleases cleave between consecutive nucleotides, starting at either the 5'- or 
the 3' end of an RNA strand (Gerlt 1993). In contrast, endoribonucleases are capable of 
cleaving the internal phosphodiester bonds in an RNA strand (Gerlt 1993). 
Exoribonucleases generally do not recognize specific RNA targets but degrade any RNA 
that is single-stranded. In contrast, endoribonucleases differ greatly among each other in 
their individual substrate specificities. Furthermore, endonucleases possess diverse 
functionality in the processing of RNA. Their function ranges from the generation of 3' 
ends of mRNAs to processing tRNAs, microRNA's, small nuclear RNAs and nucleolar 
RNAs. Endoribonuclease recognition of RNA sequences displays a range of specificity 
(Dodson and Shapiro 2002). For example, RNases T2 and VI exhibit cleavage of the 
bonds between nucleotides in a single- or double-stranded configuration, respectively; 
thus exhibit little sequence specificity (Lockard and Kumar 1981). RNase 1 and RNase 
Tl exhibit some degree of sequence specificity as they cleave 3' to single-stranded 
pyrimidines and G-residues, respectively (Czaja et al. 2004; Thompson et al. 1995). In 
addition, more complex recognition determinants are required for cleavage. Bacterial 
RNase E cleaves single-stranded regions near the 5'-terminus (close to the translation 
initiation site). It specifically cleaves upstream of 5' secondary structural features of 
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target mRNA and generates fragments that can be degraded by 3'-5' exonucleases and by 
RNase E itself (Coburn and Mackie 1998). In addition, studies have shown that RNase E 
preferentially cleaves 5' to AU dinucleotides within A/U-rich regions (Coburn and 
Mackie 1998; Mackie 1998). 
a Deadenyfation-depsndant mRNA decay b Deadenylation-independerrt mRNA decay 
5' UTR ORF 3' UTR 
in'G —-^IISHJKI™ JSS..'...' !•••——MM 
c Endonutlease-riKKfated mRNA d«cay 
- M M 
Endonuetesse 
(for example, 1RE1, PMR1, 
RNase MRP) 
5'-»3' decay | 
S E Z H I AAA* 
1*1 
Exosome 'XRN1 
Figure 1: A schematic representation of the normal pathways of mRNA degradation 
in yeast (Garneau et al. 2007) 
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Figure 2: A schematic representation of the specialized surveillance mechanisms of 
mRNA degradation in yeast (Garneau et al. 2007) 
1.2.1 Messenger RNA Decay in Prokaryotes (Bacteria) 
A significant amount of research within the field of prokaryotic mRNA turnover 
has been based on studies using the simple bacteria Escherichia coli as the primary model 
organism. Initially it was believed that the processes that operated within these systems 
would be true of any organism. However, it is now abundantly clear that there are many 
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differences between the mechanistics of mRNA metabolism in prokaryotes and that of 
eukaryotic cells. Prokaryotic mRNA is accessible to the protein synthetic machinery as 
soon as it is transcribed from DNA. Since translation and transcription occur somewhat 
simultaneously, bacterial mRNA is utilized very rapidly. This process is highly efficient 
since many genes can be transcribed together in a single polycistronic mRNA, 
consequently mRNAs generally have relatively short half-lives. Bacterial RNA 
transcripts initially possess a triphosphate at the 5' end and a stem-loop structure at the 3' 
end. In E. coli, the degradation of most mRNAs is thought to begin with internal 
cleavage by RNase E, an endonuclease that cuts RNA in single-stranded regions that are 
AU-rich (Mudd et o/.1990; Babitzke and Kushner 1991; Melefors and von Gabain 1991; 
Taraseviciene et al. 1991; McDowall et al. 1994). Less frequently, mRNA decay in E. 
coli starts with cleavage by another endonuclease, such as RNase III, RNase G, or RNase 
P (Schmeissner et al. 1984; Portier et al. 1987; Umitsuki et al. 2001; Li and Altman 
2003). The transcript is no longer protected by the 3' stem-loop, and the resulting 
endonuclease-mediated cleavage products with monophosphorylated 5' termini are 
rapidly degraded by 3' exonucleases (Mackie 1998; Feng and Cohen 2000). The 
downstream endonuclease-mediated cleavage products can also undergo further 
endonucleolytic cleavage as RNase E exhibits a strong preference for 
monophosphorylated RNA substrates (Mackie 1998; Feng and Cohen 2000). 
Intriguingly, RNase E has been shown to function within a large multiprotein complex 
termed the RNA degradosome (Regonesi et al. 2006). In addition to RNase E, the 
degradosome contains the exoribonuclease polynucleotide phosphorylase (PNPase), an 
RNA helicase RhlB, and enolase that functions within the glycolytic pathway (Jain 2002; 
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Kushner 2002). A number of other endoribonucleases also participate in the mRNA 
decay processes although their involvement is believed to be considerably less important. 
These include RNase G, a known homolog of RNase E (Li and Deutscher 1994), RNase 
III which acts on double stranded RNA substrates (Li and Deutscher 1994), RNase P 
which acts predominantly on tRNA precursors but has been shown to possess the ability 
to cleave several polycistronic operon mRNAs in vitro in E. coli (Li and Deutscher 1994) 
and several bacterial toxins such as RelE, MazF, Kid and PemK (Li and Deutscher 1994; 
Zhang et al. 2004). The major endoribonucleases present in E. coli are shown in Table 1. 
5'-3' exonucleases are not thought to participate in bacterial mRNA degradation, as no 
such ribonucleases have been identified in any prokaryotic organism (Deana and Belasco 
2005). There are, however, three major 3'-5' exoribonucleases in E. coli: PNPase, RNase 
II, and oligoribonuclease as shown in Table 1, that appear to be involved in mRNA decay 
(Li and Deutscher 1994). RNase II, is a hydro lytic enzyme that removes nucleoside 
monophosphates from an RNA (Li and Deutscher 1994). PNPase is a phosphorolytic 
enzyme that utilizes inorganic phosphate to remove nucleotides from RNA ends, yielding 
nucleoside diphosphates (Carpousis et al. 1994; Blum et al. 1997). Oligoribonuclease 
functions to degrade small oligonucleotide substrates (4-7 nt) to mononucleotides and has 
been shown to be essential for cell viability (Yu and Deutscher 1995; Ghosh and 
Deutscher 1999). Additionally, the enzyme RNase R has been implicated in 
exoribonucleolytic decay of repetitive extragenic palindromic (REP) sequences in 
prokaryotic and eukaryotic systems (Cheng and Deutscher 2005; Baker and Condon 
2004; Deutscher 2003). 
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Table 1: A summary of the major mRNA degrading endo- and exo-
ribonucleases present in E. coli. (Steege 2000) 
Enzyme Gene 
Etectrophoreiic 
Monomer mobility 
size (kDa) Subunit 
(Wa) on SDS-PAGE structure Reference 
A. Endoribonucleases 
RNase E 
RNase G 
RNase 111 
me 
mg {cafAftwe) 
mc 
118 180 dimef? 
55 55 ? 
25 25 «2 dtmer 
Coburn et al„ 1989 
Dunn, 1976 
B. 3' ~> 5' Exoribonucleases 
RNase [I 
Polynucleotide phosphorytase 
Oligoribonuciease 
mb 
pnp 
orn 
72.5 72.5 monomer 
77 85 «3 trirmer 
20.7 20 «2 dtmer 
Gupta et a!., 1977 
Portier. 1975; Soreq & Uttauer, 1977 
Ghosh & Deutsciw, 1999; Zhang et ai. ,1998 
1.2.2 Messenger RNA Decay in Lower Eukaryotes 
(Saccharomyces cerevisiae) 
Much of our current knowledge of eukaryotic mRNA decay systems stems from 
research using yeast, specifically, Saccharomyces cerevisiae. In contrast to prokaryotic 
mRNA turnover, transcription in eukaryotes occurs in the nucleus and translation 
generally occurs in the cytoplasm, a circumstance that imposes spatial barriers between 
the transcription and translation processes. These barriers are further enhanced by the 
necessity of splicing intervening sequences from most eukaryotic transcripts prior to 
translation. As a result, the primary transcripts, which generally code for a single protein, 
must be processed and translocated across the nuclear membrane prior to translation and 
as such, these mRNAs have relatively long half-lives. The predominant mechanism of 
mRNA decay in yeast involves deadenylation (shortening of poly (A) tail) with the 
primary deadenylase composed of nine proteins termed CCR4-NOT or with a secondary 
deadenylase Poly(A) ribonuclease enzyme (PARN). The deadenylation process is then 
followed by decapping with Dcplp, Dcp2p and subsequent 5'-3' exoribonuclease decay of 
the transcript by the exoribonuclease Xrnlp (Parker and Song 2004). More recently, a 
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10-12 multisubunit complex of 3'-5' exoribonucleases, termed the exosome, was 
discovered and appears to be involved in the cytosolic 3'-to-5' degradation of mRNA and 
in the 3' processing of noncoding RNAs in the nucleus (Garneau et al. 2007). Following 
3'-5' exonucleolytic decay, the 5' oligonucleotide cap is hydrolyzed by the scavenger 
decapping enzyme DcpS (Parker and Song 2004; Liu et al. 2002). Several accessory 
proteins are also required for efficient decapping. After the mRNA has been 
deadenylated, a complex of Sm-like (Lsm 1-7) proteins associates with the 3' end of the 
mRNA (Tharun et al. 2000; Tharun and Parker 2001). Other proteins, namely Lsm 16 
(also termed enhancer of decapping-3 or EDC3), Lsm 14, Poly(A) binding protein-1 
(Pbpl), Patl, and the DExD/H-box RNA helicase Dhhl are known to help mediate the 
decapping process (Garneau et al. 2007; Coller et al. 2001; Bonnerot et al. 2000). The 
deadenylation-dependent and deadenylation independent mRNA decay pathways are 
summarized in Figure 1 (a and b). Endoribonucleolytic decay represents an additional 
method of mRNA degradation (see Figure 1-c) 
There are several other specialized 'surveillance' mRNA degradation pathways in 
yeast. A summary of these pathways is shown in Figure 2 (a,b and c). The first such 
pathway termed nonsense-mediated decay (NMD) is activated by the presence of a 
premature stop codon (nonsense termination codon) within an otherwise normal open 
reading frame. The premature stop codons can be created through mutation, frame-shifts, 
incomplete translation initiation and incorrect 3' UTRs (Garneau et al. 2007). Once 
detected, these incorrect transcripts are degraded by several pathways; however, much 
remains to be discovered about these pathways. The next surveillance type pathway is 
termed nonstop decay (NSD). mRNAs that do not possess translation termination codons 
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results in the ribosome proceeding onto the poly(A) tail, thereby displacing the poly(A)-
binding protein and stalling at the 3' end of the transcript (Garneau et al. 2007). As 
shown in Figure 2 (b), there are two proposed pathways for decay of such mRNAs. The 
first pathway which is conserved in yeast and mammalian cells degrades mRNAs 3'-5' 
with the cytoplasmic exosome (van Hoofed al. 2002, Frischmeyer et al. 2002; Garneau et 
al. 2007) and the second pathway, found solely in yeast, utilizes a 5'-3' decay mechanism 
(Garneau et al. 2007). The third mRNA surveillance decay pathway is no-go decay 
(NGD). As outlined in Figure 2 (c), this pathway is initiated as a result of ribosomal 
stalling and is believed to be triggered by the associated translation initiation complex 
(Doma and Parker 2006). The mRNA is subsequently endonucleolytically cleaved near 
the stall site. The mRNA fragments are released and subsequently degraded by the 
exosome and by Xrnl (Doma and Parker 2006). 
1.2.3 Messenger RNA Decay in Higher Eukaryotes (Mammalian Cells) 
By and large, homologous degradation pathways and enzymes are present in 
lower eukaryotes (yeast) and in higher eukaryotes (Tucker and Parker, 2000). 
Deadenylation followed by 3'-5' exonucleolytic degradation catalyzed by a putative 
complex of exonucleases (exosome) and 5' decapping followed by 5'-3' exonucleolytic 
degradation are relatively well established mRNA degradative pathways in mammalian 
cells. In support of the exosome-mediated degradation pathway, the mammalian 
exosome has been purified and its composition is very similar to its yeast counterpart 
(Mukherjee et al. 2002). Also, the recent discovery of a mammalian homolog to yeast 
decapping enzymes (Lykke-Andersen 2002) and the 5'-3' exonuclease Xrnl (Bashkirov 
1997) suggests that decapping followed by 5'-3' degradation are evolutionarily conserved 
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mechanisms. In addition, there are other known specialized degradation pathways 
similar to their yeast counterparts including: nonsense mediated decay (NMD) nonstop 
decay (NSD), no-go decay (NGD) and endonucleolytic cleavage. While many of the 
endonucleolytic decay pathways remain poorly characterized, there has been substantial 
in vivo evidence of decay products for specific mRNA transcripts. 
1.3 RNA-Binding Proteins 
In order to fully understand the interactions between RNA and RNA-binding 
proteins, one must be somewhat familiar with the basic structural features inherent in 
RNA-binding proteins. The specific interaction of a protein with RNA occurs through 
various peptide motifs in the protein, termed RNA-binding domains. Often these are 
structural features of the folded protein. The binding domains enable the protein to 
recognize and bind to target areas in an RNA molecule. Often, RNA-binding proteins 
contain multiple copies of these domains. Furthermore, RNA binding can be determined 
via cooperative interaction of two or more domains (Perez-Canadillas and Varani 2001; 
Deo et al. 1999). The multiple interactions of repeat domains within an RNA-binding 
protein or the interaction with various types of domains in other RNA-binding proteins 
permits great diversity in RNA molecule recognition. Ultimately, this translates into a 
greater variety of biological function (Maris et al. 2005; Siomi et al. 1997). 
There are three general categories of eukaryotic RNA-binding protein domains. 
The most extensively characterized single stranded RNA-binding domain is the 
ribonucleoprotein (RNP) motif, also referred to as RNA-binding domain (RBD) or RNA 
recognition motif (RRM) (Perez-Canadillas and Varani 2001; Maris et al. 2005; Siomi et 
al. 1997). RRM's are frequently found in proteins that function in post-transcriptional 
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regulation of RNA (Maris et al. 2005; Siomi et al. 1997). The second domain termed 
hnRNP K homology domain or K-homology domain (KH) is one of the most commonly 
identified motifs found in RNA-binding proteins. KH domains have been associated with 
a wide variety of cellular functions including nuclear localization (Nielsen et al. 1999), 
nuclear export (Nielsen et al. 1999) and post-transcriptional mechanisms governing 
mRNA stability (Ioannidis et al. 2004). The third major RNA-binding domain found in 
eukaryotic cells is the double stranded RNA-binding domain (dsRBD). The dsRBD 
functions in binding to double stranded regions of structured RNA molecules (Chang et 
al. 2005; Chen 2005). The dsRBD motif is found in both eurkaryotic and prokaryotic 
systems, and has been implicated in a variety of RNA metabolic processes including 
RNA localization (Chang et al. 2005; Chen 2005; Siomi 1997). 
In addition to the motifs found within RNA binding proteins, specific secondary 
structural conformations can be adopted by single stranded RNA. These conformations 
are often required for protein recognition and include regions of base-pairing (Watson-
Crick) interspersed among regions that form single stranded loops (hairpin and internal), 
bulges and helical junctions (Chen and Varani 2005). It should be noted, however, that 
the study of protein-RNA binding in vitro as a model for mechanisms in vivo is difficult 
and is complicated by the secondary structures adopted by single-stranded RNA in vivo 
and by the structural alteration as a result of the binding of additional proteins or ligands 
in vivo (Perez-Canadillas and Varani 2001; Chen and Varani 2005). 
In summary, our knowledge of the fundamental mechanisms and basic principles 
involved in protein-RNA interaction provide the underlying foundation for many areas of 
study within the field of RNA metabolism including the field of mRNA decay. 
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1.3.1 mRNA Stability and RNA-Binding Proteins 
The 3' UTR of mRNA transcripts has a major role in controlling their stability 
(Guhaniyogi and Brewer, 2001). Several proteins that bind the 3' UTR of mRNA's in 
vivo such as AUF 1 (Brewer 1991), Aldolases A and C (Canete-Soler et al. 2005) and 
HADHB (Adams et al. 2003) are known to function as mRNA-destabilizing factors. In 
addition, there are numerous 3' UTR mRNA-binding proteins such as GAPDH (Nagy and 
Rigby 1995), HuD, HuC (Levine et al. 1993), HuR (Ma et al. 1996; Levy et al. 1998), 
aCP (Wilson and Brewer 1999; Kiledjian et al. 1997), IRE-BP (Rouault and Klausner, 
1997), and vigilin (Cunningham et al. 2000; Kruse et al. 2003). These proteins are 
proposed to specifically bind AU-rich elements (AREs) within the 3' UTR of specific 
mRNAs and prevent ARE-mediated decay (Park-Lee et al. 2003). 
The interaction between RNA-binding proteins and the 5' UTR of select mRNAs 
has been shown to influence their stability in vivo. Examples include: nucleolin and YB-
1 proteins which bind to and stabilize the JNK-response element (JRE) in the 5' UTR of 
IL-2 mRNA (Chen et al. 2000) and the IL-la protein which binds to the 5' UTR and 
stabilizes KC mRNA (Tebo et al. 2000). 
In addition to 3' UTR- and 5' UTR-binding proteins, there are proteins which bind 
to the coding regions or instability (decay) elements of several mRNAs. A complex of 
proteins including AUF1, NSAP1, PABP, Unr and hnRNP-R bind to and function to 
destabilize c-fos mRNA (Schiavi et al. 1994; Chen et al. 1992). The coding region of c-
myc mRNA, which will be the focus of this thesis, is bound by a protein termed CRD-BP 
(Prokipcak et al. 1994). The binding of CRD-BP is hypothesized to stabilize c-myc 
mRNA by protecting it from cleavage by cellular ribonucleases (Prokipcak et al. 1994). 
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In fact, this hypothesis has been directly demonstrated and confirmed in vitro (Sparanese 
and Lee, 2007). 
1.4 The c-myc Proto-Oncogene 
Rapid advances in understanding of cellular genetics have enabled a greater depth 
of understanding into the mechanisms that govern cancer cell biology. Proto-oncogene 
refers to a sequence of DNA that has been altered or mutated from its original form. 
Generally, they code for proteins that are involved in normal cellular growth and 
proliferation. Consequently, they promote specialization and division of normal cells. A 
change in their genetic sequence can result in uncontrolled cell growth, ultimately 
causing the formation of a cancerous tumor (Varmus 1984). 
In humans, proto-oncogenes can be transformed into oncogenes in three ways: 
point mutation (alteration of a single nucleotide base pair), translocation (in which a 
segment of the chromosome breaks off and attaches to another chromosome), or 
amplification (increase in the number of copies of the proto-oncogene). Oncogenes were 
first discovered in certain retroviruses and were later identified as cancer-causing agents 
in many animals (Varmus 1984). The myc gene was first discovered in Burkitt's 
lymphoma patients whom exhibit chromosomal translocations; most often involving VIII. 
Subsequent cloning of the break point of the fusion chromosomes revealed a gene that 
was similar to avian myelocytomatosis viral oncogene (v-myc). Thus, the newly 
discovered cellular gene was named c-myc (Varmus 1984). It is roughly estimated that 
the c-myc proto-oncogene influences the expression of at least 10% of all human genes 
(Levens 2003). The c-Myc protein or the c-myc gene is overexpressed in a wide variety 
of human cancers with 80% of breast cancers, 70% of colon cancer, 90% of 
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gynecological cancers, 50% of hepatocellular carcinomas and a variety of hematological 
tumors possessing abnormal myc expression. On the basis of these frequencies, it is 
estimated that approximately 100,000 US cancer deaths per year are associated with 
changes in the c-myc gene or its expression (Gardner et al. 1998). Given that alterations 
in the expression of the c-myc gene may contribute to one-seventh of U.S. cancer deaths, 
it continues to be a target for the development of specific anti-cancer therapies. 
1.4.1 The Functional Importance of the c-myc Gene in Mammalian 
Cells 
The c-myc gene codes for the protein c-Myc that functions as a transcription 
factor by heterodimerizing with a partner protein, termed Max, to regulate gene 
expression. Thus it acts as a regulator of cell proliferation, differentiation and apoptosis 
(Levens 2003). In fact, c-myc is expressed in almost all proliferating normal cells, and its 
repression is required for terminal differentiation of many cell types (Levens 2003). 
Deregulated expression of c-myc prevents differentiation of many cell types, can induce 
apoptosis, can induce genomic instability, and is associated with many tumor phenotypes 
(Felsher and Bishop 1999a). Mutations, amplification, chromosomal rearrangements, 
and translocation of this gene in addition to mRNA stabilization have been associated 
with a variety of hematopoietic tumors, leukemias and lymphomas, including Burkitt 
lymphoma (Hermeking 2003). Regardless of the mechanism by which the c-myc gene is 
activated, the final outcome is the overexpression of c-myc mRNA and the associated 
higher level of c-Myc protein. 
The ultimate function of the c-Myc protein is largely influenced by its interaction 
with numerous networks of proteins (Atchley and Fernandes 2005). A variety of cellular 
responses are generated by the expression and suppression of different overlapping 
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subsets of target genes (Hoffman et al. 2002). Moreover, the final cellular response to c-
Myc is most probably situation-specific and is dictated by the expression of numerous 
other genes including oncogenes and tumor suppressor genes (Hoffman et al. 2002). 
Although the c-Myc protein is responsible for the activation of several growth-promoting 
genes in a variety of cancers, the precise mechanisms by which these transformations 
occur remain somewhat unclear (Levens 2003). 
1.5 c-myc, mRNA-Binding Proteins and mRNA-Degrading Enzymes 
The complexity of mRNA metabolism from post-transcriptional maturation to 
degradation of messenger RNA (mRNA), requires specific RNA-protein interactions. In 
addition, these RNA-protein interactions must occur with a high level of specificity to 
ensure the correct control and sequence of events leading to the decay or the stabilization 
of the mRNA transcript. In light of these critical interactions, considerable research has 
focused on the proteins and associated factors that bind or interact with the instability 
elements present in mRNA transcripts. The following sections will address the 
interactions between RNA-binding proteins, RNA-degrading enzymes and the c-myc 
mRNA transcript. 
1.5.1 c-myc mRNA Stability and Degradation 
c-myc gene expression is regulated at many levels including: transcriptional 
initiation (Brewer 2003; Lee et al. 2003), translational elongation (Lemm and Ross 2002) 
and post-transcriptional processes (Yeilding et al. 1996). Furthermore, there is 
widespread evidence that mRNA stability plays a critical role in the regulation of c-myc 
gene expression (Brawerman 1987; Ross 1995). The stability of c-myc mRNA, like 
many other mRNAs is believed to be a result of several factors including the presence of 
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as-acting adenosine and uridine (AU)-rich instability elements (AREs) inherent in the 3' 
untranslated regions (3'UTRs) of the RNA sequence, ^rarcs-acting regulatory factors such 
as RNA-binding proteins, and the presence of exo- and endo-ribonucleases that function 
to degrade the mRNA transcripts (Ross 1995). 
The half-life of c-myc mRNA is also controlled by multiple instability elements 
located within both the 249-nucleotide coding region instability determinant known as 
the coding region determinant (CRD) and the 3' untranslated region (3' -UTR) (Bremer et 
al. 2003; Doyle et al. 2000; Brewer 1999) as shown in Figure 3. Highly unstable 
transcripts such as c-myc generally contain one to three AUUUA elements spaced 
throughout the 3'-UTR (Jones et al. 1987; Langa et al. 2001; Brewer 2003). In addition, 
ARE's are often targeted and bound by proteins that trigger the removal of the poly(A) 
tail and the 5' cap structure. Consequently, the mRNA transcripts become susceptible to 
exonucleolytic degradation (Park et al. 2000; Brewer 2003). 
In vitro and in vivo evidence has shown that the CRD region of the c-myc mRNA 
transcript plays a fundamental role in destabilizing c-myc mRNA during translation 
(Lemm and Ross 2002). Evidence from these studies suggests that pausing of the 
ribosome during translation due to the presence of rare codons in a region upstream of the 
CRD results in rapid decay of the c-myc transcript (Lemm and Ross 2002). Interestingly, 
in vivo experiments have shown that removing the 3'- or 5'-UTR of c-myc mRNA has 
little effect on stability thus lending further support for the notion that the CRD plays an 
important role in regulating c-myc stability (Bonnieu et al. 1988; Laird-Offringa et al. 
1991). Furthermore, the sequence spanning the CRD has been shown to be an essential 
regulator of mRNA stability in vivo. Firstly, when the CRD region of c-myc was inserted 
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into the coding region of the stable globin mRNA, it became rapidly destabilized (Ross 
and Herrick 1994). Secondly, several studies have shown that the CRD was required to 
post-transcriptionally down-regulate c-myc mRNA during differentiation of C2 myoblasts 
(Kren et al. 1996). Thirdly, cell-free mRNA decay experiments using polysome extracts 
and a 180nt RNA sense strand for c-myc CRD was sufficient to induce endonucleolytic 
cleavage within the CRD region and an 8-fold increase in c-myc mRNA destabilization 
(Berstein et al. 1992). In addition, this increase in c-myc mRNA destabilization was 
highly specific as experiments using competitor RNA corresponding to other areas of c-
myc mRNA did not result in transcript destabilization (Berstein et al. 1992). 
c-MYC 5'-CRD PROBE FOR ASSAYING THE SOLUBLE 
LIVER ENDONUCLEASE 
j-,. „™ Coding Region 
'
 :
 ^ | 2-JE1. ivvggn 3'-UTR 
c*m>-r atRKA y^ CRD 
Fell-lragth c-myc Coding Region 
Figure 3: Human c-myc mRNA with 3'-, 5'-UTRs and the full length CRD 
(nts 1705-1886) regions highlighted (Lee et al. 1998) 
Endoribonuclease-mediated decay in vivo (Hanson and Schoenberg 2001) and in 
vitro (Wennborg et al. 1995; Tourriere et al. 2001; Tourriere et al. 2003; Lee et al. 1998; 
Bergstrom et al. 2006) of c-myc mRNA has also been shown to occur in a stem-loop 
structure within nucleotides 1705-1790 of the CRD region (Lemm and Ross 2002). 
Therefore, c-myc mRNA degradation can occur in vivo via two pathways: deadenylation 
followed by 3'-5' exonucleolytic decay starting in the AU-rich region of the 3' UTR 
(Brewer 1999; Doyle et al. 2000; Bremer et al. 2003) or endonucleolytically within the 
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CRD at the carboxyl terminal end of the coding region shown in Figure 3 (Hanson and 
Schoenberg 2001; Wennborg et al. 1995; Tourriere et al. 2001; Tourriere et al. 2003; Lee 
et al. 1998; Bergstrom et al. 2006). 
1.5.2 c-myc mRNA and the Coding Region Determinant Binding 
Protein (CRD-BP) 
The CRD region of the c-myc mRNA transcript is the target of a 68-kDa RNA-
binding protein known as the coding region determinant binding protein (CRD-BP). 
CRD-BP contains two RNA recognition motifs and four hnRNP K homology domains 
(Lemm and Ross 2002). The proposed model functions such that under normal cellular 
conditions when CRD-BP is bound to c-myc mRNA, the CRD of the mRNA is shielded 
from endonucleolytic attack (Bernstein et al. 1992; Doyle et al. 1998; Prokipcak et 
al. 1994). In this case, the mRNA transcript is degraded only by an ARE-dependent 
deadenylation pathway (Brewer and Ross 1988). When the CRD-BP dissociates from the 
c-myc mRNA, the CRD is believed to be exposed and susceptible to endonucleolytic 
attack (Bernstein et al. 1992). The transcript is then rapidly degraded by endonucleolytic 
cleavage within this CRD region. Additionally, direct in vitro evidence in support of this 
shielding hypothesis has recently been demonstrated (Sparanese and Lee, 2007). 
Several in vivo observations support the hypothesis that CRD-BP binds to and 
protects c-myc mRNA. Firstly, the overexpression of CRD-BP in colorectal cancer is 
associated with a slight elevation in c-myc mRNA levels (Ross et al. 2001). Secondly, a 
decrease in c-myc mRNA levels were observed in MCF-7 cells (Ioannidis et al. 2005) 
and colorectal cells (Noubissis et al. 2006) following downregulation of CRD-BP. 
Finally, the addition of sense RNA corresponding to c-myc CRD in cells was shown to 
result in an increased decay of c-myc mRNA (Coulis et al. 2000). In contrast to the 
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aforementioned supporting evidence for the CRD-BP-c-myc CRD shielding hypothesis, 
two recent studies do not support this hypothesis. For example, transgenic mice over 
expressing CRD-BP in mammary tissue, did not exhibit elevated levels of c-myc mRNA 
(Tessier et al. 2004). In addition, knockdown of CRD-BP in a K562 cell line, had no 
effect on levels of c-myc mRNA (Liao et al. 2004). 
1.6 Mammalian Endoribonucleases 
Many of the mRNA-degrading pathways characterized to date in mammalian cells 
involve cellular exoribonucleases; however, there is substantial evidence for the 
functional involvement of endoribonucleases within mammalian mRNA degradation 
pathways; the CRD region of c-myc mRNA is a prime example (Bernstein et al. 1992; 
Doyle et al. 1998; Prokipcak et a/.1994). Several of the known mammalian proteins that 
possess endoribonucleolytic function are shown in Table 2. In vivo evidence of mRNA 
decay products has been documented for several transcripts such as: transferrin receptor 
(Cairo et al. 1994), insulin-like growth factor-II (van Dijk et al. 2000), avian apo-very 
low density lipoprotein II (Binder et al. 1989), Xenopus Xlhbox2B mRNA, Xenopus p-
globin (Bremer et al. 2003), albumin (Cunningham et al. 2000), c-myc (Lee et al. 1998; 
Bergstrom et al. 2006), vitellogenin (Cunningham et al. 2000), hepatitis B virus (Hou et 
al. 2005), and a-globin (Liu and Kiledjian 2000), cytokine groct (Stoeckle 1992), and 
several maternal homeodomain proteins (Brown and Harland 1990; Brown et al. 1993). 
Although most proteins with endoribonucleolytic properties exibit some degree of 
substrate specificity, few of the endoribonucleases characterized in mRNA decay 
pathways have been shown to target specific transcripts in vivo (Dodson and Shapiro 
2002). One of the major challenges remains identifying and assessing the significance of 
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Table 2: A summary of mammalian endoribonucleases that have been characterized 
Mammalian 
Endoribonucleases 
PMR-1 
ErEN 
ARD-l/NIPP-1 
RNase L 
IRE-1 
RasGAP-associated 
G3BP 
Aldolase A, 
Aldolase C 
Argonaute 2 
Dicer 
RNase A Family 
*pt RNase 1 
**nptRNase2 
Eosinophil-Derived 
Neurotoxin (EDN) 
npt RNase 3 
Eosinophil Cationic 
Protein (ECP) 
pt/npt RNase 4 
Angiogenin/RNase 5 
npt RNase 6 
npt RNase 7 and 8 
Size 
60kDa 
40kDa (denaturing 
conditions) 
ARD-1: 13.3kDa 
NIPP-l:38.5kDa 
741 kDa 
110 kDa 
52 kDa 
- 4 0 kDa 
130 kDa 
218 kDa 
-13 kDa 
***12-17kDa 
***12-17kDa 
***12-17kDa 
***12-17kDa 
***12-17kDa 
***12-17kDa 
Cellular 
Location of 
Action 
RNP complex, 
sequestered to 
polysomes 
Non-Polysomal, 
Precise location 
unknown 
Polysomes 
Cytoplasm/ER 
ER membrane 
Cytoplasm 
Neuronal RNP 
complex 
RISC complex 
RISC complex 
Extracellular 
Eosinophils, 
spleen, liver, 
placenta, and 
kidney tissues 
urine 
Granulocytes 
Exibits 
neurotoxicity 
Pancreas, liver, 
lung, skeletal 
muscle, heart, 
kidney tissues 
Human plasma 
Primarily lung 
tissue 
Primarily liver 
Activation 
Signal 
Estrogen 
ATP-dependent, 
Deadenylation 
ofmRNA 
transcript 
-
INF, 2-5A 
Unfolded/ 
proteins in ER 
lumen 
Phosphorylation 
-Dependent 
Unidentified 
Unidentified 
ds RNAs in 
RNAi pathway 
miRNAs 
unknown 
unknown 
unknown 
unknown 
unknown 
unknown 
unknown 
Cleavage 
Specificity 
ssUG 
dinucleotides 
ss AYUGA 
(Y= C or U) 
dinucleotides 
63-64-CU in 
CU- rich 
regions 
ss AREs 
ss UA and UU 
dinucleotides 
ss GC, GA, 
UG, AC, CU 
dinucleotides 
ssCA 
dinucleotides 
UG 
dinucleotides 
3' UTR AREs 
None 
ss UA, CA, CC, 
UG; preference 
for poly(C) over 
poly(U) 
Preference for 
poly (U) over 
poly(C) 
Preference for 
poly (U) over 
poly (C) 
Predominantly 
poly(U) 
Weak activity 
against ss UA, 
CA, 
unknown 
unknown 
Reference 
Cunningham etal. 2001a; 
Stevens et al. 2002; Bremer 
et al. 2003; Chernokalskaya 
etal. 1998 
Wang and Kiledjian 2000a; 
Wang and Kiledjian 2000b 
Claverie-Martin et al. 1997; 
Change^/. 1999 
Zhou etal. 1993; 
Mishra2001 
Tirasophon et al. 2000; 
Lee et al. 2002; 
Hollien and Weissman 2006 
Tourriere et al. 2001; 
Barnes et al. 2002; 
Gallouzie^a/. 1998 
Canete-Soler et al. 2005 
Hammond et al. 2001; 
Liu et al. 2004 
Fortin et al. 2002; Nicholson 
and Nicholson 2002; Doi et 
al. 2003; Zhang et al. 2004a 
Barnard 1969; Sorrentino 
and Libonati 1994 
Sorrentino 1998 
Barker etal. 1989; 
Sorrentino etal. 1992 
Hofsteenge et al. 1998 
Shapiro etal. 1986; 
Saxena etal. 1992 
Riordan 1997 
Rosenberg and Dyer 1996 
Zhang et al. 2003 
* pt refers to pancreatic-type, with homology to bovine pancreatic RNase 
** npt refers to nonpancreatic-type 
***unglycosylated state 
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these enzymes within the context of normal cell function. With these challenges in mind, 
the following sections endeavor to explore the features of known mammalian 
endoribonucleases. In addition, the structural and functional similarities and the cellular 
distribution of bi- or multi-functional proteins that possess documented 
endoribonucleolytic activity will be highlighted. 
1.6.1 The Diversity of Mammalian Endoribonuclease Proteins and their 
Role in RNA Processing 
Research continues to uncover and highlight the importance of endoribonuclease-
mediated mRNA decay pathways. Endonucleolytic RNA cleavage pathways 
characterized to date have largely been represented as site-specific mechanisms for fine 
tuning levels of specific mRNA transcripts, under specialized cellular conditions of stress 
(Dodson and Shapiro 2002). Perhaps the most striking feature of recent studies is the 
diversity of proteins responsible for RNA degradation and their site-specific distribution 
within the mammalian cell. In fact endoribonucleases are present in a wide range of 
locals within the cell, including the nucleolus, nucleus, cytosol, endoplasmic reticulum, 
polysomes, and specialized foci such as stress granules and processing bodies (Dodson 
and Shapiro 2002; Yang and Schoenberg 2004; Tourriere et ah 2001). In addition, there 
are secreted extracellular members and non-secretory cytoplasmic members of the RNase 
A superfamily; however, the extent to which this group of endoribonucleases functions in 
mRNA remains uncertain. Current belief is that the primary mechanistic regulation of 
endoribonuclease enzymes occurs by one of two methods; regulating the access to 
mRNA transcripts with trans-acting RNA-binding proteins such as CRD-BP and by the 
sequence specificity of the endoribonuclease itself (Dodson and Shapiro 2002). In 
contrast to decapping and exonuclease degradation where the mRNA is no longer 
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engaged by translating ribosomes, endonuclease-mediated mRNA degradation requires 
that either the endonuclease proteins that promote cleavage be targeted to the site of 
function or that the endonuclease proteins reside in the location of function (ie. within an 
mRNP complex) (Dodson and Shapiro 2002; Yang and Schoenberg 2004; Hollien and 
Weissman 2006). 
1.6.2 Mammalian Endoribonucleases that function in mRNA Decay in 
vitro and in vivo 
n PMR-l 
Polysomal ribonuclease 1 (PMR 1) is a well-characterized endoribonuclease 
belonging to the peroxidase gene family, that is capable of initiating the destabilization of 
albumin mRNA (Bremer et al. 2003; Yang et al. 2004; Yang and Schoenberg 2004). In 
addition, estrogen stimulation in Xenopus hepatocytes activates a pathway in which 
PMR1 functions to destabilize certain serum protein mRNAs via endonucleolytic 
cleavage (Chernokalskaya et al. 1998; Cunningham et al. 2001a; Stevens et al. 2002; 
Yang and Schoenberg 2004). There is, however, some uncertainty as to whether PMR1 
is latent in ribonuclear protein (RNP) complexes associated with polysomes or recruited 
to an appropriate RNP complex bound to the polysome. Recent evidence suggests the 
latter as PMR1 is uniformly distributed throughout the cytoplasm, on polysomes and does 
not co-localize in cytoplasmic processing bodies with proteins such as human Dcpl 
(Yang and Schoenberg 2004). Additionally, it has been shown that PMR 1 requires 
phosphorylation-dependent activation which may be required for targeting PMR 1 to 
polysomes (Peng and Schoenberg 2007). In the 'recruitment' model of PMR 1 
activation, the binding of one or more specific proteins to a substrate mRNA (e.g., 
albumin) generates a platform for the binding of PMR1 to the larger complex of proteins 
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present on the actively- translating RNP complex (Chernokalskaya et al, 1997). PMR 1 
can then gain access to the mRNA substrate. Studies have revealed that vitellogenin 
mRNA is selectively stabilized relative to albumin mRNA (Cunningham et al. 2001a). 
The mechanism by which this occurs is believed to involve binding of the protein vigilin 
in the 3'UTR binding site of vitellogenin mRNA (Cunningham et al. 2000). When the 
vigilin protein is bound, cleavage of vitellogenin mRNA is effectively blocked from 
PMR 1 (Cunningham et al. 2000). In the absence of vigilin, PMR 1 cleaves vitellogenin 
mRNA within the 3'UTR region in vivo and in vitro (Cunningham et al. 2000). Evidence 
has shown that the 3'UTR of vitellogenin mRNA binds the vigilin protein with a -30 fold 
higher affinity as compared to albumin mRNA containing known PMR 1 recognition 
sequences (Cunningham et al. 2000). 
Specific domains of PMR1 in both the C-terminal and N-terminal domains are 
necessary for targeting to polysomes and a loss of the targeting domains has been shown 
to result in stabilization of several mRNAs (Yang and Schoenberg 2004). Additionally, it 
has been suggested that PMR 1 may function in the NMD pathway. Nonsense-containing 
P-globin mRNA exhibits endonuclease-mediated decay in erythroid cells in vivo and the 
cleavage products are similar to those generated by PMR1 in vitro (Bremer et al., 2003; 
Stevens et al., 2002). In vitro studies have also shown that PMR 1 generates cleavage 
products with free 3' ends; ideal substrates for subsequent degradation by the exosome 
(Chernokalskaya et al, 1997). 
PMR 1 may also be implicated in signal transduction mechanisms in response to 
extracellular stimuli (Chernokalskaya et al. 1998; Peng and Schoenberg 2007). In support 
of this notion, increasing estrogen levels have not been sufficient to directly stimulate 
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PMR1 activity, consequently, researchers have hypothesized that a signal transduction 
mechanism is required from the estrogen receptor to activate PMR1 present in an mRNP 
complex (Chernokalskaya et al. 1998). Recently, it has been shown that phosphorylation 
of a tyrosine residue at position 650 in the C-terminal portion of the protein by the 
tyrosine kinase c-Src activates the endonuclease activity of PMR 1 and is required for 
efficient targeting of PMR 1 to polysomes (Peng and Schoenberg 2007). A summary of 
RNA cleavage specificities, cellular location and properties of PMR 1 are shown in Table 
2. 
ii) RNase L 
RNase L is a 740 kDa endoribonuclease that has been shown to target and 
endonucleolytically cleave single stranded mRNA, rRNA and viral RNAs (Silverman 
2003) and is believed to play a role in interferon-inducible antiviral defense (Li et al. 
2000). RNase L catalytic activity necessitates activation. When there is no activating 
stimulus present, the RNase L protein exists in a latent, catalytically inactive monomeric 
form and is bound by an inhibitory protein (RLI) (Bisbal et al. 1995). However, upon 
binding 5'-triphosphorylated-2'-5'-A synthetase molecules, the protein forms a dimerized 
structure that activates the cytosolic endoribonucleolytic domain (Zhou et al. 1993). In 
mammalian cells, activation of the RNase L protein leads to cell death via an apoptotic 
pathway (Pandey and Rath 2004). A summary of RNA cleavage specificities, cellular 
location and properties of RNase L are shown in Table 2. 
iift IRE-1 
In a somewhat analogous oligomerization-based mechanism, similar to the type I 
growth factor receptors that require dimerization/oligomerization for activation, the 
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endoplasmic reticulum located Inositol-Requiring type 1 transmembrane protein (IRE 1) 
requires activation of its respective kinase and endoribonuclease domains for RNase 
activity (Niwa et al. 1999, Tirasophon et al. 2000; Lemmon and Schlessinger 1994; 
Wrana et al. 1994). IRE 1 possesses a lumenal stress sensor domain, a hydrophobic 
transmembrane anchor sequence, and cytosolic kinase/endoribonuclease domain. IRE-1 
was initially discovered in yeast (S. cerevisiae) in a stress-induced pathway termed the 
unfolded protein response (UPR). The UPR is responsible for transmitting information 
about the status of protein folding in the lumenal portion of the ER to the cytoplasm and 
nucleus (Dong et al. 2001: Yin-Liu and Kaufman 2003). In mammalian cells, IRE 1 
induces the synthesis of chaperone proteins that assist in the refolding and assembly of 
misfolded proteins within the ER (Pillai 2005). Misfolded proteins can result from a 
number of different causes of ER stress including: viral infection, heat shock, and nutrient 
deprivation (Kaufman 2002; Sitia and Braakman 2003). 
The mechanism of activation of IRE 1 in mammalian cells is hypothesized to 
occur such that the ER lumenal sensory domains, normally bound by the ER chaperone 
Bip, are released from Bip when misfolded proteins are present. This promotes 
dissociation of Bip from IRE 1 and allows Bip to associate with misfolded proteins. The 
release of Bip results in the oligomerization and activation of the IRE 1 kinase and 
endoribonuclease domains (Yin-Liu and Kaufman 2003; Shamu and Walter 1996; Pillai 
2005). The activation of the endoribonucleolytic domain of IRE 1 is believed to promote 
splicing and activation of the XBP1 gene (Yin-Liu and Kaufman 2003; Shamu and 
Walter 1996; Pillai 2005). In support of this theory in vertebrate cells, IRE 1 lies 
upstream of X-box-binding protein 1 (XBP1 mRNA), the vertebrate homolog of HAC1 
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mRNA in yeast. Studies suggest that XBP1 orchestrates the transcriptional activation of 
target genes that include ER chaperones and enzymes that facilitate this mechanism of 
protein folding (Yin-Liu and Kaufman 2003; Shamu and Walter 1996; Pillai 2005). 
Research has added additional insight into the critical role of IRE 1 in localized 
mRNA processing events. Based on studies utilizing S2 cells from Drosophila, novel 
IRE 1-targeted mRNA substrates have been discovered (Hollien and Weissman 2006). 
The substrate mRNAs appear to be specifically targeted based on their localization to the 
ER membrane and on the secondary structure of the mRNA itself (Hollien and Weissman 
2006). It is still not yet known whether IRE 1 mediates all of the observed 
endonucleolytic cleavages and it has been proposed that a second ribonuclease by itself 
or in combination with IRE 1 may be responsible for some of these observed mRNA 
decay events. 
iv) RasGAP-Associated G3BP 
RasGAP-associated G3BP is a 52 kDa single strand-specific endoribonuclease 
exhibiting no sequence homology with other known mammalian endoribonucleases. 
G3BP was initially characterized with the ability to cleave within the 3'UTR of c-myc 
mRNA in vitro (Barnes et al. 2002; Guitard et al. 2001; Tourriere et al. 2001). 
Interestingly, it has been shown in vitro that G3BP requires phosphorylation-dependent 
activation for endonucleolytic function (Gallouzi et al. 1998; Tourriere et al. 2001; Irvine 
et al. 2004; Zekri et al. 2005). Gene knockout animal model studies involving G3BP 
have resulted in both embryonic lethality and growth retardation (Zekri et al. 2005). 
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v)ErEN 
Erythroid enriched endoribonuclease (ErEN) was discovered and characterized as a 
part of a 160 kDa multiprotein complex which possessed the ability to cleave within the 
3' UTR of a-globin mRNA in vivo and in vitro (Rodgers et al. 2002; Wang and Kiledjian 
2000). Subsequent studies utilizing denaturing gel filtration have shown that ErEN is a 
40 kDa protein requiring ATP for endoribonucleolytic activity (Wang and Kiledjian 
2000b; Rogers et al. 2002). ErEN appears to be poly (A) tail-dependent in that it requires 
deadenylation of the mRNA transcript prior to cleavage within the 3' UTR of a-globin 
mRNA (Rodgers et al. 2002; Wang and Kiledjian 2000). 
vi) ARD-l/NIPP-l 
ARD-1 (Activator of RNA Decay) was initially found in humans as a a cDNA 
sequence that possessed the ability to reverse the pleiotropic effects of temperature-
sensitive and deletion mutations in the E. coli rne gene (Claverie-Martin et al. 1997; 
Chang et al. 1999). Studies have shown that human ARD-1 protein is a 13.3 kDa single-
strand-specific endoribonuclease that cleaves RNA in much the same fashion as bacterial 
RNase E; moreover, it cleaves at similar sites and produces cleavage products with 5'-
phosphates (Claverie-Martin et al. 1997). It has also been shown to function as a domain 
of the NIPP-1 protein (Claverie-Martin et al. 1997). 
NIPP-1 (Nuclear Inhibitor of Protein Phosphatase 1) isolated from bovine cells is a 
38.5 kDa protein that was found to contain a peptide sequence at its carboxyl terminal 
region with homology to that of human ARD-1 cDNA (Claverie-Martin et al. 1997; 
Chang et al. 1999). It has now been established that in human cells, ARD-1 and NIPP-1 
are isoforms, encoded by a single gene and are produced by alternatively splicing 
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precursor mRNA (Chang et al. 1999). Recent studies have shown that both ARD-1 and 
NIPP-1 contain lysine-rich regions in their carboxy-terminal regions that associate with 
AU rich sequences and promote endoribonucleolytic cleavage within these areas (Parker 
et al. 2002; Chang et al. 1999). 
vii) Argonaute 2 
The field of RNA interference in mammalian cells has also served as a reminder of 
the complexity and importance of the spatial localization of mRNA processing events 
required for correct protein expression. Argonaute 2 (Ago 2) is a member of a larger 
complex which is made up of Dicer and TAR RNA-binding protein (TRBP) located 
within the RNA-induced silencing complex (RISC) and is believed to be the enzyme 
required for endonucleolytic cleavage of the target mRNA (Martinez and Tuschl 2004; 
Liu et al. 2004). Ago 2 contains an N-terminal PAZ domain, two middle domains and a 
fourth C-terminal PIWI domain. These domains are believed to interact and form a 
supportive structure required for efficient cleavage of the mRNA transcript (Liu et al. 
2004; Parker et al. 2004). The N-terminal PAZ domain is believed to function in RNA-
binding (Parker et al. 2004) whereas the C-terminal PIWI domain, based on structural 
similarity with RNase H, is believed to be the catalytic domain required for 
endoribonucleolytic cleavage (Parker et al. 2004). Ago 2 exhibits several distinct cellular 
locales including cytoplasmic P-bodies. The widespread distribution of Ago 2, including 
known RNA decay centers may indicate that it functions in overlapping RNA 
degradation pathways (Sen and Blau 2006; Jing et al. 2005). RNA cleavage specificities 
and a summary of the properties of Ago 2 are shown in Table 2. 
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viii) Dicer 
Dicer is a large 218 kDa endoribonuclease belonging to the RNase III family of 
endoribonucleases (Fortin et al. 2002). Dicer cleaves without sequence specificity, 
double stranded RNA substrates into smaller 21-23 nucleotide segments which are 
referred to as siRNAs (small interfering). Dicer also functions in the excision of 
microRNAs (miRNAs) from hairpin precursors (Fortin et al. 2002; Nicholson and 
Nicholson 2002; Doi et al. 2003; Zhang et al. 2004a). In mammalian cells, Dicer 1 gene 
{Deri) has been discovered which encodes a Dicer-like protein that is essential for the 
viability of cells (Zhang et al. 2004a). RNA cleavage specificities, cellular location and 
properties of Dicer are shown in Table 2. 
ix) RNase A siiperfamily 
This family of proteins includes eight known members (1-8) in human cells which 
are grouped into four RNase families based on structural, catalytic and biological 
characteristics (Sorrentino and Libonati 1997). In fact, the RNase A superfamily of 
endoribonucleases have been the subject of some of the most intensive biochemical 
studies dating back over 50 years (Sorrentino and Libonati 1997). During the mid-1980s, 
a group of human RNases garnered interest based on some of the properties that they 
were found to possess (reviewed in Beintema et al. 1988; Benner and Allemann 1989; 
D'Alessio 1993). Subsequent studies have shown that several RNase A proteins possess 
special biological actions such as neurotoxicity, angiogenic activity, 
immunosuppressivity and antitumor activity (reviewed in Beintema et al. 1988; Benner 
and Allemann 1989; D'Alessio 1993). RNA-cleavage specificities and general properties 
of this group of enzymes are shown in Table 2. 
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1.7 Research Objectives 
Mammalian endonuclease-mediated mRNA degradation pathways identified to 
date include the RNAi pathway, the ER stress response, no-go decay and the decay of 
several specific mRNA transcripts; however, the identity of many of the 
endoribonucleases responsible for these decay products have yet to be conclusively 
identified. In addition, there remains significant debate as to the precise role of 
endonucleolytic degradation in controlling basal mRNA levels in mammalian cells. One 
of the major questions that remains is whether endonucleolytic cleavage events play a 
significant role in controlling mRNA abundance under normal cellular conditions as 
opposed to specialized conditions such as cellular stress. Given their role in a seemingly 
diverse set of mRNA degradation pathways, the numerous requirements for functional or 
structural activation, the lack of primary amino acid sequence homology among 
endoribonucleases, and the difficulties associated with detecting endonucleolytic mRNA 
decay products in vivo, it is not surprising that identifying novel members of this family 
of mammalian enzymes poses many challenges. 
Recently, a mammalian endoribonuclease was purified and biochemical 
characterization was subsequently undertaken (Bergstrom et al. 2006). The 
endoribonuclease was originally isolated in high salt ribosomal salt washes from rat liver 
tissue. Fractions from the heparin-sepharose column containing peak endonuclease 
activity were pooled and analyzed on an SDS-PAGE gel using silver stain. Five clear 
proteins of sizes ranging from 15-35 kDa co-purified with endonuclease activity. The 
major component of this enzyme complex was tentatively identified as a 35 kDa protein; 
however, the amino acid sequence and identity of the endoribonuclease has not been 
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determined. Given the lack of mammalian endoribonucleases identified and characterized 
to date, the identity of this endoribonuclease is of paramount importance for advancing 
our knowledge of endoribonucleases that function within the field of mRNA degradation. 
In order to fully understand the biological role of the endoribonuclease that had 
been purified it was necessary to re-purify and definitively identify this enzyme. In light 
of these gaps in our understanding of this endoribonuclease, the main objective of this 
thesis was to re-purify, identify and further characterize all of the major proteins that co-
purified with endoribonucleolytic activity against the CRD region of c-myc mRNA. 
The first aim of this research was to re-purify the native enzyme and the 
associated proteins from juvenile rat liver tissue that co-purified with endoribonucleolytic 
activity. The purification scheme was designed such that one pH precipitation step and 
five separate liquid column chromatography steps were used. The resulting eluted 
fractions from the final gel filtration purification column were resolved on a Coomassie 
Blue-stained SDS-PAGE gel. SDS-PAGE gel slices containing each of the proteins were 
sent to the Proteomics Centre at the University of Victoria for protein identification using 
LC-MS Mass Spectrometry. The results obtained were expected to definitively identify 
the 35 kDa protein and the four co-purified proteins. 
The second aim of this research was to confirm the identity of the protein(s) 
responsible for endoribonucleolytic activity against the CRD region of c-myc RNA. 
Given the strong probability that the novel mammalian endoribonuclease being studied 
formed a complex with the co-purified proteins, the identity and a test designed to assess 
potential in vitro interactions among the co-purified proteins was performed. The 
techniques employed for this were Western blotting and immunoprecipitation 
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experiments. Ultimately, the immunoprecipitation experiments were performed in an 
attempt to immuno-deplete native endoribonucleolytic activity. The second aim was also 
to understand the kinetics of the native enzyme(s); namely Vmaxand Km values. In order 
to accomplish this, a 17 base pair (mer) synthetic oligonucleotide substrate with a single 
incorporated ribonucleotide site was designed to rapidly assess the catalytic capabilities 
of the native enzyme. 
The third aim of this research was designed to generate the recombinant form of 
the mammalian endoribonuclease(s) and if necessary generate recombinant forms of the 
co-purified proteins. The final portion of this research utilized RNA sequencing gels in 
an attempt to map the cleavage sites of the recombinant form of the endoribonuclease 
against the CRD of c-myc RNA. 
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CHAPTER 2 
Purification and Identification of Two Distinct Mammalian 
Hepatic Endoribonucleases with the Ability to Degrade c-myc 
CRD RNA in vitro 
This chapter describes and discusses the approach taken to purify two mammalian 
endoribonuclease proteins isolated from juvenile rat liver tissue. It includes the steps 
required to generate the in vitro transcribed c-myc CRD RNA substrate that was used to 
assay endoribonuclease activity throughout the purification. This chapter also presents 
the results of each step in the purification, discusses the observed results, and 
identification of protein bands as determined by mass spectrometry. 
2.1 Methodology 
2.1.1 Isolation of Polysomes and Preparation of Ribosomal Salt Wash from Rat 
Liver Tissue 
95 juvenile frozen rat livers (approximately 175g each) from male Sprague-
Dawley rats purchased from Harlan Bioproducts (Madison, Wisconsin) were placed in 
liquid nitrogen, crushed using a pestle, re-suspended in Buffer A (buffer contents listed in 
Table 3) and homogenized at 14,000 rpm for 2-3 min with a Polytron 3000 (Brinkmann). 
All procedures were performed on ice unless otherwise indicated. The slurry was further 
hand-homogenized with 20 strokes to ensure adequate cell breakage. Approximately two 
livers were re-suspended and homogenized in 50 mL of Buffer A (buffer contents listed 
in Table 3). The tissue extract was centrifuged at 12,500 rpm for 10 min at 4°C. The 
supernatant was carefully removed and the pelleted cellular debris discarded. The 
supernatant was then placed in 10 mL of Buffer B (30% sucrose w/v) (buffer contents 
listed in Table 3). This solution was then placed into SW28 Beckman ultracentrifuge 
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tubes and centrifuged at 27,000 rpm for 90 min at 4°C. The supernatant was 
subsequently removed, and the pofysome-enriched pellet was re-suspended in 35 ml of 
Buffer A. This mixture was transferred to a 50 mL Falcon tube. 
Five ml of Buffer C was added to the 35ml of isolated polysomes in each 50 mL 
Falcon tube. The tubes were gently inverted 10 times. This mixture was then placed into 
SW28 Beckman ultracentrifuge tubes each containing 10 mL of Buffer B (30% sucrose 
w/v) and centrifuged at 27,000 rpm for 90 min at 4°C. The supernatant, termed 
Ribosomal Salt Wash (RSW) was subsequently removed and placed in 50 mL Falcon 
tubes. A total volume of 9 L of RSW (10 g of protein) was isolated and refrigerated at 
4°C. 
Table 3: Reagents and composition utilized in the preparation and purification of 
rat liver tissue extract 
Reagent 
Buffer A 
Buffer B 
Buffer C 
Composition 
ImM potassium acetate (KOAc) (Fisher Scientific, New Jersey 
NY), 1.5 mM magnesium acetate (MgOAc) (Fisher Scientific, 
New Jersey NY), 2mM DTT, 10% (v/v) glycerol, O.lmM 
ethylene glycol tetraacetic acid (EGTA) (EM Sciences Darmstadt, 
Germany), lOmM Tris-Cl, pH 7.4 
1 mM potassium acetate (KOAc) (Fisher Scientific, New Jersey 
NY), 1.5mM magnesium acetate (MgOAc) (Fisher Scientific, 
New Jersey NY), 2mM DTT, 10% (v/v) glycerol, 0.1 mM 
ethylene glycol tetraacetic acid (EGTA) (EM Sciences Darmstadt, 
Germany), lOmM Tris-Cl pH 7.4, 30% w/v sucrose 
4M potassium acetate (KOAc) (Fisher Scientific, New Jersey 
NY), 1.5mM magnesium acetate (MgOAc) (Fisher Scientific, 
New Jersey NY), 2mM DTT, 10% (v/v) glycerol, O.lmM 
ethylene glycol tetraacetic acid (EGTA) (EM Sciences Darmstadt, 
Germany), lOmM Tris-Cl pH 7.4, 30% w/v sucrose 
2.1.2 Non-Chromatographic Protein Purification 
The RSW was subjected to a pH-dependent protein precipitation step to remove 
bulk, non-soluble proteins. All procedures were performed on ice unless otherwise 
indicated. The pH of the RSW was lowered to 5.0 using a solution of 1M hydrocholoric 
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acid (HCL) (BDH Toronto, Ontario). The RSW was subsequently centrifuged at 18,000 
rpm for 25 min at 4°C. The supernatant was carefully removed, and the pH was re-
adjusted to 7.0 using a solution of 1M sodium hydroxide (NaOH). The final solution was 
then placed in 50 ml Nalgene tubes and frozen at -20°C for storage. 
2.1.3 Plasmid Digestion 
Prior to plasmid digestion, stock solutions of 10 mg/mL Proteinase K (EM 
Sciences, Darmstadt, Germany) and a 10 X Proteinase K buffer (100 mM Tris-Cl pH 8.0, 
50 mM ethylenediamine tetra-acetic acid (EDTA) pH 8.0 (Sigma-Aldrich, St. Louis, 
MO), 500 mM sodium chloride (NaCl) (Sigma-Aldrich, St. Louis, MO) were prepared. 
The plasmid construct used in this study was pUC19-CRD-wyc-1705-1886. Plasmid 
digestion was performed using a single restriction enzyme, EcoRI (New England 
Biolabs). Approximately 7.0 u.g of pUC19-CRD-wyc-1705-1886 plasmid in a 10 uL 
reaction mixture was subjected to restriction enzyme digest (1U/ uL) at 37°C for 60 min. 
Immediately following plasmid digestion, the mixture was treated with 0.5 % sodium 
dodecyl sulfate (SDS) (EM Sciences, NJ) and 50 ug/mL diluted aliquot of Proteinase K 
solution in 10X Proteinase K buffer. This mixture was subsequently incubated at 50 °C 
for 30 min. 
Following incubation with Proteinase K, 90 uL of Milli-Q-ddHaO was added. 
The mixture was then subjected to a standard phenol/chloroform extraction, followed by 
ammonium acetate/isopropanol precipitation. One half volume of phenol (Sigma) and 
one half volume of chloroform: isoamyl alcohol (CHCI3: IAA) (49:1) (Fluka) was added 
and vortexed thoroughly. After the mixture was centrifuged at 13,200 rpm for 2.5 min 
the top aqueous layer was extracted and placed in a fresh eppendorf tube. One full 
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volume of CHCI3: IAA was then added and the mixture was vortexed thoroughly and 
centrifuged at 13,200 rpm for 2.5 min. The aqueous top layer was again extracted and 
transferred to a fresh eppendorf tube. This procedure was repeated once again. The 
DNA was precipitated by adding 1/10 volume of 7.5 M ammonium acetate and 1 volume 
of isopropanol (Sigma). Following centrifugation at 13,200 rpm for 45 min at 1°C, the 
supernatant was removed and the pellet was washed once with 200 u.1 of isopropanol. 
The supernatant was again removed and the pellet was air dried for 10 min prior to 
resuspension in 25 uL of nuclease-free water (Ambion). 
The resuspended DNA was quantified using an ND-1000 UV-Spectrophotometer 
(NanoDrop Wilmington, Delaware). DNA concentrations were determined at 260nm 
using the following relationship: DNA concentration (ug/ml) = (OD260) x (dilution factor) 
x (50 ug DNA/ml)/ (1 OD26o unit). The digested products were resolved in a 50 mL 2% 
agarose (Invitrogen) gel containing 1 uL of a 10 mg/mL stock ethidium bromide solution. 
Agarose gels were resolved at 30 mA in lx TBE buffer (buffer composition shown in 
Table 4) for approximately 60 min and visualized by UV-transillumination using a 
Chemilmager™ System (Alpha Innotech Corporation, San Leandro, CA). 
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Table 4: Reagents and composition utilized in the generation of unlabeled and 5'-
radiolabeled c-myc CRD RNA 
Reagent 
lxTBE 
lx MOPS 
RNA Loading Dye 
Formamide Loading Dye 
Urea/Phenol Loading Dye 
Probe Elution Buffer 
Composition 
0.9M Tris-Cl/Boric acid (Sigma), 0.01M EDTA 
pH 8.3 (Sigma) 
0.2M MOPS (Sigma), 50mM sodium acetate 
(NaOAc) (Sigma), lOmM EDTA (Sigma) 
50% formamide, 2% formaldehyde, lx MOPS, 
0.05 mg/mL bromophenol blue (Sigma), 0.05 
mg/mL xylene cyanol (Sigma) and 0.01M 
EDTA pH 8.0 (Sigma) 
80% formamide, 0.05 mg/mL bromophenol 
blue (Sigma), 0.05 mg/mL xylene cyanol 
(Sigma), 0.01 M EDTA pH 8.0 (Sigma) 
9M Urea (Fisher Scientific), 10% Phenol v/v, 
0.05 mg/mL bromophenol blue (Sigma), 0.05 
mg/mL xylene cyanol (Sigma) and 0.01M 
EDTA pH 8.0 (Sigma) 
lOOmM Tris-Cl (pH 7.5), 0.5M EDTA (Sigma), 
Vi volume phenol (Sigma), Vi volume 
chloroform: isoamyl alcohol (49:1) (Fluka) 
2.1.4 Generation of Unlabeled c-myc CRD RNA 
Generation of RNA was accomplished from linearized plasmid using either T7 or 
SP6 RNA polymerase-mediated in vitro transcription kits (MEGAscript, Ambion, Austin, 
TX). Transcription reactions were carried out in a final volume of 20 uL. The reaction 
mixture typically contained 1.5 ug of linearized plasmid, 5mM ATP, CTP, GTP and 
UTP, respectively, 20 mM DTT (Promega Madison, WI), IX reaction buffer (Ambion), 1 
uL/40U RNasin (Promega, Madison, WI), and 4 |JL/40 units of SP6 or T7 polymerase 
enzyme (Ambion). In vitro reactions were incubated at 37°C for approximately 90 min. 
Following the incubation period, 2U of TURBO DNase 1 (Ambion) was added to the 
reaction mixture and incubated at 37°C for 15 min. The RNA was isolated using a 
standard phenol/chloroform extraction and ammonium acetate/isopropanol precipitation. 
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The RNA pellet was air dried for 10 min and resuspended in 25 uL of 
diethylpyrocarbonate (DEPC) (Sigma) Milli-Q-ddFbO. The RNA was quantified by 
measuring the absorbance at a wavelength of 260 nm on a UV/Visible Spectrophotometer 
(Biochrom, Ultrospec 1000). RNA concentration was determined using the relationship 
RNA (ug/mL) = (OD26o) x (dilution factor) x (40 ug RNA/mL)/ (1 OD26o unit). The 
purity of the RNA was also examined by assessing the A260 : A2so ratio using the ND-
1000 UV-Spectrophotometer (NanoDrop Wilmington, Delaware). The quality of the 
RNA product was also assessed using a 50 mL, 2% agarose (Invitrogen) gel containing 
37% formaldehyde (v/v) (Sigma) and 1 uL of a stock 10 mg/mL solution of ethidium 
bromide. Approximately 500 ng of RNA was mixed with RNA loading dye (composition 
shown in Table 4), and electrophoresed at 35 raA in lx MOPS buffer (buffer composition 
shown in Table 4) for approximately 90 min. The agarose gels containing the RNA were 
visualized by UV-transillumination using a Chemilmager System (Alpha Innotech 
Corporation, San Leandro, CA). 
2.1.5 Preparation of 5'-Radiolabeled c-myc CRD RNA 
c-myc CRD RNA (nts 1705-1886) was subsequently dephosphorylated at the 5' 
terminus. A typical dephosphorylation reaction contained 7 ug of RNA, 10 U (1 uL = 
1U) alkaline phophatase from calf intestine (Roche Diagnostic Inc., Montreal), 2.5 uL of 
a lOx dephosphorylation buffer, lOmM DTT and 40 U (40U/ uL) of RNasin (Promega). 
The volume of the reaction mixture was brought up to 50 uL by adding DEPC (Sigma)-
treated Milli-Q-ddH20. The mixture was incubated at 37°C for 60 min. The 
dephophorylated RNA was isolated using a standard phenol/chloroform extraction and 
ammonium acetate/isopropanol precipitation. RNA pellets were air dried for 10 min and 
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re-suspended in 25 uL of nuclease-free water (Ambion). The RNA was subsequently 
quantified using the ND-1000 UV-Spectrophotometer (NanoDrop Wilmington, 
Delaware). 
5'-y32P-radiolabeling of c-myc CRD (nts 1705-1886) RNA transcripts were carried 
out using the following conditions. Approximately 8 ug of dephosphorylated RNA was 
phosphorylated using 3 uL of 100 mM DTT, 80 U RNasin (80U/ uL) (Promega), 5 uL of 
a 10 X reaction buffer (New England Biolabs), 60 uCi (6 uL) y 32 P-ATP (Amersham 
Biosciences), and 40U (10 U/ uL) T4 Polynucleotide Kinase (PNK) (New England 
Biolabs). The reaction was incubated for 60 min at 37°C and the RNA was isolated using 
a standard phenol/choloroform extraction and ammonium acetate/isopropanol 
precipitation. 
The RNA pellet was air dried for 10 min and resuspended in 20 uL of formamide 
loading dye (composition shown in Table 4), loaded onto an 8% denaturing 
polyacrylamide/ 7M urea (Fisher Scientific) gel and electrophoresed at 30 mA in lx TBE 
running buffer for approximately 60 min. The RNA bands that were separated within the 
gel were visualized using a Cyclone Storage Phophor Screen System (Packard, Meriden, 
CT). The screen was then visualized with a Cyclone Phopholmager (Packard, Meriden, 
CT) and OptiQuant software. A full-sized image of the audioradiographed gel containing 
the visible RNA bands was printed and placed below the gel. The appropriate bands 
were excised and the gel slices were placed into 1.5 mL eppendorf tubes containing probe 
elution buffer (composition of probe elution buffer shown in Table 4). The gel slices 
were incubated at 60°C for 5 hrs and vortexed periodically (45 min intervals). 
40 
CHAPTER 2- PURIFICATION OF TWO MAMMALIAN ENDORIBONUCLEASES 
RNA was recovered following the elution by way of standard phenol/chloroform 
extraction and ammonium acetate/isopropanol precipitation. The RNA pellet was air 
dried for 10 min and resuspended in 50 uL of nuclease-free water (Ambion). The 
radioactivity of the RNA measured in counts per minute (cpm) was assessed using a 
Packard 1600 TR liquid scintillation analyzer. The 5'- y 32P-radiolabeled c-myc CRD was 
further diluted into working aliquots of 50,000 cpm and stored at -20 °C. 
2.1.6 Performing Endoribonuclease Assays using 5'-Radiolabeled c-myc CRD 
RNA 
To assess the enzyme activity of the purified endoribonuclease, a standard in vitro 
endoribonuclease assay was performed. The reaction mixture used for the standard assay 
consisted of final concentrations of 10 mM Tris (pH 7.5), 2mM MgOAc, 50 mM KOAc, 
O.lmM spermidine (Sigma), 2mM DTT, 0.5U RNasin (40U/ uL). DEPC-treated Milli-Q-
ddFfcO was added to ensure that the appropriate final reaction mixture volume was 
attained. 18 uL of the reaction mixture was aliquoted into 20 separate 1.5 mL eppendorf 
tubes. 
The appropriate amount of enzyme was added to the bottom of each tube 
containing 18 uL of reaction mixture. 4 uL of DEPC-treated H2O was placed in the tube 
serving as negative control (in place of the enzyme). 1 uL of 30 000 cpm, 5'-y P-
radiolabeled c-myc CRD RNA was added to the side of the tubes containing the reaction 
mixture and the tubes were pulsed to ensure the aliquot of radiolabeled RNA entered the 
enzyme/reaction mixture at the bottom of the tube. The reactions were incubated in a 
heat block at 37°C for 5 min unless otherwise stated. The reaction was terminated by 
placing the tubes in a heat block at 100°C for 3 min followed by the addition of 4 uL of 
urea/phenol loading dye (contents of dye shown in Table 4). The samples in the tubes 
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were then loaded onto an 8% or 12%/7M urea denaturing polyacrylamide gel. The gel 
was electrophoresed at 30 mA for 60 min in IX TBE buffer (until the primary dye front, 
bromophenol blue approached the bottom of the glass plates). Following electrophoresis, 
the gel plates were separated and the gel was transferred to filter paper and placed in a gel 
dryer (LABCONCO, Kansas City, MI) for approximately 45-60 min. The dried gel was 
exposed to a phosphor image storage screen overnight and the image was subsequently 
visualized using the Cyclone Phospholmager and Optiquant software. 
2.1.7 Protein Purification Utilizing Column Chromatography 
It should be noted that prior to each step in the chromatographic sequence of 
purification, the quantity of protein was determined using the Bradford Assay 
methodology. All column chromatographic purifications were performed using an ISCO 
Model 160 Gradient Former and a FoxyR Jr. Fraction Collector (ISCO, Lincoln NB, 
USA). 
2.1.7.1 Ion Exchange Chromatography 
Cellulose-Phophate Matrix 
The post-pH precipitated RSW, pH 7.0 samples were dialyzed in dialysis Buffer A 
(composition shown in Table 5) for 12 hrs using SnakeSkinR Pleated Dialysis Tubing 
(PIERCE, Rockford, IL) with a 10,000 molecular weight cutoff. This was performed to 
remove high salt concentrations prior to loading onto the column matrix to ensure that 
proteins would bind efficiently. The cellulose phosphate column matrix (Sigma) (bed 
volume 900 mL) was equilibrated with 3 column volumes of Buffer D (buffer 
composition shown in Table 5). Approximately 1.5-2.0 g of RSW proteins were then 
loaded onto a 100cm x 5.0 cm, XK 50 chromatographic column (Amersham Pharmacia 
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Biotech.Quebec) at a flow rate of 1.8 mL/min. The column was washed until the 
absorbance at 280 nm (A280) as measured by the UV chart recorder unit (UA-6 UV/Vis 
Spectrophotometer, ISCO) returned to base line (2 column volumes Buffer D). Bound 
proteins were then eluted in 1.5 column volumes of Buffer E using a linear gradient from 
0.1 to 0.75 M KC1. A total of 80, 15 mL fractions were collected. A 4 uL aliquot of a 
subset of fractions were assayed for the presence of endonuclease activity as previously 
described (section 2.1.6). Given the large quantity of protein that was purified, 20 
separate cellulose phosphate matrix-based chromatography runs were performed using 
the 100cm x 5.0 cm, XK 50 column. Column runs were highly reproducible. 
2.1.7.2 Affinity Chromatography 
Reactive Green-19 Dye Matrix 
The post-phosphocellulose pooled fractions with peak endonuclease activity were 
dialyzed in dialysis Buffer A (composition shown in Table 5) for 12 hrs using 
SnakeSkinR Pleated Dialysis Tubing (PIERCE, Rockford, IL) with a 10,000 molecular 
weight cutoff. Again, this was performed to remove high salt concentrations prior to 
loading onto the column matrix to ensure that proteins would bind efficiently. The 
reactive green matrix (Sigma) (bed volume 160 mL) was equilibrated with 3 column 
volumes of Buffer F (buffer composition shown in Table 5). Approximately 2 mg of 
post-phosphocellulose protein with peak endonuclease activity were then loaded onto a 
XK 26, 70cm x 2.6 cm chromatographic column (Amersham Pharmacia Biotech.) at a 
flow rate of 1.25 mL/min. The column was washed until the absorbance at 280 nm 
(A280) returned to base line (2 column volumes Buffer F). Bound proteins were then 
eluted in 1.5 column volumes of Buffer G using a linear gradient from 0.1 to 0.75 M KC1. 
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A total of 140, 2.5 mL fractions were collected. 10 separate reactive green-19 columns 
were run. A 2.5 uL aliquot of a subset of fractions were assayed for the presence of 
endonuclease activity as previously described (section 2.1.6). Column runs were highly 
reproducible. 
Affi-Gel Heparin Matrix 
Pooled post-Reactive Green-19 fractions with maximum endonuclease activity 
were dialyzed in dialysis Buffer B (composition shown in Table 5) for 12 hours using 
SnakeSkinR Pleated Dialysis Tubing (PIERCE, Rockford, IL) with a 10,000 molecular 
weight cutoff. The Affi-gel/heparin gel matrix (Biorad) (bed volume 120 mL) was 
equilibrated with 3 column volumes of Buffer F (buffer composition shown in Table 5). 
Approximately 1 mg of proteins were loaded onto a XK 26, 70cm x 2.6 cm 
chromatographic column (Amersham Pharmacia Biotech.,Quebec) at a flow rate of 1.5 
mL/min. The column was washed until the absorbance at 280 nm (A280) returned to 
base line (2 column volumes Buffer F). Bound proteins were then eluted in 1 column 
volume of Buffer G using a linear gradient from 0.1 to 0.75 M KC1. A total of 120, 1.5 
mL fractions were collected. 8 separate AffiGel-Heparin columns were run. Column runs 
were highly reproducible. A 1.5 uL aliquot of each was assayed for the presence of 
endonuclease activity as previously described (section 2.1.6). 
Heparin-Sepharose Matrix 
Pooled post-AffiGel-Heparin fractions with maximum endonuclease activity were 
dialyzed in dialysis Buffer B (composition shown in Table 5) for 12 hrs using 
SnakeSkinR Pleated Dialysis Tubing (PIERCE, Rockford, IL) with a 10,000 molecular 
weight cutoff. The pre-packed 5 mL HiTrap Heparin-Sepharose HP column (Amersham 
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Biosciences) equilibrated with 10 column volumes of Buffer F. Approximately 0.50 mg 
of proteins were loaded at a flow rate of 1.2 mL/min onto the column. The column was 
washed until the absorbance at 280 nm (A280) returned to base line (4 column volumes 
Buffer F). Bound proteins were then eluted in three column volumes of Buffer G using a 
linear gradient from 0.1 to 0.75 M KC1. A total of sixty, 0.5 mL fractions were collected. 
The post heparin-sepharose fractions with maximum endonuclease activity were pooled. 
Three separate column runs were performed and each was highly reproducible. One u,L 
aliquot of each fraction was assayed for the presence of endonuclease activity as 
previously described (section 2.1.6). 
2.1.7.3 Gel Filtration Chromatography 
The gel filtration column was equilibrated with 5 column volumes of Buffer F 
(composition shown in Table 5). The column was calibrated with molecular weight 
standards using a flow rate of 1.0 mL/min and a total column/elution volume of 100 mL 
as follows: 1.80 mL of Buffer F (Table 4) was used to dilute 0.2 mL (0.5 mg/mL) BSA 
0.2 mL (4.0 mg/mL) Ovalbumin, 0.200 (4.0 mg/mL) Carbonic Anhydrase, 0.2 mL (6.0 
mg/mL) Myoglobin, 0.2 mL (6.0 mg/mL) Cytochrome C. BSA (66 kDa) eluted at volume 
(Ve) of 40.6-42.2 mL, Ovalbumin (49 kDa) Ve of 43.5-45.6 mL, Carbonic Anhydrase (29 
kDa) Ve of 52.4-55.2 mL, Cytochrome C (Dimeric form, 24.8kDa) Ve 60.8-63.6mL, 
Myoglobin (17 kDa) Ve of 66.5-70.5 mL, Cytochrome C (monomeric form, 12.5 kDa) Ve 
of 72.8-78.4 mL. 
Approximately 3.0 mL of pooled post heparin-sepharose sample exhibiting peak 
endonuclease activity was placed in 1.0 mL aliquots using 1.5 mL eppendorf tubes and 
centrifuged at 10, 400 rpm for 10 min. The sample was again pooled and loaded onto a 
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Superdex 75 Hi Load 16/60 prep grade gel filtration column (GE Healthcare) at a flow 
rate of 1.0 mL/min. A total of two hundred fractions of 0.5 ml were collected in 
microcentrifuge tubes (total of 100 mL column/elution volume). A 4 uL aliquot of each 
fraction was assayed for the presence of endonuclease activity as previously described 
(section 2.1.6). 
Table 5: Reagents and composition utilized in the chromatographic purification of 
two mammalian endoribonucleases. 
Reagent 
Buffer D: Potassium phosphate 
binding/wash buffer 
Buffer E: Potassium phosphate elution 
buffer 
Buffer F: TEA binding/wash buffer 
Buffer G: TEA elution buffer 
Dialysis Buffer A 
Dialysis Buffer B 
Composition 
50 mM KC1 (Fisher Scientific), 100 mM 
K2HP04/ KHP04 (Sigma) pH 7.0 
1M KC1 (Fisher Scientific), 100 mM 
K2HPO4/ KHPO4 (Sigma) pH 7.0 
50 mM KC1 (Fisher Scientific), 50 mM 
Triethanolamine (TEA) (Sigma), pH 7.4 
1M KC1 (Fisher Scientific), 100 mM 
Triethanolamine (TEA) (Sigma), pH 7.4 
25 mM KC1 (Fisher Scientific), 100 mM 
K2HPO4/ KHPO4 (Sigma) pH 7.0 
25 mM KC1 (Fisher Scientific), 50 mM 
Triethanolamine (TEA) (Sigma), pH 7.4 
2.1.8 SDS-PAGE/Silver Stain Analysis of Post Heparin-Sepharose and Gel 
Filtration Elution Fractions. 
Following purification using heparin-sepharose and gel filtration column 
chromatography steps, and after the routinely performed standard endoribonuclease 
assay, elution fractions were frequently concentrated by pooling and subjecting them to a 
standard acetone precipitation procedure. In brief, an equal volume of ice-cold acetone 
(-20°C) was added to the tubes containing the protein sample. Tubes were placed in 
-20°C for 60 min and centrifuged at 13,200 rpm for 45 min. The acetone was removed 
and the protein pellets were air-dried for 10 min. The protein pellets were re-suspended 
and pooled in 10 uL of Milli-Q-dd H2O and 10 uL of IX SDS loading dye (composition 
shown in Table 6). The 20 uL mixture was boiled for 5 min, allowed to cool to room 
46 
CHAPTER 2- PURIFICATION OF TWO MAMMALIAN ENDORIBONUCLEASES 
temperature and loaded onto a sodium dodecyl sulphate 15% polyacrylamide, 19:1 
acrylamide/N,N'-methylenebisacrylamide (Invitrogen) gel (SDS PAGE gel). The 
samples were electrophoresed at 120V until the bromophenol blue dye front reached the 
bottom of the gel. The gel was then fixed with gently shaking for twenty minutes in a 
solution of 100 mL methanol, 20 mL acetic acid, 20 mL of Bio-Rad fixative enhancer 
concentrate, and 60 mL of Milli-Q-dd H2O. The gels were subsequently rinsed twice for 
10 minute intervals in Milli-Q-dd H2O. As per BioRad Silver Stain Plus protocol, 35 mL 
of Milli-Q-dd H2O, 5.0 mL of Bio-Rad silver complex solution, 5.0 mL of Bio-Rad 
reduction moderator solution, 5.0 mL of Bio-Rad image developing reagent, and 50 mL 
of Bio-Rad development accelerator solution were mixed thoroughly in a 250 mL 
Erlenmeyer flask and added to the gels. The gels were allowed to stain with gentle 
shaking for 10-15 min at room temperature. Once the desired staining was achieved, the 
gel was placed in a 5% acetic acid solution and fixed with gentle shaking for 20 min. 
The gel was then rinsed with Milli-Q-dd H2O for 5 minutes and visualized using the 
Chemilmager™ System. 
2.1.9 Determining Specific Activity of Endoribonuclease Activity 
One unit (U) of enzyme was defined as the quantity of post heparin-sepharose 
partially purified enzyme required to cleave 25% of the 5'- y 32P-radiolabeled c-myc CRD 
RNA input probe to decay product in the standard endoribonuclease assay reaction as 
described in section 2.1.6. 
Post-gel filtration purified native endoribonuclease samples corresponding to 17 
kDa and 35 kDa respectively, were assigned units of enzyme activity based on 
comparative ratio of their endonuclease activities against c-myc CRD RNA. 1U of 17 
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kDa enzyme was defined as 1 uL of post gel filtration-purified sample (elution volume 
65-80mL) in a standard endoribonuclease assay (described in section 2.1.6). 1U of 35 
kDa enzyme was defined as 5 uL of post gel filtration-purified sample (elution volume 
30-40 mL) in a standard endoribonuclease assay (described in section 2.1.6) 
The yield of the enzyme, shown in Table 7, was calculated by dividing the activity 
in each step of the purification by the activity present in the initial sample of RSW. The 
fold purification as shown in Table 6 was calculated by dividing the specific activity 
(units/mg) in each step of the purification by the specific activity (units/mg) of the initial 
starting sample of RSW. 
2.1.10 Sample Preparation and SDS-PAGE/Coomassie Staining for the First 
LC/MS/MASS Spectrometry Analysis 
Approximately 20 mL (0.3 mg) of post-Heparin/Sepharose purified protein was 
utilized for MASS Spectrometry Analysis. The 20 mL volume was measured into forty, 
0.5 mL aliquots and pipetted into forty separate eppendorf tubes which had been 
thoroughly rinsed with methanol to avoid keratin protein contamination. The tubes were 
then subjected to a standard acetone precipitation procedure as previously described in 
section 2.1.8. The protein pellets were re-suspended and pooled in 10 uL of Milli-Q-dd 
H2O and 10 uL of IX SDS loading dye (composition shown in Table 6). The 20 uL 
mixture was boiled for 5 min, allowed to cool to room temperature and loaded onto a 
sodium dodecyl sulphate 15% polyacrylamide, 19:1 acrylamide/N,N'-
methylenebisacrylamide (Invitrogen) gel (SDS PAGE gel). The samples were 
electrophoresed at 120V until the bromophenol blue dye front reached the bottom of the 
gel. The gel was subsequently stained for 3 hrs with gentle shaking in a solution of 
Coomassie Brilliant Blue G dye (composition shown in Table 6). The gel was then de-
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stained (composition of de-stain shown in Table 6) with gentle shaking for 1 hr. The 
appropriate bands were excised from the gel with a razor blade and placed in eppendorf 
tubes which had been pre-rinsed with 100% methanol. The tubes containing the protein 
bands of interest were sent to the Genome B.C. Proteomics Center at the University of 
Victoria for LC/MS/Mass Spectrometry/trypsin digest analysis and protein identification. 
Table 6: Reagents used in the preparation and staining of SDS-PAGE gels 
Reagent 
IX SDS loading dye 
Coomassie blue staining solution 
Coomassie blue de-staining solution 
Composition 
25 mM Tris-Cl pH 7.4, 20% glycerol (v/v) 
(Sigma), 4% SDS (v/v) (OmniPur/EM Science, 
Gibbstown NJ), 0.2 % bromophenol blue (w/v) 
(Sigma), 0.1 % p-mercaptoethanol (v/v) (Sigma) 
50% methanol, 10% acetic acid, 1% (w/v) 
Coomassie Brilliant Blue G 
50% methanol, 10% acetic acid 
2.1.11 Sample Preparation and SDS-PAGE/Coomassie Staining for the Second 
LC/MS/MASS Spectrometry Analysis 
Fractions from gel filtration columns 5 and 7 containing peak endonuclease 
activity corresponding to an elution volume of 44-50 mL (30-40 kDa protein size range) 
were pooled. The total volume of 6 ml was measured into 0.5 mL aliquots and pipetted 
into twelve separate eppendorf tubes. The eppendorf tubes had been thoroughly rinsed 
with 100% methanol to avoid keratin protein contamination. Due to the sensitivity of 
LC/MS/MASS Spectrometry analysis, keratin protein contamination prevents accurate 
identification of target proteins. A standard acetone precipitation procedure was 
performed as previously described in section 2.1.8. The protein pellets were re-
suspended in 10 uL of Milli-Q-dd H2O and 10 uL of IX SDS loading dye (composition 
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shown in Table 6) for a total of 20 uL/ tube. The samples were then boiled for 5 min, 
allowed to cool to room temperature and loaded onto 15% polyacrylamide SDS-PAGE 
gel. The samples were electrophoresed at 120V until the bromophenol blue dye front 
reached the bottom of the gel. The gel was subsequently stained for 3 hours with gently 
shaking in a solution of Coomassie Brilliant Blue G dye (composition shown in Table 6). 
The gel was then de-stained (composition of de-stain shown in Table 6) with gentle 
shaking for 1 hr. The appropriate bands were subsequently excised from the gel and 
placed in eppendorf tubes which had been pre-rinsed with 100% methanol. The tubes 
containing the protein bands of interest were sent to the Genome B.C. Proteomics Center 
at the University of Victoria for LC/MS/Mass Spectrometry/trypsin digest analysis and 
protein identification. 
2.2 Results and Discussion 
2.2.1 Protein Purification 
The first non-chromatographic/pH precipitation step used to purify a total volume 
of nine liters of Ribosomal (Liver) Salt Wash (RSW or LSW) generated a seven-fold 
increase in protein purity and a total increase in units of enzyme activity, as shown in 
Table 7. The total protein, total volume, specific activity and yield are also shown in 
Table 7. 
Chromatographic purification of two endoribonucleases was successfully 
accomplished using ion exchange, affinity, and size exclusion chromatography. The 
column matrices utilized yielded highly reproducible results. The matrices used in this 
purification scheme were chosen based on previous work done in Dr. Lee's lab 
(Bergstrom et al. 2006). There were, however, two major differences in the purification 
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used in this research as compared to previous research undertaken to purify these 
mammalian endoribonucleases. Firstly, the purification described in this research 
omitted a Reactive-Blue-4 dye affinity matrix. Secondly, a dialysis procedure was 
performed to remove excess KC1 prior to loading pooled elution fractions (with peak 
endoribonuclease activity) onto subsequent column matrices. To reduce the 
concentration of KC1, previous work done to purify the endoribonucleases (Bergstrom et 
al. 2006) diluted pooled elution fractions (exhibiting peak endoribonuclease activity) 
with buffer prior to loading onto subsequent column matrices. 
Table 7: Summary of the Partial Purification of Two Mammalian Endoribonucleases 
from Rat Liver Tissue. 
Step 
Ribosomal Salt 
Wash 
pH Precipitation 
Phosphocellulose 
Reactive Green-
19 
AffiGel/Heparin 
Heparin-
Sepharose 
Total 
Protein 
mg 
36,000 
26,000 
679.80 
21.00 
5.33 
0.84 
Volume 
mL 
9,000 
9,350 
7,590 
3,250 
750 
45 
Activity 
units 
4.41 x 107 
2.15 x10s 
3.22 xl0 v 
8.30x10" 
4.15 xlO6 
9.97 x10s 
Specific 
Activity 
units/mg 
1225 
8269 
43,367 
395,238 
778,612 
1,186,905 
Yield 
% 
100 
100 
73 
18.9 
9.4 
2.3 
Purification 
Fold 
1 
6.80 
35 
323 
635.6 
1069 
Each ion exchange column matrix composed of cellulose phosphate 
(phosphocellulose) with a bed volume of 900 mL was capable of binding approximately 
2-3 g of post-pH treated proteins. Endoribonuclease activity eluted from the column at a 
gradient KC1 concentration of 0.45-0.55M (Figure 4, top panel). 
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Figure 4: Analysis of endonucleolytic activity of samples from column 
chromatography purification. All reactions were performed using 5'- y 32P-
radiolabeled c-myc CRD (30,000 cpm/lane). RNA was resolved on 12% denaturing 
polyacrylamide/7M urea gels. Fully intact c-myc CRD RNA is shown with a filled arrow. 
The top panel depicts 4.0 uL (1U) sample aliquots from eluted fractions of 
phosphocellulose column 5. The middle panel depicts 2.5 uL (1U) sample aliquots from 
eluted fractions of reactive green-19 column 2. The lowest panel depicts 1.5 uL (1U) 
sample aliquots from eluted fractions of affi-gel/heparin column #3. Lanes containing no 
enzyme are labeled 'none'. Lanes used as positive control are labeled LSW (liver salt 
wash), post-PC (pooled phosphocellulose elution fractions with endonuclease acitivity 
and post-RG (pooled Reactive Green-19 elution fractions with endonuclease activity) 
respectively. Filled arrow indicates intact c-myc CRD RNA. Bracket and unfilled arrow 
indicates RNA decay products 
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Cellulose phosphate chromatography was efficient at binding endoribonuclease proteins; 
however, there was significant endonucleolytic activity exhibited in the first flow through 
fraction collected during column loading (Figure 4 top panel, FT-1 lane 6). This was 
most likely due to overloading the binding capacity of the column matrix. Optimal 
protein load needed for efficient binding of endoribonucleases to the phosphocellulose 
column matrix was roughly 1.5 g. Overall, phosphocellulose chromatography yielded a 
35-fold increase in enzyme purity as judged by specific activity (Table 7). 
The Reactive Green-19 affinity matrix exhibited a high capacity to bind 
endoribonucleases present in post-phosphocellulose purified sample. The Reactive 
Green-19 dye affinity matrix (bed volume 160 mL) was capable of binding 
approximately 50 mg of protein. Endoribonuclease activity eluted from the column at a 
gradient KC1 concentration of 0.35-0.45M (Figure 4, middle panel). The 
endoribonuclease assay of the fraction collected for flow through 1 (FT-1) during column 
loading (Figure 4, middle panel, lane 6) exhibited strong endoribonucleolytic activity. 
Again, this was most likely due to overloading the binding capacity of the column matrix. 
Optimal protein load needed for efficient binding of endoribonucleases to the Reactive 
Green-19 dye matrix was 30-40 mg. Overall, Reactive Green-19 affinity 
chromatography resulted in a 323-fold increase in enzyme purity (Table 7). 
Affi-gel/Heparin affinity chromatography also exhibited a high capacity to bind 
endoribonucleases isolated from rat liver tissue. Optimal protein load concentration for 
each column run was approximately 1.5 mg. Endoribonuclease activity eluted from the 
column at a gradient KC1 concentration of 0.55-0.65M (Figure 4, lower panel). Overall, 
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affi-gel/heparin affinity chromatography resulted in a 635-fold increase in enzyme purity 
(Table 7). 
Heparin-Sepharose affinity chromatography exhibited a high degree of binding 
capability for endoribonucleases present in post affi-gel/heparin pooled elution fractions. 
Endoribonuclease activity eluted from the column at a gradient KC1 concentration of 
0.35-0.60M (Figure 5A). Overall, heparin-sepharose affinity chromatography resulted in 
a 1069-fold increase in enzyme purity (Table 7). 
A subset of elution fractions from the first heparin-sepharose column containing 
endoribonuclease activity (assay shown in Figure 5A) were visualized by SDS-PAGE 
electrophoresis/silver staining (Figure 5B) to gauge the degree of protein purity within 
the sample fractions. Not surprisingly, there were several major protein bands remaining 
in the post-heparin-sepharose elution fractions (Figure 5B, lanes 5-8). Furthermore, the 
correlation between the fractions assayed in Figure 5A and the proteins visualized by 
SDS-PAGE in Figure 5B reveals that there is a mixture of proteins present in the eluted 
fractions with endonucleolytic activity (lanes 5 and 6). There is an increase in the 
intensity of a protein band at 33 kDa, 37 kDa, and 45 kDa (Figure 5B, lanes 4-8; fractions 
32, 38, 41, 44, and 47, respectively); however, when comparing these fractions to the 
endoribonuclease assay in Figure 5A, it is evident that the increase in the intensity of the 
aforementioned proteins does not correlate with the observed peak endonucleolytic 
activity present in fractions 20-42. Moreover, the presence of a mixture of protein bands 
in the post heparin-sepharose sample coupled with the lack of correlation between protein 
band intensity (Figure 5B) and endoribonucleolytic activity (Figure 5A) prevented an 
accurate size estimate of the proteins responsible for endoribonuclease activity. 
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Figure 5: Endonucleolytic activity and SDS-PAGE analysis of post heparin-
sepharose purified fractions (A) Autoradiograph depicting sample 1 uL aliquots (1U) 
taken from eluted fractions and incubated with 5'- y P-radiolabeled c-myc CRD RNA. 
Filled arrow indicates intact c-myc CRD RNA. Bracket and unfilled arrow indicates 
RNA decay products (B) 15% polyacrylamide SDS-PAGE gel visualized with silver 
stain. Lane 1 corresponds to protein marker (M). Lanes 2-10 correspond to selected 0.5 
mL elution fractions containing peak endonuclease activity from heparin-sepharose 
column 1. Molecular weights are indicated on the left. 
Gel filtration chromatography was utilized as a means of size separating proteins 
remaining in pooled post heparin-sepharose elution fractions containing peak 
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endoribonucleolytic activity. Interestingly and somewhat unexpectedly, standard 
endoribonuclease assays of gel filtration fractions revealed two distinct regions of 
endoribonucleolytic activity (Figures 6A and 6B). The first activity was observed within 
elution volume 44-50 mL (Figure 6A). The second activity was observed within an 
elution volume of 64-85 mL (Figure 6A). The elution volumes exhibiting 
endoribonucleolytic activity correspond to proteins of sizes 30-40 kDa and 15-20 kDa, 
respectively, as calculated from the molecular weight standards used to calibrate the 
column (section 2.1.7.3). 
As shown by Figures 6A, 6B and 7A, gel filtration columns exhibited a high 
degree of reproducibility. It should be noted, however, that the standard endoribonuclease 
assay (shown in Figure 6B) of the elution fractions from gel filtration column eight, does 
not exhibit sharp, clear boundaries between larger molecular weight and smaller 
molecular weight endonucleolytic activities. Given the larger amount of post heparin-
sepharose sample loaded onto this column (approximately 0.4 mg) as compared to the 
lesser amount of protein loaded onto columns shown in Figures 6A and 7A 
(approximately 0.10 mg), the observed results are most probably due to excessive amount 
of protein. 
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Figure 6: Analysis of endonucleolytic activity of fractions from gel filtration 
chromatography. (A) Depicts gel filtration column 7. 4.0 uL (0.75 U) sample aliquots 
taken from the corresponding elution volume was incubated with 5'-y P-radiolabeled c-
myc CRD RNA in a standard endoribonuclease assay. Filled arrow indicates intact c-myc 
CRD RNA. Bracket and unfilled arrow indicates RNA decay products (B) Depicts gel 
filtration column 8. 4.0 uL (0.75U) sample aliquots taken from the corresponding elution 
volume, labeled above each lane, was incubated with 5'-y P-radiolabeled c-myc CRD 
RNA in a standard endoribonuclease assay. Filled arrow indicates intact c-myc CRD 
RNA. Bracket and unfilled arrow indicates RNA decay products 
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To accurately determine the protein size responsible for endoribonucleolytic 
activity, a standard endoribonuclease assay was performed on eluted fractions from gel 
filtration column run five. The fractions from this column were pooled and visualized on 
an SDS-PAGE/silver stained gel. As shown in Figure 7B (lanes 4-7), there appears to be 
an increase in intensity of a protein band corresponding to a molecular weight of 35 kDa. 
In addition, there appears to be an increase in protein bands corresponding to molecular 
weights of 25 kDa, 18 kDa, and 14 kDa (Figure 7B, lanes 9 and 10). The protein band at 
35 kDa in Figure 7B, lanes 4-7 appears to exhibit a slight correlation with 
endonucleolytic activity in elution volumes 46-50 mL (Figure 7A). The proteins bands at 
18 kDa, and 14 kDa (Figure 7B, lanes 9 and 10) appear to correlate with endonucleolytic 
activity in elution volumes 62-70 mL (Figure 7A). 
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Figure 7: Endonucleolytic activity and SDS-PAGE analysis of elution fractions 
from gel filtration chromatography. (A) Autoradiograph depicting 4.0 uL (0.75U) 
aliquots taken from eluted fractions and incubated with 5'- y 32P-radiolabeled c-myc CRD 
RNA. Filled arrow indicates intact c-myc CRD RNA. Bracket and unfilled arrow 
indicates RNA decay products (B) 15% SDS-PAGE gel visualized with silver stain. 
Lane 1 corresponds to protein marker (M), molecular weights are labeled on the left. 
Lanes 2-10 depict pooled elution volumes from gel filtration column 5. The pooled 
elution volumes labeled above lanes 2-10 in (B) correspond to elution volumes labeled 
above lanes in (A). 
To confirm the findings of the aforementioned correlation experiment, a second 
endoribonuclease assay/SDS-PAGE correlation-type experiment, using elution fractions 
from gel filtration column runs 7 and 8, was performed. The endoribonuclease assays of 
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fractions from gel filtration column runs 7 and 8 are shown in Figure 6A and 6B, 
respectively. The SDS-PAGE/silver stained gel used for the analysis gel filtration 
column run 7 and the pooled sample from gel filtration column 8 is shown in Figure 8. It 
is apparent from Figure 8, lanes 4-6, there is an increase in intensity of a protein band at 
35 kDa, corresponding to elution volumes of 42-49 mL. Additionally, there is a an 
increase in intensity of protein bands with molecular weights of 25 kDa, 18 kDa, and 14 
kDa which corresponds to gel filtration elution volumes of 62-67 mL (Figure 8, lanes 9 
and 10). The protein with apparent molecular weight of 35 kDa exhibited in gel filtration 
column 7 (Figure 8, lanes 4, 5 and 6) correlates with increasing endoribonucleolytic 
activity from gel filtration column 7, elution volumes 42-51 mL (Figure 6A). The 
proteins with apparent molecular weights of 18 kDa and 14 kDa (Figure 8, lanes 9 and 
10) correlate with endoribonucleolytic activity from gel filtration column 7, elution 
volumes 62-85 mL (Figure 6A). The pooled sample of elution volumes 45-50 mL (gel 
filtration column runs 7 and 8) shown in Figure 8, lane 8 lends further support for the 
notion that a protein of a molecular weight 35 kDa is responsible for endoribonucleolytic 
activity in gel filtration elution volumes 40-50 mL. It is evident in Figure 8, lane 8 that 
there is an intense band of protein with an apparent molecular weight of 35 kDa. 
Unfortunately, the presence of additional protein bands below and above the 35 kDa band 
(Figure 8, lane 8) contribute to the uncertainty in determining the precise molecular 
weight of the protein band responsible for endoribonucleolytic activity in elution volumes 
40-50 mL. 
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Figure 8: SDS-PAGE analysis of elution fractions from gel filtration 
chromatography. The gel was silver stained. Lane 1 depicts protein marker with 
molecular weights labeled to the left of the lane. Lanes 2-7, 9 and 10 depict elution 
fraction volumes from gel filtration column run 7. Lane 8 depicts a 2.0 mL pooled 
sample representing elution volumes 45-50 mL from both gel filtration columns 7 and 8. 
Overall, the data collected to date suggests that the protein with apparent 
molecular weight of 35 kDa in Figure 7B (lanes 4-7) and Figure 8 (lanes 4-6 and 8) is the 
candidate protein responsible for endoribonucleolytic activity in gel filtration elution 
volumes 40-50 mL. In addition, the data suggests that either the protein band of apparent 
molecular weight 18 kDa or the protein band of 14 kDa (Figure 7B, lanes 9 and 10; 
Figure 8, lanes 9 and 10) is responsible for endoribonucleolytic activity in gel filtration 
elution volumes 60-85 mL. 
Post heparin-sepharose purified sample was chosen for protein identification 
using LC/MS/Mass Spectrometry because of the high abundance of protein present 
relative to that of gel filtration purified sample. This was particularly important because 
there is a minimum quantity of protein needed in gel bands for accurate mass 
spectrometry analysis. Also, the gel staining reagents are required to be non-silver 
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containing, as silver ions interfere with the mass spectrometry analysis procedure. Given 
the conditions required for accurate mass spectrometry analysis, Coomassie Brilliant 
Blue stain was used, although the lower end detection limits of protein using Coomassie 
Blue stain is far less than the lower end detection limits of protein using silver-based 
stains. The Coomassie Brilliant Blue-stained gel from which proteins were excised and 
sent for mass spectrometry analysis is shown in Figure 9. It was decided that the major 
proteins of sizes corresponding to the general molecular weights ranges were: 40-50kDa 
(Figure 9, #1), 30-40kDa (Figure 9, #2), 20-25kDa (Figure 9, #3 and #4), and 10-20kDa 
(Figure 9, #5 and #6). These size ranges were chosen as they best-correlated with 
endoribonucleolytic activities as judged by gel filtration chromatography. 
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66 kDa __». [ ,Ammm. 
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36 k D a — * • • « • 
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Figure 9: SDS-PAGE analysis of partially purified liver endoribonuclease following 
heparin-sepharose column chromatography. SDS-PAGE gel was stained with 
Coomassie Blue. Lane 1 represents protein marker. Lane 2 represents pooled post 
heparin-sepharose sample. The protein bands indicated with arrows to the right of lane 2 
(labeled 1-6) represent the bands that were excised and sent to Genome BC Protemics 
Center at UVIC for LC/MS/Mass Spectrometry protein identification. Lane 3 represents 
another sample of protein molecular weight marker. Molecular weights are indicated 
with arrows to the left. 
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The results of protein identification using LC/MS/Mass Spectrometry enabled the 
formulation of a short list of plausible protein candidates which could be responsible for 
endoribonucleolytic activity as judged by heparin-sepharose chromatography. The list of 
protein candidates resulting from mass spectrometry analysis is shown in Table 8. There 
are several possible protein candidates for several of the protein bands. This is most 
likely due to a mixture of proteins with similar molecular weight within the stained 
(visible) protein band that were excised. The identity of the largest protein band #1 
(Figure 9) was either thioredoxin reductase or glutamate dehydrogenase (Table 8). 
Neither of these proteins possesses known endoribonucleolytic activity in vivo or in vitro. 
Furthermore, the molecular weights of 57 kDa and 61 kDa, respectively, do not correlate 
with the 35 kDa molecular weight protein associated with endoribonucleolytic activity 
and were thus excluded as possible endoribonuclease candidates. 
Table 8: Summary of LC/MS/Mass Spectrometry data and peptide analysis results used 
to identify purified proteins from the post heparin-sepharose column shown in 
Figure 9. 
Protein 
Band# 
1 
2 
3 
4 
5 
6 
Top Protein Matches {Rodentia Species) of 
Relevant 
1) Thioredoxin reductase 2 (57kDa) 
2) Glutamate dehydrogenase 1 (61 kDa) 
1) L-3-hydroxyacyl-CoA dehydrogenase (HADHSC) (34 kDa) 
2) Apurinic/apyrimidinic lyase (AP 
endonuclease/APEl) (35 kDa) 
1) Cyclophilin B (Peptidyl prolyl isomerase) (23 kDa) 
1) Pancreatic Ribonuclease A (17 kDa) 
1) Cytochrome C (12.5 kDa) 
1) Small nuclear ribonucleoprotein E (11 kDa) 
2) Small nuclear ribonucleoprotein sm dl, chain A (9 kDa) 
3) SNRPF (small nuclear ribonucleoprotein F) (10 kDa) 
Sequence 
Coverage 
(%) 
1) 34% 
2) 41% 
1) 62% 
2) 3% 
1) 56% 
1) 45% 
1) 55% 
1) 65% 
2) 74% 
3) 50% 
# of Matched Peptides 
(Continuous Stretches 
of Amino Acids) 
1)12 
2)16 
1)10 
2)1 
1)14 
1)5 
1)11 
1)4 
2)4 
3)2 
The identity of protein band #2 was confidently narrowed to two choices. As 
shown in Table 8, the mass spectrometry data for HADHSC exhibited 62% sequence 
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coverage (10 major peptides identified). The other possible protein candidate was APE 
1; however, the mass spectroscopy data for APE1, shown in Table 8, was very weak as 
there was one peptide match (3% sequence coverage). HADHSC has no known 
endoribonuclease activity although its molecular weight of 34 kDa corresponds to the 
largest endoribonucleolytic activity from gel filtration chromatography. Given the high 
degree of certainty in identifying this protein, the commercially-available recombinant 
form of HADHSC was obtained for further investigation. Details of the investigation 
using recombinant HADHSC are provided in Chapter 3. 
Mass spectrometry data for protein band #3 was clearly identified as cyclophilin 
B (Table 8). The mass spectrometry data did not identify any plausible protein 
alternatives at or near 25 kDa. 
Mass spectrometry data for protein band #4 was identified as a known 
endoribonuclease; rat pancreatic ribonuclease A (RNase 1) (Table 8). Five major 
peptides were matched which translated into a sequence coverage of 45%. Given the fact 
that the identity of this band was a known endoribonuclease and the fact that the mass 
spectrometry peptide sequence data shown in Table 8 was strong, it was tentatively 
concluded that pancreatic RNase A was responsible for the endoribonucleolytic activity 
observed in elution volumes 60-85 mL (protein size of 10-20kDa) from gel filtration 
chromatography. Further evidence to support this conclusion is provided in Chapter 3. 
Mass spectrometry data for protein band #5 conclusively identified it as 
cytochrome C (Table 8). The mass spectrometry data did not identify any plausible 
protein alternatives at or near 12-14 kDa. 
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The identity of the final protein band #6 was not entirely clear. The mass 
spectrometry data (Table 8) identified three possible protein candidates which were all 
within the small ribonucleoprotein family of proteins. There was no further investigation 
undertaken to determine the identity of this protein. This is due in large part to the 
unavailability of specific antibodies against this group of proteins. 
In an attempt to conclusively identify the 35 kDa protein responsible for 
endoribonucleolytic activity, a second set of pooled samples containing peak 
endoribonucleolytic activity from gel filtration column runs 5, 6, 7 and 8, were sent for 
LC/MS/Mass Spectrometry analysis. The Coomassie Brilliant Blue-stained SDS-PAGE 
gel from which candidate stained protein bands were excised, is shown in Figure 10. As 
shown in Figure 10, lane 2, a range of major protein bands (#1, #2, and #3) corresponding 
to molecular weights of 38 kDa, 34 kDa, and 28 kDa, respectively, were chosen based 
largely on the data from gel filtration chromatography. 
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kl)a 
Figure 10: SDS-PAGE analysis of partially purified liver endoribonuclease from gel 
filtration chromatography. SDS-PAGE gel was stained with Coomassie Brilliant Blue 
Lane 1 represents protein marker with molecular weight indicated to the left. Lane 2 
represents post-gel filtration purified pooled elution volumes of 43-50mL (protein sizes 
30-40kDa) from gel filtration column runs. The arrows indicate the protein bands that 
were excised and sent to Genome BC Protemics Center at UVIC for LC/MS/Mass 
Spectrometry protein identification. Lane 3 represents post-gel filtration purified pooled 
elution volumes 65-85 mL (protein sizes 10-20kDa). 
The results of LC/MS/Mass Spectrometry protein identification using the second 
set of samples is shown in Table 9. The largest protein band (#1) was identified as either 
APE1, annexin III or aldo-keto reductase. The similarity in their molecular weights 
(shown in Table 9, protein band #1) and the high degree of amino acid sequence coverage 
from the matching peptides (Table 9, protein band #1) suggests that all three proteins 
may have co-migrated within the band that was excised. 
Interestingly, APE1 was observed in the data from the first mass spectrometry 
analysis (Table 8, protein band #2). Given its predicted molecular weight of 35 kDa and 
its known multifunctionality as a DNA-specific endonuclease (Demple and Harrison 
1994), redox activator of transcription factor DNA-binding (Xanthoudakis et al. 1992; 
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Evans et al. 2000), mediator of parathyroid hormone (PTH) gene (Okazaki et al. 1992; 
Okazaki et al. 199'4) and additional properties such as 3'-5' exonuclease activity 
(Richardson and Kroenberg 1964), phosphodiesterase activity (Richardson et al. 1964) 
and RNase H-like activity (Barzilay et al. 1995), it was decided to further investigate 
APE1. The amino acid sequences of the seven matching peptide fragments for APE 1 are 
shown in Table 10. 
Protein band #2 (Figure 10, lane 2) was definitively identified as HADHSC. The 
mass spectrometry analysis did not present plausible protein alternatives for this protein 
band. Protein band #3 (Figure 10, lane 2) was not conclusively identified; however, upon 
closer examination, the most plausible protein listed in Table 9, protein band #3 appears 
to be Glutathione S-transferase. The predicted molecular weight of Glutathione S-
transferase is 26 kDa (Table 9, protein band #3) and the protein band that was excised 
from the gel (Figure 10, lane 2, #3) corresponded to a protein band of 25kDa-30 kDa. 
Table 9: Summary of LC/MS/Mass Spectrometry data and peptide analysis results to 
identify purified proteins following gel filtration chromatography. 
Protein Band 
# 
1 
2 
3 
Top 3 Protein Matches (Rodentia 
Species) 
1) Apurinic/apyrimidinic lyase (AP 
endonuclease/APEl) (35 kDa) 
2) Annexin III (36.5 kDa) 
3) Aldo-keto reductase El (34.8 kDa) 
1) L-3-hydroxyacyl-CoA dehydrogenase 
(HADHSC) (34 kDa) 
1) Peroxisomal enoyl hydratase-like 
protein (36.5 kDa) 
2) HADHSC (34 kDa) 
3) Glutathione S-transferase (25.6 kDa) 
Sequence 
Coverage 
(%) 
1) 32% 
2) 38% 
3) 40% 
1) 55% 
1) 46% 
2) 20% 
3) 54% 
Matched Peptides (Amino Acid 
Sequences) 
1)7 
2)10 
3)11 
1)8 
1)12 
2)3 
3)7 
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Table 10: Matched peptides and the corresponding amino acid sequences of rat 
Apurinic/apyrimidinic endonuclease (AP endonuclease-APE 1) 
Peptide Fragment 
1 
2 
3 
4 
5 
6 
7 
Amino Acid Sequence of Peptide Fragment 
KICSWNVDGLRA (amino acids 61-72) 
KEEAPDILCLQETKC (amino acids 83-97) 
KLPAELQELPGLTHQYW (amino acids 101-123) 
KEGYSGVGLLSRQ (amino acids 124-136) 
KVSYGIGEEEHDQEGR (amino acids 140-155) 
RQGFGEMLQAVPLADSF (amino acids 236-252) 
KALGSDHCPITLYLAL (amino acids 301-316) 
Evidence presented in this chapter highlights several candidate proteins that may 
contribute to native endoribonuclease activity against c-myc CRD RNA. Three major 
protein candidates, HADHSC, annexin III and APE1 were chosen as possibilities for 35 
kDa endoribonuclease activity. HADHSC was chosen because it contains a predicted 
RNA-binding Rossmann fold motif. The Rossmann fold motif is known to bind 
nucleotides, in particular, the cofactor NAD and its structure is composed of three or 
more parallel beta strands linked by two alpha helices (Arnez and Cavarelli, 1997; Rao 
and Rossmann 1973). Annexin III was chosen because another member of the annexin 
family of proteins (annexin A2) has been shown to bind ribonucleotide homopolymer 
RNA and human c-myc RNA (Filipenko et al. 2004). APE1 was the most intriguing 
candidate since it had known multifunctionality, including DNA-specific endonuclease 
activity. Consequently, APE1 became the prime candidate for our investigation into the 
identity of the 35 kDa protein responsible for endoribonuclease activity observed in gel 
filtration elution volume 40-50 mL. 
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CHAPTER 3 
Identification and Characterization of the 35 kDa and 17 kDa 
Hepatic Endoribonucleases 
This chapter presents the methods and discusses the results of the experiments used to 
identify 35 kDa and 17 kDa endoribonucleases, including Western blots, standard 
endoribonuclease assays, electrophoretic mobility shift assays (EMSA) and 
immunoprecipitation/immunodepletion of native endoribonuclease activity. This chapter 
also includes characterization experiments and kinetic analysis of purified 
endoribonucleases with apparent molecular weights of 17 kDa and 35 kDa, respectively. 
3.1 Methodology 
To conclusively determine the identity of the purified enzymes and to better 
characterize the properties of each enzyme, numerous experiments were designed and 
conducted. The following chapter covers the experimental approach used to definitively 
confirm the identity of two mammalian endoribonucleases. This chapter describes the 
techniques used and discusses the relevant findings from the variety of protein 
identification and protein characterization experiments. The biochemical properties of 
both endoribonucleases are discussed; however, emphasis will be given to the 
endoribonuclease with an apparent molecular weight of 35 kDa. 
3.1.1 Western Blotting to Confirm the Proteins Identified with LC/MS/Mass 
Spectrometry 
Western Blotting analysis was used in an attempt to confirm the identity of the 
candidate proteins identified by mass spectrometry analysis. The standard SDS-
PAGE/Western Blot protocol and reagents outlined below were similar for all samples 
unless stated otherwise. Pooled samples from post heparin-sepharose chromatography 
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and gel filtration chromatography were divided into the appropriate number of 1.5 mL 
eppendorf tubes. Proteins were concentrated using the standard acetone precipitation 
procedure as outlined in chapter 2, section 2.1.8. Protein pellets were resuspended in 10 
uL of IX SDS/p-mercaptoethanol loading dye (composition shown in Table 6) and 10 uL 
of Milli-Q-ddH20. 8 uL of rainbow marker (GE Healthcare, Montreal) was mixed with 
10 uL of IX SDS/p-mercaptoethanol loading dye. All samples except the rainbow 
marker were boiled for 5 min and electrophoresed on a 15% SDS-PAGE gel as described 
in chapter 2, section 2.1.11. 
Prior to protein transfer from the SDS-PAGE gel to a nitrocellulose membrane, 
four pieces of filter paper and one piece of nitrocellulose membrane were soaked in 
western transfer buffer (composition shown in Table ) for 10 min. The SDS-PAGE gel 
was placed in a 'sandwich' consisting of (in order): one foam spacer, two pieces of filter 
paper, nitrocellulose membrane, SDS-PAGE gel, two pieces of filter paper, one foam 
spacer. The 'sandwich' was then placed in a Bio-Rad western blot sandwich cassette, 
and submerged in transfer buffer, within a Western blot apparatus. An ice block and a 
stir bar were added to the apparatus. Proteins in the gel were transferred to the 
nitrocellulose membrane at a constant 190 raA for 100 min. 
After protein transfer was complete, the nitrocellulose membrane was removed 
from the sandwich and placed in Western blocking buffer (composition shown in Table 
11) and shaken for 90 min at room temperature. Following the blocking step, the 
membrane was rinsed twice for 5 min in Western wash buffer (composition shown in 
Table 11). Primary antibodies used were anti-RNase 1 (GeneTex Inc., San Antonio, TX), 
anti-cyclophilin B (Abeam Inc. Cambridge MA), anti-cytochrome c (Abeam Inc. 
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Cambridge MA), anti-HADHSC (GenWay Biotech Inc., San Diego, CA), anti-APEl 
(Affinity BioReagents, Golden, CO) and anti-annexin III (GenWay Biotech Inc., San 
Diego, CA). All primary antibodies were diluted 1:2500 in Western wash buffer. 
Primary antibody solutions were added to the blot and incubated with gentle shaking at 
room temperature for 60 min. Blots were then rinsed three times (5 min/rinse) with 
gentle shaking. Secondary antibodies containing the appropriate Ig chain and the 
horseradish-peroxidase (HRP) conjugation (all secondary antibodies obtained from 
Promega Corporation, Madison, WI) were diluted 1:4000 in Western wash buffer. 
Secondary antibody mixture was added to the blots and incubated at room temperature 
with gentle shaking for 60 min. The blot was then rinsed for 20 min in Western wash 
buffer. The wash step was repeated three times. After the final wash, PIERCE 
SuperSignal West Pico Chemiluminescent visualizing solution (MJS BioLynx Inc. ON, 
Canada) was prepared. This was accomplished by mixing equal parts (total 8 mL) of the 
luminal/enhancer solution with the stable peroxidase buffer solution. The 
Chemiluminescent solution was added to the blot and the blot was shaken vigorously for 
1 min. Prior to visualization, excess Chemiluminescent solution was removed from the 
blot. The blot was visualized with the Chemilmager™ System (Alpha Innotech 
Corporation, San Leandro, CA). 
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Table 11: The identity and composition of reagents used for Western Blotting 
Reagent 
Transfer buffer 
Western blocking buffer 
Western wash buffer 
Western stripping buffer 
Composition 
0.050M Tris (w/v), 0.040M glycine (w/v), 20% methanol 
(v/v) 
70% Milli-Q-ddH20 
7% Skim milk powder (w/v) (Nestle Carnation), IX TBS, 
0.01M Tris, 45 mL Milli-Q-ddH20 
2.0% Skim milk powder (w/v) (Nestle Carnation), IX TBS, 
0.01% Tween 20 (v/v), 900 mL Milli-Q-ddH20 
lOOmM p-mercaptoethanol, 2% SDS, 62.5mM Tris pH 6.7 
3.1.2 Determining the Identity of the 17 kDa Endoribonuclease 
Western Blots were used to confirm the identity (pancreatic RNase A, based on 
mass spectroscopy data) of the enzyme responsible for endoribonucleolytic activity 
corresponding to 17 kDa as judged by gel filtration chromatography. Affinity-purified 
polyclonal antibodies for RNase 1 (GeneTex Inc., San Antonio, TX) were obtained. The 
RNase 1 antibodies were used to probe post-gel filtration fractions, and post-heparin-
sepharose fractions. Sample fractions from post-heparin sepharose and gel filtration 
exhibiting endoribonucleolytic activity were acetone precipitated using the standard 
acetone precipitation procedure (chapter 2, section 2.1.8). The samples were then loaded 
onto 15% SDS-PAGE gel and transferred to a nitrocellulose membrane and visualized 
with Chemiluminescent substrate as previously described for the standard Western blot 
protocol (section 3.1.1). 
3.1.3 Determining the Identity of the 35 kDa Endoribonuclease 
Several approaches were used to conclusively identify the 35 kDa protein 
responsible for endoribonucleolytic activity exhibited by endoribonuclease assays of 
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elution fractions from gel filtration chromatography. The following sections describe the 
methodologies utilized in these approaches. 
3.1.3.1 Stripping Antibodies from Western Blots 
Western stripping buffer (composition shown in Table 11) was heated to 60°C 
and 100 mL was added to the specific nitrocellulose blot. The blot was shaken 
vigorously in a fume hood for 20 min. The stripping buffer was removed and 50 mL of 
fresh 60°C Western stripping buffer was added to the blot, and the blot was shaken 
vigorously for an additional 10 min. The Western stripping buffer was then removed. 
The blot was washed 3 times (5 min each wash) in Western wash buffer (composition 
shown in Table 11). The blot was then re-blocked in Western blocking buffer 
(composition shown in Table 11) for 60 min at 37°C. Blots were then re-probed with 
desired primary antibody appropriate secondary antibody, and visualized as previously 
described (section 3.1.1). 
3.1.4 Characterizing the 35 kDa and 17 kDa Endoribonucleases 
To confirm the identity of candidate proteins responsible for endoribonucleolytic 
activity against 5'-radiolabeled c-myc CRD RNA, and to distinguish between 
endoribonuclease activity corresponding to molecular weights of 17 kDa and 35 kDa as 
observed with gel filtration chromatography, it was necessary to assess the differences 
between the 17 kDa and 35 kDa endoribonucleases with respect to cleavage specificity, 
differences in enzyme kinetic and sensitivity to known RNase inhibitory proteins. 
3.1.4.1 Assessing the Sensitivity of the 35 kDa and 17 kDa Enzymes to 
Ribonuclease Inhibitor Protein (RNasin) 
Post-gel filtration purified pooled fractions corresponding to elution volumes 40-
50mL (protein sizes 30-40kDa) and 65-80mL (protein sizes 10-20kDa) were utilized for 
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RNasin experiments. 5 uL (1U) aliquots from elution volumes 40-50mL (protein sizes 
30-40kDa) and 5 uL (5U) aliquots from elution volumes 65-80mL (protein sizes 10-
20kDa), respectively, were utilized for assay reactions. The reaction incubations and the 
assay procedures were identical to those previously described for a standard 
endoribonuclease assay (Chapter 2, section 2.1.6). All RNasin assays were performed 
using 5'-y32P-radiolabeled c-myc CRD (30,000 cpm/lane) and 1U RNasin (1U=1 uL). 
RNA was resolved on a 12% denaturing polyacrylamide/7M urea gel. 
3.1.4.2 Endoribonuclease Assays of Recombinant Protein Candidates Using 
5'-Radiolabeled c-myc CRD mRNA 
Commercially available recombinant proteins for HADHSC (GenWay Biotech.), 
annexin III (GenWay Biotech), APE1 (Hickson lab, Oxford, UK) were obtained and 
tested for endoribonucleolytic activity. A second sample of recombinant APE1 was 
obtained from Dr. Mitra Sankar's lab (University of Texas Medical Branch [UTMB], 
Galvestin, TX). Prior to testing recombinant proteins for endoribonucleolytic activity, 
samples were dialyzed overnight. Dialysis of recombinant protein samples was 
performed with 10,000 molecular weight cutoff Slide-A-Lyzer dialysis cassettes 
(PIERCE, Rockford, IL). Dialysis buffer (Dialysis Buffer B, composition is shown in 
Table 5) was utilized for all recombinant protein samples. Standard endoribonuclease 
assays using 5'-radiolabeled c-myc CRD RNA (nts 1705-1886) were performed as 
previously outlined in Chapter 2, section 2.1.6. 
3.1.4.3 Mapping the Cleavage Sites of the 35 kDa and 17 kDa 
Endoribonucleases using 5'-Radiolabeled c-myc CRD mRNA 
Prior to performing the mapping experiments, an RNase Tl digest and an alkaline 
hydroxy 1 ladder of c-myc CRD RNA were prepared. RNase Tl digests were generated 
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by incubating 200,000 cpm 5'-radiolabeled c-myc CRD RNA (nts 1705-1886) in 10X 
sequencing buffer (Ambion Inc., Austin, TX) (total volume of 30 uL). 2U of RNase Tl 
(1U= luL) was added to the 30 uL mixture and incubated at room temperature for 10 
minutes. The reaction was terminated and the RNA was extracted using a standard 
phenol/chloroform and ammonium acetate/isopropanol precipitation procedure as 
outlined in Chapter 2, section 2.1.3. The dried RNA pellet was re-suspended in 10 uL of 
urea/phenol loading dye (composition shown in Table 4). RNase Tl digest was stored at 
-20°C until required. 
Alkaline hydroxyl ladders were generated by combining 100,000 cpm 5'-
radiolabeled c-myc CRD RNA (nts 1705-1886) with IX alkaline hydrolysis buffer for a 
total reaction mixture of 20 uL. The reaction mixture was heated to 95°C in a heat block 
for 10 min. The mixture was immediately transferred to ice and 20 uL of formamide 
loading dye was added. The mixture was stored at -20°C until required. 
Mapping of cleavage sites for both the 35 kDa and 17 kDa endoribonucleases was 
carried out using reaction incubation conditions identical to those that were outlined in 
the standard endoribonuclease assay (Chapter 2, section 2.1.6). Assays were resolved at 
25 mA for 90 min on a 12% poly aery lamide/7M urea gel, dried and visualized using 
Cyclone Phosphor Imager and Optiquant Software. 
3.1.4.4 Assessing the Possibility of N-linked Glycosylation 
Additional experiments to conclusively determine the identity of the enzyme 
responsible for endoribonucleolytic activity (from candidate proteins identified by mass 
spectrometry corresponding to 35 kDa were performed (Table 8, protein band #2; Table 
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9, protein band # 1). These experiments were needed to rule out the possibility of post-
translational modification within a member of the RNase A family of proteins. 
The first such experiment tested the possibility of N-linked glycosidations present 
on the endoribonuclease. The enzyme N-glycosidase F (removes N-linked protein 
glycosylations) was utilized. 100 U of recombinant N-glycosidase F (Roche Diagnostics, 
Mannheim, Germany) was incubated with 3.0 mL of post heparin-sepharose sample 
overnight at 30°C. The N-glycosidase F-treated post heparin-sepharose sample was 
aliquoted into separate 1.5 mL eppendorf tubes. The tubes were centrifuged at 10,400 
rpm for 10 min. The samples were then pooled and loaded onto a Superdex 75 Hi 
Loadl6/60 prep grade gel filtration column (GE Healthcare) at a flow rate of 0.75 
mL/min using Buffer F (composition shown in Table 5, Chapter 2). A total of two 
hundred, 0.5 mL fractions were collected in microcentrifuge tubes (total of 100 mL 
column/elution volume). A 5 uL aliquot (1U native 35 kDa enzyme) from separate 
elution fractions was incubated with 5'-radiolabeled c-myc CRD RNA (nts 1705-1886) 
and visualized using the standard endoribonuclease assay as previously described (section 
2.1.6). 
3.1.4.5 Determining if the 35 kDa Endoribonuclease is Dimeric 
To assess whether the endoribonuclease with apparent molecular weight of 35 
kDa was a hetero- or homodimeric protein, an experiment using DTT was designed to 
assess whether the 35 kDa endoribonuclease was composed of multi subunits (with 
disulfide linkages). 3.0 mL of post heparin-sepharose sample was incubated for 60 min at 
4°C in the presence of 250mM DTT. The DTT-treated post heparin-sepharose sample 
was aliquoted into separate 1.5 mL eppendorf tubes. The tubes were centrifuged at 
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10,400 rpm for 10 min. The samples were then pooled and loaded onto a Superdex 75 Hi 
Loadl6/60 prep grade gel filtration column (GE Healthcare) at a flow rate of 0.75 
mL/min in Buffer F (composition shown in Table 5, Chapter 2). A total of two hundred 
0.5 ml fractions were collected in microcentrifuge tubes (total of 100 ml column/elution 
volume). A 5 uL aliquot (1U native enzyme) from separate elution fractions was 
incubated with 5'-radiolabeled c-myc CRD RNA (nts 1705-1886) and visualized using a 
standard endoribonuclease assay as previously described (section 2.1.6). 
3.1.5 Electrophoretic Mobility Shift Assays 
EMSA protocols were adopted from the methodologies previously described by 
Prokipcak et ah (1994), with modifications made by Sparanese and Lee (2007). EMSA 
protocols were designed for CRD-BP; however, similar reaction conditions were adopted 
for binding of HADHSC, APE1 and annexin III to 5'-y32P-radiolabeled c-myc CRD-
1705-1886 RNA. EMSA binding buffers were prepared fresh on ice prior to each 
-IT 
experiment. 5'-y P-radiolabeled c-myc CRD was denatured (heated to 75°C) and 
renatured (cooled to room temperature) prior to addition in the EMSA binding buffer 
(composition shown in Table 12). This was done to ensure proper folding of the RNA 
transcript. EMSA binding buffer containing radiolabeled c-myc RNA was incubated in 
separate experiments with commercially obtained recombinant HADHSC protein 
(GenWay Biotech., San Diego, CA), recombinant APE1 protein (Dr. Sankar's lab, TX) 
and commercially obtained recombinant annexin III protein (GenWay Biotech., San 
Diego, CA). The final reaction mixture for all EMSA experiments was 20 \iL and 
reactions were incubated at 30°C for 10 min, transferred to ice for 5 min and then again 
incubated at 30°C for 10 min. Following the final 10 min incubation at 30°C, heparin 
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(Sigma) was added to a final concentration of 5 mg/mL and the reaction was placed on 
ice for 5 min. 2 uL of EMSA loading dye (composition shown in Table 12) was added 
to the reaction mixture. The entire reaction mixture was loaded onto a 6% native 
polyacrylamide gel and resolved at 20 mA for approximately 90 min. Following 
electrophoresis, the gel was transferred to filter paper and dried using a gel drying 
apparatus (LABCONO, Kansas City, MO) for 45 min. The dried gel was then exposed to 
a phosphorimager screen overnight. The autoradiographs were visualized using a 
Cyclone Storage Phosphor Screen System and Optiquant Software. 
Table 12: The identity and composition of reagents used in the EMSA experiments 
Reagent 
EMSA binding buffer 
EMSA loading dye 
Composition 
5mM Tris-Cl (pH 7.4), 2.5 mM EDTA (pH 8.0), 2mM 
DTT, 5% glycerol, 0.1 mg/mL (BSA), 0.5 mg/mL yeast 
tRNA (Ambion), 5U RNasin 
250 mM Tris-Cl (pH 7.4), 0.2% bromophenol blue, 0.2% 
xylene cyanol, 40% sucrose (w/v) 
3.1.6 Enzyme Kinetic Analysis of the 35 kDa and 17 kDa Endoribonucleases 
Using 5'-labeled Oligonucleotide Substrate. 
Kinetic analysis of the 35 kDa and 17 kDa endoribonucleases was performed 
using a synthetic DNA oligonucleotide substrate (Integrated DNA Technologies [IDT], 
Coralville, IA). The synthetic oligo substrate was designed based on a short stretch of 
sequence from the CRD region of the c-myc mRNA transcript, as shown in Table 13. 
The substrate was composed of 16 chimeric DNA bases and 1 RNA base. The predicted 
secondary structure is shown in Table 13. The commercially-obtained oligo was initially 
lyophilized and required re-suspension in 100 uL of DEPC-treated Milli-Q-ddH20. 
Stock oligonucleotide was quantified using the NanoDrop spectrophotometer. Amount 
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of oligo was calculated using the formula provided by IDT (Table 13). Oligonucleotide 
substrate was frozen at -80°C for storage. 
Prior to performing kinetic assays, 16 ug (4 uL) of oligonucleotide substrate 
(stock concentration 4.1 ng/uL) was dephosphorylated and subsequently 5'-y P-
radiolabeled. The remaining steps used for dephosphorylation reactions were identical to 
those previously described for c-myc CRD RNA, in Chapter 2, section 2.1.5. 5'-y32P-
radiolabeled reactions were performed using half (roughly 8 ug or 2 uL) of the previously 
generated dephosphorylated oligonucleotide substrate. Preparation and procedures for 5'-
y 32P-radiolabeled reactions using oligonucleotide substrate were performed as previously 
described for c-myc CRD RNA, in Chapter 2, section 2.1.5. 
The first step in preparation for assays used to assess Michaelis Menten kinetics 
involved determining a workable or 'optimal' concentration range of gel filtration-
purified 35 kDa and 17 kDa enzyme, respectively, for a given time period. Stop-time 
assays using various enzymes concentrations over several time periods were performed. 
Data from the intensities of decayed 5'-radiolabeled oligonucleotide RNA (calculated as 
DLU/time) was obtained and was subsequently entered into a Microsoft Excel 
spreadsheet. Of note, DLU intensities were obtained directly from autoradiographs using 
Optiquant Software. All data was then transferred to KaleidaGraph 3.6.2 (Synergy 
Software) for linear and nonlinear regression analysis. DLU decay intensities for the 
different time periods were plotted against enzyme concentration using linear regression 
analysis. It should be noted that all procedures herein were performed in duplicate; once 
for the analysis of the native 17 kDa enzyme and once for analysis of the native 35 kDa 
enzyme. 
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The next step was performed using an 'optimized' value of native 17 kDa or 35 
kDa enzyme. The optimal quantity of enzyme was then incubated with a set 
concentration of 5'-y P-radiolabeled oligonucleotide substrate in a stop-time assay . This 
procedure was repeated for multiple substrate concentrations. The second set of data 
was plotted as DLU intensities (at various [substrate]) versus time, and analyzed using 
linear regression. 
To obtain data for the nonlinear regression plots (Michaelis Menten plots) of the 
respective 17 kDa and 35 kDa enzymes, slope values (rate of appearance of decay 
product) from the aforementioned linear regression analysis were plotted against the 
varying substrate concentrations utilized. Nonlinear regression analysis was performed 
using KaleidaGraph 3.6.2. The values from the nonlinear regression analysis were fit 
into the Michaelis Menten equation v = V[S] /(Km + [S]) to obtain Km and Vmax values 
for the 17 kDa and 35 kDa endoribonuclease, respectively where v = velocity, [S] is 
molar amount of substrate, V= maximum velocity, Km = Michaelis Menten constant ([S] 
at half-maximal velocity). 
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Table 13: Sequence, structure and calculation the amount of the synthetic 
oligonucleotide used to assess kinetic properties of the respective 35 kDa and 
17 kDa endoribonucleases. Filled arrow indicates the ribonucleotide UA 
base-pair that is predicted to be cleaved by native endoribonucleases 
Substrate 
DNA Oligonucleotide Sequence 
Structure of Oligonucleotide 
Substrate 
Amount of Oligonucleotide 
Calculation 
Data 
5'-CAA GGT AGT
 rUAT CCT TG-3' 
G T r U > t 
A A 
T T 
G-C 
G - C 
A - T 
1 7 4 3 A - T 1 7 5 7 
5 ' 3 ' 
11.1=66.80 = 0.35 
OD 260 nmoles mg 
3.1.7 Immunoprecipitation of Gel Filtration-Purified Native Extract 
Immunoprecipitation experiments were designed to immunodeplete the native 35 
kDa endoribonuclease candidate protein, APE1. Pooled post-heparin sepharose and 
pooled gel filtration elution fractions corresponding to elution volumes of 40-50 mL were 
utilized for immunodepletion experiments. 
Immunoprecipitation reaction preparations and experimental procedures were 
performed as follows and were identical unless otherwise stated: 400 uL of PIERCE 
Immunopure Immobilized Protein A slurry (MJS BioLynx Inc. ON, Canada) was placed 
in a Pierce Seize X kit Handee™ Spin Cup and centrifuged at 3000 rpm for 30 sec. The 
flow through was discarded and 400 uL of binding/wash buffer (PIERCE; composition 
shown in Table 14) was added to the beads. The Handee™ Spin Cup Column was 
capped and inverted 10 times. The spin cup was then centrifuged at 3000 rpm for 30 sec 
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and the flow through was discarded. The wash/centrifugation steps as previously 
described were repeated two more times. 
The spin cup was placed in a fresh 1.5 mL eppendorf tube and a total volume of 
200 uL primary APE1 antibody solution (equivalent to about 25 tig of primary APE1 
polyclonal antibody diluted in 175 uL of binding/wash buffer [PIERCE]) was added to 
the beads contained in the spin cup. Primary antibody solutions were incubated with 
gentle rocking for 2 hrs at 4°C. The tubes were centrifuged at 3000 rpm for 30 sec. The 
flow-through was saved and identified as antibody flow through 1. 400 uL of 
binding/wash buffer was added to the spin cup and mixed by inverting 10 times. The 
tubes were centrifuged at 3000 rpm for 30 sec and the flow through was saved and 
termed wash 1. The wash/centrifugation steps were repeated two more times. The spin 
cup was then transferred to a new 1.5 mL eppendorf tube. 
One pre-packaged lyophilized sample of DSS (disuccinimidyl suberate; PIERCE) 
was opened and re-suspended in 80 uL of DMSO (dimethyl sulfoxide). 25 uL of the 
DSS crosslinking agent was added to the spin cup. The mixture was incubated with 
gentle rocking at room temperature for 60 min. The spin cup was then centrifuged at 
3000 rpm for 30 sec and the flow through was discarded. 400 uL of binding/wash buffer 
was then added to the spin cup and mixed by inverting 10 times. The spin cup was 
centrifuged at 3000 rpm for 30 sec. The flow through was discarded. Addition of wash 
buffer and centrifugation was repeated two more times. The spin cup was placed in a 
fresh 1.5 mL eppendorf tube. 
In duplicate, a spin cup containing DSS-crosslinked polyclonal syntaxin 18 
antibodies was prepared using a procedure identical to that previously described above to 
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prepare the APE1 monoclonal antibody containing spin cup. The spin cup containing 
cross-linked polyclonal syntaxin 18 antibodies was used as negative control. 
Table 14: Composition and identity of the reagents used in immunoprecipitation 
experiments 
Reagent 
Binding/Wash buffer (PIERCE) 
Elution Buffer (PIERCE) 
Antibody Crosslinking Agent (PIERCE) 
Handee™ Spin Cup Columns (PIERCE) 
Composition 
0.14M NaCl, 0.008M sodium phosphate, 
0.002M potassium phosphate, 0.01M KC1 
Final pH= 7.4 
Primary amine solution, Final pH = 2.8 
DSS (disuccinimidyl suberate) 
0.45 urn cellulose acetate filter 
One hundred uL of post-heparin sepharose purified sample or 400 uL of pooled 
gel filtration elution volumes 40-50mL (protein sizes 30-40kDa) were utilized (separate 
spin cup trials) for immunodepletion experiments. Post-heparin-sepharose purified 
sample or gel filtration purified sample was pipetted on top of the beads in the spin cup. 
Spin cups were capped, and incubated with gentle rocking for 2 hrs at 4°C. Spin cups 
were then centrifuged at 3000 rpm for 30 sec. The flow through was saved and labeled 
flow through 1 (FT-1). 400 uL of binding/wash buffer was then added to the top of the 
spin cup. The spin cup was capped, inverted 10 times and centrifuged at 3000 rpm for 30 
sec. The wash/centrifugation step was repeated two more times. 
Elution of bound proteins was performed as follows. 200 uL of PIERCE Seize X 
Immunoprecipitation kit Immunopure IgG Elution Buffer (pH 2.8) was added to the spin 
cups. The cups were capped and inverted 10 times. The cups were then centrifuged at 
3000 rpm for 30 sec and the flow through fraction was saved and labeled elution 1. 
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Elution steps were repeated two more times for a total of 3 times. The elution fractions 
were immediately neutralized with the addition of an equal volume of Tris-Cl pH 9.5. 
A total of one control column using syntaxin 18 polyclonal antibodies and post 
heparin-sepharose purified sample, two APE 1-specific immunodepletion column using 
post heparin-sepharose sample, and one APE 1-specific immunodepletion column using 
pooled (40-50mL) gel filtration purified sample, were performed. 
3.2 Results and Discussion 
3.2.1 Identification of Co-purified Proteins by Western Blot 
Candidate proteins identified in the first and second LC/MS/Mass Spectrometry 
analysis were confirmed using Western blot. Co-purified proteins included cytochrome c 
(lanes 2 and 3, Figure 11-A), cyclophilin B (lanes 2 and 3, Figure 11-B), pancreatic 
ribonuclease A (RNase A) (lane 2, Figure 12; lanes 2 and 3 Figure 13; lane 5, Figure 15-
A; lanes 6-8, Figure 16-A; lanes 6-8, Figure 17-A; lane 3, Figure 18-A), HADHSC (lane 
1, Figure 18-B), and APE1 (lane 2, Figure 15-B; lane 6, Figure 16-B; lanes 5-7, Figure 
17-B) and annexin III (Figure 18-C). Rabbit affinity-purified polyclonal antibodies for 
thioredoxin reductase were obtained and used to determine the presence of thioredoxin 
reductase in post heparin-sepharose purified sample; however, this protein was not 
detected (data not shown). It was concluded that either thioredoxin reductase was not 
present in purified heparin-sepharose sample or was present in extremely low 
concentrations thus preventing detection using Western blot analysis. 
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#*W 
1 2 3 1 2 3 
Anti- Cytochrome c Anti- Cyclophilin B 
Figure 11: Western blot analysis confirming the presence of cytochrome c and 
cyclophilin B in partially purified liver extract. (A) Depicts a Western blot for 
cytochrome c protein using commercially-obtained mouse monoclonal antibody (Abeam 
Inc, Cambridge, MA). Lane 1 contains 2 ug of recombinant bovine pancreatic RNase A. 
Lane 2 contains 5 ug of pooled post-heparin-sepharose purified sample. Lane 3 contains 
pooled post gel filtration purified sample (protein not quantifiable) corresponding to 
elution volumes 65-85 mL. Molecular weight markers (kDa) are shown to the left of blot 
(B) Depicts a Western blot for cyclophilin B protein using rabbit polyclonal antibody 
(Abeam Inc., Cambridge, MA). Lane 1 contains 2 ug of recombinant bovine pancreatic 
RNase A. Lane 2 contains 5 ug of pooled post-heparin-sepharose purified sample. Lane 
3 contains 5 ug of post-Affigel purified sample. Molecular weight markers (kDa) are 
shown to the left. 
A summary of the results from Western blots used to confirm the presence of co-
purified proteins identified using LC/MS/Mass Spectrometry analysis is shown in Table 
15. Several of the protein candidates identified with mass spectroscopy analysis 
including: glutamate dehydrogenase, peroxisomal enoyl hydratase, aldo-keto reductase 
El, glutathione S-transferase, and small nuclear ribonucleoprotein E, were not 
investigated. 
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Table 15: Summary of results from Western blots used to determine the presence of co-
purified proteins identified with LC/MS/Mass Spectrometry analysis one and 
two. 
Protein Candidate from 
LC/MS/Mass Spectroscopy 
Analysis 
Glutamate dehydrogenase 
Thioredoxin reductase 
Peroxisomal enoyl hydratase-like-protein 
Annexin III 
Apurinic/apyrimidinic lyase (AP-
endonuclease) -APE 1 
Aldo-keto reductase El 
L-3 -hydroxyacyl-CoA dehydrogenase 
(HADHSC) 
Glutathione S-transferase 
Cyclophilin B (Peptidyl prolyl isomerase) 
Pancreatic ribonuclease A (RNase A) 
Cytochrome C 
Small nuclear ribonucleoprotein E 
Probed using 
Western blot 
analysis 
No 
Yes 
No 
Yes 
(Figure 33) 
Yes 
(Figures 15,16,17) 
No 
Yes 
(Figure 18) 
No 
Yes 
(Figure 11-B) 
Yes 
(Figures 12,13, 
15-18) 
Yes 
(Figure 11-A) 
No 
Present in post-
heparin-
sepharose sample 
Not determined 
No 
Not determined 
Yes 
Yes 
Not determined 
Yes 
Not determined 
Yes 
Yes 
Yes 
No 
Predicted 
molecular 
weight/Observed 
molecular weight 
(kDa) 
61/-
57/-
36.5/-
36.5/55 
35/34.5 
34.8/-
34/32 
25.6/-
23/22 
17/17 
12.5/13 
11/-
3.2.2 Identifying the 17 kDa Hepatic Endoribonuclease 
One of the major challenges of this research was conclusively identifying the 
proteins responsible for the endoribonuclease activities corresponding to 17 kDa and 35 
kDa as observed from endoribonuclease assays of gel filtration-purified fractions. 
Identification of the 17 kDa endoribonuclease was relatively straight forward as 
compared to the identification of the 35 kDa endoribonuclease. LC/MS/Mass 
Spectrometry data for the 17 kDa endoribonuclease in post heparin-sepharose purified 
sample suggested that it was a member of the RNase A family (RNase 1). Western blot 
86 
CHAPTER 3- IDENTIFICATION AND CHARACTERIZATION OF 35 kDa AND 
17 kDa HEPATIC ENDORIBONUCLEASES 
data using RNase 1 affinity-purified polyclonal antibody, conclusively demonstrated that 
RNase 1 was present in post-heparin-sepharose purified sample (Figure 12, lane 2) and in 
post-gel filtration elution volumes of 60-80 mL (10-20 kDa) (Figure 13-B, lane 3; Figure 
15-A, lane 5; Figure 16-A, lanes 6-8; Figure 17-A, lanes 6-8; Figure 18-A, lane 3). In 
addition, correlation between endoribonucleolytic activity in gel filtration elution 
fractions assayed using the standard endoribonuclease assay (Figure 13-A) and a subset 
of the same gel filtration elution fractions visualized with Western blot analysis (Figure 
13-B, lane 3) support the presence of RNase 1. 
Somewhat surprisingly, however, was the presence of multiple bands with 
molecular weights ranging from 30-37 kDa in several of the Western blot samples. Post 
heparin-sepharose sample probed with RNase 1 polyclonal antibody (Figure 12, lane 2) 
exhibit the predicted band at 17 kDa; however, there is a clear band present at 35 kDa. 
Gel filtration elution fraction volumes corresponding molecular weights of 30-40 kDa 
(Figure 13-B, lane 2; Figure 15-A, lane 2) probed with RNase 1 antibody clearly exhibit 
respective bands at 30 kDa and 37 kDa. In addition, anti-RNase 1 Western blot data of 
pooled gel filtration elution fraction volumes (40-50 mL), without treatment with 
reducing agent P-mercaptoethanol, exhibits a dark band of protein at 37 kDa (see Figure 
18-A, lane 1). 
Numerous factors may potentially account for these observations. The polyclonal 
nature of the commercial RNase 1 antibody source may contribute to cross-reaction with 
proteins with approximate molecular weights of 30 kDa and 37 kDa, respectively, present 
in post heparin-sepharose and post gel filtration-purified samples. Alternatively, there 
has been documented glycosylated (Barrabes et al. 2007; Ye et al. 2006) and dimeric 
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(Piccoli et al. 2000; Arnold et al. 1999) mammalian isoforms of RNase 1 -like proteins 
(within the RNase A superfamily) that migrate with molecular weights larger than the 
observed standard sizes of 12- 17 kDa (see Table 2, Chapter 1). This topic will be further 
discussed in section 3.2.4.2. 
V & 
Anti-
RNase 1 
Figure 12: Western blot analysis demonstrating the presence of pancreatic 
ribonuclease A (RNase 1). Lane 1 contains 2 ug of recombinant bovine pancreatic 
RNase A. Lane 2 contains 5 ug of pooled post heparin-sepharose purified sample. The 
blot was probed with commercially obtained RNase 1 polyclonal antibody (GeneTex 
Inc., San Antonio, TX). Molecular weight markers are shown to the left. 
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Figure 13: RNase A is present in partially purified rat liver extract from elution 
volumes following gel filtration chromatography. (A) Depicts an endoribonuclease 
assay of gel filtration column 9. 3.5 ml of post heparin-sepharose sample was loaded at a 
flow rate of 1 mL/min. 4.0 uL sample aliquots taken from fractions with the 
corresponding elution volumes were used for the standard endoribonuclease assay. Filled 
arrow indicates intact c-myc CRD RNA. Bracket and unfilled arrow indicates RNA 
decay products (B) Depicts Western blot analysis of pooled fractions from gel filtration 
column 9. Lane 1 contains 5 ug of recombinant bovine pancreatic RNase A protein. 
Lane 2 contains pooled gel filtration fractions (protein not quantifiable) corresponding to 
elution volumes 40-50 mL. Lane 3 contains pooled gel filtration fractions (protein not 
quantifiable) corresponding to elution volumes 40 -50 mL. 
In summary, substantial evidence gathered using LC/MS/Mass Spectrometry 
analysis, Western blot analysis, and endonuclease activity/protein identity correlation 
experiments using standard endoribonuclease assays and Western blotting, coupled with 
known endoribonucleolytic properties of the RNase A family of proteins, supports the 
notion that rat pancreatic ribonuclease A (RNase 1) is responsible for the observed 
endoribonuclease activity in gel filtration elution volumes 60-80 mL (10-20 kDa). 
89 
CHAPTER 3- IDENTIFICATION AND CHARACTERIZATION OF 35 kDa AND 
17 kDa HEPATIC ENDORIBONUCLEASES 
3.2.3 Identifying the 35 kDa Hepatic Endoribonuclease 
As previously stated, identification of the 35 kDa endoribonuclease proved to be 
extremely challenging. Evidence from LC/MS/Mass Spectrometry data, previously 
discussed in Chapter 2 (Table 8 protein band #2; Table 9 protein band #2) supported 
HADHSC (native molecular weight 32 kDa (see Figure 18-B, lane 1) as the 35 kDa 
protein present in both post-heparin-sepharose and gel filtration elution volumes 40-50 
mL (30-40 kDa) which best-correlated with endoribonucleolytic activity. Western blot 
data (Figure 18-B, lane 1) also confirmed the presence of HADHSC in gel filtration 
elution volumes 40-50 mL (30-40 kDa). However, native HADHSC possesses no known 
endonuclease activity. Furthermore, as shown in the standard endoribonuclease assay 
(Figure 14-A, lanes 4-9), the commercial recombinant HADHSC possesses no 
endoribonucleolytic activity in vitro. Standard endoribonuclease reaction cocktail 
mixtures (see Chapter 2, section 2.1.6) were used to test recombinant HADHSC. Based 
on this data, alternative routes were explored in an attempt to elucidate the identity of the 
35 kDa endoribonuclease. 
As shown in Figure 33 (lane 2), the presence of annexin III was confirmed using 
Western blot analysis. Unexpectedly, the observed molecular weight of annexin III was 
approximately 55-60 kDa; a significant discrepancy from the predicted molecular weight 
of 36.5 kDa (see Table 15). Several possible explanations for the observed differences 
include; post-translational modifications and multi-subunit/covalent interactions (non-
disulfide linkages). In addition, annexin III antibodies were rabbit polyclonal in origin, 
thus it is plausible that the commercially-obtained polyclonal antibody source may have 
bound non-specifically to one of the proteins present in post-heparin purified sample. 
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Recombinant commercial annexin III was also tested for endoribonucleolytic activity. As 
shown in Figure 14-B (lanes 4-6 and 10-12), annexin III did not exhibit 
endoribonucleolytic capabilities in vitro. Once again, standard endoribonuclease reaction 
cocktail mixtures outlined in Chapter 2, section 2.1.6, were used to test recombinant 
annexin III. 
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Nuclease (Post-Hep) 
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c-myc RNA MDR\RNA 
+ + 
'''"w -i»«Hwi wn^ m v c-myc CRD 
RNA 
1 2 3 4 5 6 7 8 9 4 5 8 9 10 11 12 
Figure 14: Recombinant HADHSC and annexin III do not exhibit endonuclease 
activity against c-myc CRD RNA. (A) Lanes 1 and 2 contain 1 uL (1U) of post-heparin-
sepharose-purified sample. Lane 3 contains c-myc CRD RNA alone. Lanes 4-9 contain 
increasing concentrations (0.5 uL, 1.0 uL, 1.5 uL, 2.0 uL, 2.5 uL, 3.0 uL, respectively) 
of recombinant HADHSC (stock concentration 3.5 mg/mL) (B) Lane 1 contains c-myc 
CRD RNA alone. Lanes 2 and 3 contain 2 uL (2U) and 4 uL (4U) post heparin 
sepharose purified sample, respectively, incubated with c-myc CRD RNA. Lanes 4-6 
contain 2 uL commercial recombinant annexin III (stock 1.5 mg/mL; GenWay Biotech., 
San Diego, CA) with c-myc CRD RNA. Lanes 2 and 3 contain 2 uL (2U) and 4 uL (4U) 
post heparin sepharose purified sample, respectively, incubated with c-myc CRD RNA. 
Lanes 4-6 contain 2 uL commercial recombinant annexin III (stock 1.5 mg/mL; GenWay 
Biotech., San Diego, CA). Lane 7 contains MDR 1 RNA alone. Lanes 8 and 9 contain 2 
uL (2U) and 4 uL (4U) post heparin-sepharose purified sample, respectively, incubated 
with MDR 1 RNA. Lanes 10-12 contain 2 uL commercial recombinant annexin III 
(GenWay Biotech., San Diego, CA). All reactions were performed for 7 minutes. 
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Figure 15: Western blots illustrating the presence of candidate endoribonucleases 
APE 1 and RNase 1. Elution fractions from gel filtration chromatography #10 were 
utilized (A) Depicts a blot of sequentially pooled elution fractions (lanes 1-5) probed with 
RNase 1 polyclonal antibody. Molecular weight markers (kDa) are shown to the left. (B) 
Depicts the same blot that has been stripped of RNase 1 antibody and re-probed with 
APE 1 (mouse monoclonal; Abeam Inc.). Molecular weight markers (kDa) are shown to 
the left. 
APE1 was the final recombinant protein candidate obtained in an attempt to 
determine the identity of the 35 kDa protein (s) responsible for endoribonuclease activity 
observed in gel filtration elution volumes 40-50 mL. Western blots that were probed for 
RNase 1 and subsequently stripped and re-probed for APE1 clearly demonstrate a protein 
band corresponding to a molecular weight of 34 kDa (Figure 15-B, lane 2; Figure 16-B, 
lane 6; Figure 17-B, lanes 4 and 5). It should be noted that the protein band exhibited in 
Figure 17-B, lane 1 is RNase 1 from the corresponding lane (1) in Figure 17-A. The 
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presence of this band in Figure 17-B was most likely due to incomplete stripping of the 
antibodies from the Western blot exhibited in Figure 17-A. 
In summary, it is evident that APE1 is present in gel filtration elution volumes 
corresponding to peak endoribonuclease activity (40-50 mL). Consequently, two sources 
of recombinant APE1 protein were requested. Initially, APE1 was obtained from Dr. 
Hickson at Oxford University. The second sample was obtained from Dr. Mitrasankar 
UTMB, Galvestin, TX). Experiments involving recombinant APE1 will be presented and 
discussed shortly (see section 3.5.2). 
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Figure 16: Western blots illustrating the presence of candidate endoribonucleases 
APE 1 and RNase 1. Elution fractions from gel filtration chromatography #11 were 
utilized (A) Depicts a blot of sequentially pooled elution fractions (lanes 3-8) probed with 
RNase 1 polyclonal antibody. Lane 1 contains 5 jag of recombinant bovine pancreatic 
RNase A. Lane 2 contains rainbow marker. Molecular weight markers (kDa) are shown 
to the left. (B) Depicts the same blot that has been stripped of RNase 1 antibody and re-
probed with APE 1 (mouse monoclonal; Abeam Inc.). Molecular weight markers (kDa) 
are shown to the left. 
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Figure 17: Western blots illustrating the presence of candidate endoribonucleases 
APE 1 and RNase 1. (A) Depicts a blot of sequentially pooled elution fractions (lanes 3-
8) probed with RNase 1 polyclonal antibody. Lane 1 contains 3 |xg of recombinant 
bovine pancreatic RNase A. Lane 2 contains rainbow marker. Molecular weight 
markers (kDa) are shown to the left. (B) Depicts the identical blot, stripped of RNase 1 
antibody and re-probed with APE1. Molecular weight markers (kDa) are shown to the 
left. 
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Anti-RNase 1 
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Figure 18: Western blot analysis confirming the presence of candidate 
endoribonucleases RNase A, HADHSC and Annexin III (A) Depicts a blot of pooled 
elution volumes from gel filtration column 13 that were resolved on a 15 % SDS-PAGE 
gel without prior treatment with reducing agent (P-mercaptoethanol). The blot was 
probed with polyclonal RNase 1 antibody. Lane 1 consists of a total volume of 2.0 mL 
from pooled fractions corresponding to elution volumes 40-50 mL (protein sizes of 30-40 
kDa). Lane 2 represents 5 ug of recombinant bovine pancreatic RNase A. Lane 3 
contains a total volume of 2.0 mL from pooled fractions corresponding to elution 
volumes 65-80 mL (protein sizes of 10-20 kDa). Molecular weight markers (kDa) are 
shown to the left. (B) Depicts the same blot that has been stripped of RNase 1 antibody 
and re-probed with HADHSC polyclonal antibody (GenWay Biotech., San Diego, CA). 
Molecular weight markers (kDa) are shown to the left. 
3.2.4 Characterizing Native and Recombinant Endoribonucleases 
To further distinguish between the 17 kDa and 35 kDa endoribonucleases and to 
confirm the suspected identities of the proteins identified in the previous sections (3.2.2 
and 3.2.3) several characterization experiments were performed. The first such 
experiment tested the sensitivity to RNase inhibitory protein (commercially available as 
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"RNasin"). The autoradiograph in Figure 19 demonstrates the results of this experiment. 
As expected in the absence of the inhibitory protein, pooled samples from gel filtration 
corresponding to protein sizes 30-40 kDa (lanes 3-6) and 10-20 kDa (lanes 10 and 11), 
respectively exhibit endoribonuclease activity. In the presence of 1 U of RNasin (per 
reaction), endoribonuclease activity is significantly diminished for both gel filtration 
pooled samples (30-40 kDa, lanes 7-9 and 10-20 kDa, lanes 12-14). It should be noted 
that although RNasin is used in reaction mixtures for standard endoribonuclease assays 
(0.5 U/reaction; Chapter 2, section 2.1.6) and both 17 kDa and 35 kDa endoribonucleases 
are sensitive to RNasin, there does not appear to be inhibition of endonucleolytic activity. 
The most likely explanation for this is the ratio of inhibitory protein (RNasin) to 
endoribonuclease present in reaction mixtures. Moreover, the concentration of 
endoribonuclease present in purified samples was sufficiently high enough to mask the 
inhibitory effects of 0.5U RNasin used in the reaction cocktail mixture. 
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Figure 19: Sensitivity of native 35 kDa and 17 kDa endoribonucleases to 
commercial recombinant RNasin (Ribonuclease Inhibitor Protein). All assays were 
performed using 5'- y 32P-radiolabeled c-myc CRD (30,000 cpm/lane). Reactions were 
incubated for 5 minutes. RNA was resolved on a 12% denaturing polyacrylamide/7M 
urea gel. Lanes 1 and 2 contain no enzyme. Lanes 3-6 contain 5 uL aliquots (1U 
enzyme) from pooled fractions corresponding to elution volumes 40-50 mL (protein size 
of 30-40 kDa) without RNasin. Lanes 7-9 contain 1U RNasin and 5 uL aliquots (1U) 
from pooled fractions corresponding to elution volumes 40-50 mL (protein size of 30-40 
kDa). Lanes 10 and 11 contain 3 uL aliquots (3.0U) from pooled fractions corresponding 
to elution volumes of 65-80 mL (protein sizes of 10-20 kDa) without RNasin. Lanes 12-
15 contain 3 uL aliquots (3.0U) from pooled fractions corresponding to elution volumes 
of 65-80 mL (protein sizes of 10-20 kDa) with 1U of RNasin. Filled arrow indicates 
intact c-myc CRD RNA. Bracket and unfilled arrow indicates RNA decay products 
3.2.4.1 Kinetic Analysis 
Optimal enzyme concentrations for both the 17 kDa and 35 kDa native enzymes 
was found to correspond to the middle of DLU/time versus [Enzyme] linear regression 
plots (Figure 21-1(A) and 21-1(B)). Approximately 1U of post gel filtration-purified 17 
kDa native enzyme and 0.5U of post gel filtration-purified 35 kDa native enzyme were 
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used for subsequent kinetic studies. A comparative look at the autoradiographs for the 17 
kDa and 35 kDa enzymes (Figure 20, lanes 14 and 4, respectively), demonstrate that at 
the aforementioned concentrations roughly half of the substrate is decayed in a 5 min 
reaction using the 17 kDa enzyme and in an 8 min reaction using the 35 kDa enzyme. 
Analysis of the native 17 kDa and 35 kDa enzymes, using various substrate 
concentrations (Figure 21-2, (A) and (B), respectively), illustrates that both enzymes 
exhibit Michaelis Menten-type reaction kinetics. Figure 21-2 (A and B) represents assays 
of sample 5'-radiolabeled oligonucleotide substrate concentrations over various stop-time 
periods for the 35 kDa native enzyme. Figure 21-2 (C and D) represents sample 
oligonucleotide substrate concentrations over various stop-time periods for the 17 kDa 
native enzyme. Figure 21-2 (B and C), lanes 1-5, demonstrate that reaction rates as a 
function of time (measured as DLU intensity of decay products) for the 35 kDa native 
enzyme remain relatively constant using the highest subtrate concentrations (1000 pM 
and 5000 pM), respectively. A similar finding for the native 17 kDa endoribonuclease, at 
5000 pM substrate concentration, is shown in Figure 21-2 (D), lanes 1-5. 
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Figure 20: Optimizing working concentration ranges of 17 kDa and 35 kDa native 
enzyme for kinetic analysis. Autoradiographs using 5'-y32P-radiolabeled oligonucleotide 
substrate (all lanes approximately [500 pM\) and resolved on 12% denaturing 
polyacrylamide/7M urea gels. Reaction incubation times are shown on the right. Lanes 1 
and 11 contain oligonucleotide alone. Lanes 2 and 12 contain (3 uL) 3 U post heparin-
sepharose purified enzyme. Lanes 3-10 contain varying concentrations of 35 kDa native 
enzyme. Lanes 13-20 contain varying concentrations of 17 kDa native enzyme. Filled 
arrows represent intact substrate; unfilled arrows represent decay products. 
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Figure 21-1: Linear regression analysis of optimization experiments. All gels 
represent stop-time assays using different enzyme concentrations (A) Linear regression 
analysis using various concentrations of native 35 kDa enzyme. Incubation times were 5, 
8 and 12 min, respectively (B) Linear regression analysis using various concentrations of 
native 17 kDa enzyme. Incubation times were 5, 8 and 10 min, respectively. 
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Figure 21-2: A subset of sample stop-time assays used to obtain data for Michaelis 
Menten kinetic analysis of native 35 kDa and 17 kDa enzymes. Autoradiographs were 
performed using 5'-y 32P-radiolabeled oligonucleotide substrate and resolved on 12% 
denaturing polyacrylamide/7M urea gels. (A) Assay of native 35 kDa enzyme using 1000 
pM concentration of 5'-y32P-radiolabeled oligonucleotide per lane. Lanes 1-5 represent 4, 
8, 10, 12 and 15 minute incubation periods, respectively. (B) Assay of native 35 kDa 
enzyme using 5000 pM concentration of 5'-y32P-radiolabeled oligonucleotide per lane. 
Lanes 1-5 represent 4, 8, 10, 12 and 15 minute incubation periods, respectively. (C) 
Assay of native 17 kDa enzyme using 750 pM concentration of 5'-y32P-radiolabeled 
oligonucleotide per lane. Lanes 1-5 represent 2, 4, 6, 8 and 10 minute incubation periods, 
respectively. (D) Assay of native 17 kDa enzyme using 5000 pM concentration of 5'-
y32P-radiolabeled oligonucleotide per lane. Lanes 1-5 represent 2, 4, 6, 8 and 10 minute 
incubation periods, respectively. Filled arrows represent intact substrate; unfilled arrows 
represent decay product. 
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Figure 21-3: Linear regression analysis of stop-time kinetic assays using varying 5'-
radiolabeled oligonucleotide substrate concentrations Substrate concentrations are 
color-coded and shown in the bottom right corner of the plots. (A) Results for stop-time 
assays at 2, 4, 6, 8 and 10 min for eleven respective substrate concentrations using the 
native 17 kDa enzyme (B) Results for stop-time assays at 4, 8, 10, 12 and 15 min for ten 
respective substrate concentrations using the native 17 kDa enzyme. 
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Figure 21-4: Nonlinear regression analysis of Michaeiis Menten kinetics for the 
native 35 kDa and 17 kDa enzymes (A) Was generated from the slope values at the ten 
respective substrate concentrations in Figure 21-3(B). (B) Was generated from the slope 
values at the eleven respective substrate concentrations in Figure 21-3(A). 
Figure 21-3 (A) and 21-3 (B) display reaction rates (DLU intensity versus time of 
incubation) for the range of substrate concentrations used for both the native 17 kDa and 
35 kDa endoribonucleases. The data for the values of the slopes from these linear 
regression analyses were subsequently plotted as a function of substrate concentration. 
The results of nonlinear regression analysis using a Michaeiis Menten curve fit 
(KaleidaGraph 3.6.2) for the native 35 kDa and 17 kDa enzymes is shown in Figure 21-4 
(A) and (B), respectively. 
With increasing oligonucleotide substrate concentration, both the 17 kDa and 35 
kDa endoribonucleases exhibited saturation kinetics. Moreover, as substrate RNA is 
increased to very high levels, the enzymes become saturated and the rate of decay 
product approaches a constant rate. This is illustrated by a decrease in the slope values 
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exhibited in Figure 21-3 (A) and 21-3 (B) and by a horizontal flattening of the curves in 
Figure 21-4 (A) and 21-4 (B). As the enzymes become saturated with substrate (at very 
high substrate concentrations), Vmax is approached. However, theoretical Vmax values are 
never actually reached. Instead, the characteristic velocity (v) value for the enzymes is 
defined by the substrate concentration [5'-radiolabeled oligonucleotide substrate] equal to 
half of the maximum rate (Vmax/2). Moreover, Km is the concentration of substrate that 
leads to half-maximal enzyme velocity. This value is is termed the Michaelis Menten 
constant. It should also be noted that at Vmax other factors such as pH, and temperature 
may influence the rate of reaction. Km values for the 17 kDa and 35 kDa 
endoribonucleases were 381.82 pM and 75.593 pM, respectively. Vmax for the native 17 
kDa endoribonuclease was 763.64pM min"1. Vmax for the native 35 kDa endoribonuclease 
was 151.2/?M min"1. 
It should be noted that error bars were not included in Figure 21-3 (A and B), and 
Figure 21-4 (A and B) because duplicate experiments using the substrate values shown 
(see Figure 21-3 (A) and 21-3 (B), were not performed, thus no standard deviation values 
were calculated. Additionally, Vmax (±) and Km (±) values were not included as standard 
deviation values were not calculated. Future experiments designed to fully characterize 
reaction kinetics of the native 17 kDa and 35 kDa enzymes should repeat 
endoribonuclease assays two or three times for all substrate concentrations chosen. This 
will enable calculation of standard deviation values and will improve the accuracy of 
Vmax and Km values. 
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3.2.4.2 Assessing Structural Features of the Native 35 kDa Endoribonuclease 
Previous results from Western blots demonstrate that RNase 1 polyclonal 
antibody cross-reacts with proteins exhibiting molecular weights of 30 kDa and 37 kDa, 
respectively (Figure 12, lane 2; Figure 13-B, lane 2; Figure 15-A, lane 2). There are three 
possibilities to account for such observations: (i) The 17 kDa rat pancreatic RNase A is a 
monomeric N-glycosylated protein, (ii) 17 kDa rat pancreatic RNase A forms a dimer, or 
(iii) an RNase 1 -like protein within the the molecular weight range of 30-40 kDa can be 
detected by the RNase 1 polyclonal antibody source used. To test the first possibility, 
post heparin-sepharose sample was pre-treated overnight with N-glycosidase F and 
subsequently purified with gel filtration chromatography. Figure 22 clearly demonstrates 
endoribonuclease activity in elution volumes 45-53 mL (proteins in molecular weight 
ranges of 25-40 kDa), and elution volumes 62-80 mL. Therefore, it is not likely that the 
35 kDa endoribonuclease activity is due to an N-glycosylated isoform of rat pancreactic 
RNase A. Interestingly, there appears to be endonucleolytic activity in elution volumes 
38- 40 mL (corresponding to proteins within the molecular weight range of 60-70 kDa). 
These results were somewhat surprising given that endonucleolytic activity had not 
previously been observed in elution volumes 38-40 mL. It was concluded that these 
observations were most likely the result of elution fraction contamination prior to 
performing endoribonuclease assays. 
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Figure 22: Assessing post-translational modifications of native 35 kDa 
endoribonuclease using recombinant N-glycosidase F. Autoradiograph depicting a 
standard endoribonuclease assay using 5'- y 32P-radiolabeled c-myc CRD 1705-1886 of 
elution fractions from gel filtration chromatography. 3.0 mL of post-heparin sepharose 
sample was incubated overnight at 30°C with 100 U of N-glycosidase F enzyme mixture 
(100U; 1 U = 1 \iL) prior to loading on gel filtration column. 4 uL aliquots (0.75U 
enzyme) from 0.5 mL fractions corresponding to the elution volumes shown above each 
lane were utilized for the endoribonuclease assay. Intact c-myc CRD probe is shown with 
a filled arrow. RNA decay products are shown with a bracket and unfilled arrow. 
To test the second possibility, post heparin-sepharose purified sample was 
incubated with a final concentration of 250 mM DTT to determine if the 35 kDa 
endoribonuclease was monomeric or dimeric. If the 35 kDa endoribonuclease were 
dimeric, one would expect treatment with DTT to disrupt subunit linkages (disulfide 
bridging). Consequently the apparent molecular weight of endoribonuclease activity (if 
individual subunits retained enzyme activity) would become representative of individual 
subunit size. Moreover, one would expect a disappearance or a significant decrease in the 
intensity of endoribonuclease activity in elution volumes 40-50 mL (30-40 kDa 
molecular weight range). 
105 
CHAPTER 3- IDENTIFICATION AND CHARACTERIZATION OF 35 kDa AND 
17 kDa HEPATIC ENDORIBONUCLEASES 
As illustrated in the autoradiograph below (Figure 23), two distinct 
endoribonucleolytic activities are still observed. The larger activity suggests that 
endoribonuclease activity is present in elution volumes 41-49 mL (molecular weight 
range of 30 kDa-40 kDa) and elution volumes 63-82 mL (molecular weight range of 12-
20 kDa). The continued presence of endoribonuclease activity (molecular weight range 
of 30-40 kDa) indicates that the protein responsible for 35 kDa endoribonuclease activity 
is most likely monomeric. Given the evidence presented, this hypothesis appears to be 
most plausible. 
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Figure 23: Assessing the properties of native 35 kDa endoribonuclease using DTT. 
Autoradiograph depicting a standard endoribonuclease assay using 5'- y P-radiolabeled 
c-myc CRD 1705-1886 of elution fractions from gel filtration chromatography. 3.0 mL 
of post heparin-sepharose sample was incubated for 60 minutes at 4°C in the presence of 
250 mM DTT. 4 uL aliquots from 0.5 mL fractions corresponding to the elution volumes 
shown above each lane were utilized for the endoribonuclease assay. Intact c-myc CRD 
probe is shown with a filled arrow. RNA decay products are shown with a bracket and 
unfilled arrow. 
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3.2.5 Recombinant APE1 
Recombinant APE1 was obtained from a lab in Texas and from the Hickson lab in 
the UK. Following dialysis, recombinant APE1 was assayed using standard 
endoribonuclease assay protocol. Figure 24-A and 24-B depict the results of the assays. 
It is evident from Figures 24-A, lane 4 (Hickson's lab, UK) and 24-B, lanes 7-9 that both 
recombinant APE1 samples obtained exhibit endoribonuclease activity. Cleavage sites 
generated by recombinant APE1 samples appear to exhibit similarity to both post 
heparin-sepharose sample (Figure 24-B, lanes 2-6) and pooled post-gel filtration elution 
volumes 40-50 mL (30-40 kDa). In addition, recombinant samples of APE1 appear to 
generate additional cleavage products near the bottom of the gels (Figure 24-A, lane 4; 
Figure 24-B, lanes 7-9); however, sequencing gel analysis (shown in Figure 24-C) was 
required to definitively map endonucleolytic-cleaved RNA products. 
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Figure 24: Endoribonuclease assays illustrating the ability of recombinant APE 1 to 
endonucleolytically-cleave c-myc CRD RNA in vitro. All assays were carried out using 
5'- y P-radiolabeled c-myc CRD. Reactions were incubated for 5 minutes (A) 
Autoradiograph of a standard endoribonuclease assay using pooled post gel filtration 
purified sample and recombinant APE1 protein (obtained from Hickson's lab, UK). Lane 
1 contains c-myc CRD RNA alone. Lanes 2 and 3 contain 5 uL of pooled gel filtration 
elution volumes 40-50 mL (protein sizes 30-40 kDa). Lane 4 contains 1 uL dialyzed 
recombinant APE1 (stock 4 mg/mL). Intact c-myc CRD probe is shown with a filled 
arrow. RNA decay products are shown with a bracket and unfilled arrow. (B) 
Autoradiograph of a standard endoribonuclease assay using pooled post heparin-
sepharose purified sample and recombinant APE1 protein (Sankar's lab, TX). Lane 1 
contains c-myc CRD RNA alone. Lanes 2-6 contain 1 uL (1U), 2 uL (2U), 3 uL (3U), 4 
uL(4U) and 5 uL (5U), respectively, of post heparin-sepharose purified sample. Lanes 7-
9 contain 1 uL, 2 uL, 3 uL recombinant APE1 respectively (stock 0.3 mg/mL). 
Although endoribonuclease assays using recombinant APE1 samples exhibited 
endoribonucleolytic activity (Figure 24-A, lane 4; Figure 24-B, lanes 7-9) the purity of 
the recombinant samples to date was unknown. The possibility of contamination, in 
particular co-purification of RNases during recombinant APE1 preparation, could 
potentially have occurred. Figures 25-A and 25-B demonstrate the assessment of 
recombinant APE1 sample purity. As shown in Figure 25-A, lanes 2 and 3, a large 
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protein band is present corresponding to an approximate molecular weight of 33-35 kDa. 
Western blots of recombinant APE1 samples shown in Figure 25-B (lanes 1 and 2), 
clearly demonstrates the presence of a protein band corresponding to a molecular weight 
of approximately 34 kDa. The blot was probed with anti-APEl monoclonal antibody, 
thus it was concluded that the protein bands exhibited at 34 kDa were indeed recombinant 
APE1. Results to date using two different sources of recombinant APE1 strongly suggest 
that APE1 is the protein responsible for observed endoribonuclease activity exhibited by 
the 30-40 kDa purified native enzyme; however, the immunodepletion experiments 
presented and discussed shortly (see section 3.2.7) were used to further confirm these 
results. 
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Figure 25: Assessing the purity of recombinant APE 1 samples. (A) 15% SDS-
PAGE stained with Coomassie Brilliant Blue. Lane 1 contains low molecular weight 
protein marker. Lane 2 contains 5 |ug of recombinant APE1 (Dr. Sankar's lab, TX). 
Lane 3 contains 1 \ig recombinant APE1 (Hickson's lab, UK). Molecular weight marker 
sizes (M) are shown to the left of the lane 1 (B) Western blot depicting recombinant 
APE1 samples probed with mouse monoclonal APE1 antibody. Lane 1 contains 3 |ig of 
recombinant APE1 (Dr. Sankar's lab, TX). Lane 2 contains 3 (xg of recombinant APE1 
(Hickson's lab, UK). Molecular weight markers are shown to the left. 
*Note: Western blot shown in Figure 25-B does not represent the SDS-PAGE gel shown 
in Figure 25-B 
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3.2.5.1 Mapping RNA Cleavage Products Generated by Native 35 kDa, 
17 kDa and Recombinant Endoribonucleases 
A comparison of the RNA cleavage (decay) products generated with purified 
native enzyme from post heparin-sepharose, post gel filtration chromatography, bovine 
pancreatic RNase A and recombinant APE 1 are shown in Figure 26 panels A, B and C. 
The cleavage profile exhibited by post-heparin sepharose purified sample in the presence 
of c-myc CRD RNA 1705-1886 presented in Figure 26-A, lane 3 and Figure 26-B, lane 9 
was mapped according to previously reported data (Bergstrom et al. 2006) and using 
RNase Tl digest of c-myc CRD RNA 1705-1886 (Figure 26-A, lane 1; Figure 26-C, lane 
1). 
RNA cleavage products from post heparin-sepharose (Figure 26-A, lane 3; Figure 
26-B, lane 9), gel filtration 10-20 kDa (Figure 26-B, lanes 10-11), gel filtration 30-40 
kDa (Figure 26-A, lanes 4-6; Figure 26-B, lanes 12-13; Figure 26-C, lanes 4-5), and 
recombinant bovine pancreatic RNase A (Figure 26-B, lane 8) exhibited a high degree of 
similarity. Post heparin-sepharose-purified sample (Figure 26-A, lane 3; Figure 26-B, 
lane 9) and pooled gel filtration elution sample corresponding to proteins in the molecular 
weight range of 10-20 kDa (Figure 26-B, lanes 10-11) appeared to generate identical 
cleavage products. Recombinant bovine pancreatic RNase A appeared to generate nearly 
identical cleavage products (Figure 26-B, lane 8) with the exception of an additional 
cleavage product; (illustrated with the bracket, Figure 26-B, lane 8) as compared to both 
post heparin-sepharose and post gel filtration (10-20 kDa) samples. 
Pooled gel filtration elution volumes corresponding to proteins in the molecular 
weight range of 30-40 kDa (35 kDa endoribonuclease) (Figure 26-A, lanes 4-6; Figure 
26-B, lanes 12 and 13; Figure 26-C, lanes 4 and 5) produces several RNA decay products 
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identical to those observed in post-heparin, post gel filtration (10-20 kDa) and to that of 
recombinant bovine pancreatic RNase A. The major differences being that the 35 kDa 
produces fewer decay products and exhibits slightly different dinucleotide cleavage site 
preference. As shown in Figure 26-A (lanes 4-6) and Figure 26-B (lanes 12 and 13), 
native 35 kDa endoribonuclease appears to preferentially cleave the dinucleotide UA 
1751 shown by asterisks in Figure 26-A and -B. In addition, native 35 kDa 
endoribonuclease appears to preferentially cleave dinucleotide CA, 1771 and dinucleotide 
UA, 1773. 
If APE 1 is indeed the protein that exhibited endonuclease activity in native pooled 
gel filtration elution volumes (protein sizes 30-40 kDa), one would expect RNA cleavage 
fragments to have exhibited a high degree of similarity to decay products produced by 
native 35 kDa endoribonuclease. RNA decay products produced by recombinant APE1 
(Figure 26-C, lanes 5-7) and native 35 kDa endoribonuclease (Figure 26-A, lanes 4-6; 
Figure 26-B, lanes 12 and 13; Figure 26-C, lanes 3 and 4) exhibited one identical 
cleavage site. As illustrated with the un-filled arrow in Figure 26-C, both native 35 kDa 
endoribonuclease and recombinant APE1 preferentially cleave dinucleotide 1751 UA. 
This data does not conclusively prove that APE1 is the protein responsible for 35 kDa 
endoribonucleolytic activity in native extract; however, it does demonstrate that both 
recombinant APE1 and native 35 kDa endoribonuclease preferentially cleave 5'- y 32P-
radiolabeled c-myc CRD RNA at dinucleotide 1751 UA. 
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Figure 26: Mapping cleavage products generated with native endoribonuclease 
samples, recombinant RNase A and recombinant APE1. All mapping experiments 
were resolved on 12% denaturing polyacrylamide/7M urea sequencing gels. (A) 
Endoribonuclease assay using 5'-y32P-radiolabeled c-myc CRD RNA. Reactions were 
incubated for 7 minutes. Lane 1 contains RNase Tl digest of c-myc CRD RNA 1705-
1886. Lane 3 contains 2 uL (2U) of post heparin-sepharose purified sample. Lanes 4-6 
contain 4 uL (0.75U), 3 uL (0.6U), and 2 uL (0.4U) of pooled gel filtration elution 
volumes 40-50 mL (protein sizes 30-40 kDa), respectively. Tl digests are labeled to the 
left of lane 1. (B) Endoribonuclease assay using 5'-y32P-radiolabeled c-myc CRD. 
Reactions were incubated for 5 minutes. Lane 8 contains 1U (1 U=l uL) bovine 
pancreatic RNase A. Lane 9 contains 3 uL of pooled post heparin sepharose purified 
sample. Lanes 10 and 11 contain 1 uL (1U) and 3 uL (3U), respectively, from pooled 
fractions corresponding to elution volumes 65-80 mL (protein sizes of 10-20 kDa). 
Lanes 12 and 13 contain 4 uL (0.75U) and 5 uL (1U), respectively, of pooled gel 
filtration elution volumes 40-50 mL. (C) Autoradiograph of a standard endoribonuclease 
assay using 5'-y32P-radiolabeled c-myc CRD RNA. Reactions were incubated for 10 
minutes. Lane 1 contains RNase Tl digest of 5'-y32P-radiolabeled c-myc CRD 1705-
1886. Lanes 4 and 5 contain 3 uL (0.6U) and 4 uL (0.75U), respectively, of pooled gel 
filtration elution volumes 40-50 mL. Lanes 5-7 contain 1 uL, 2 uL, and 3 uL, 
respectively, of recombinant APE1 sample obtained from Dr. Sankra's lab (Texas) (stock 
0.3 mg/mL). Tl digests are labeled to the left of lane 1. 
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3.2.6 Electrophoretic Mobility Shift Assays 
EMSA experiments were designed to assess the physical interaction between 
respective recombinant samples of HADHSC, APE1 and 5'-y32P-radiolabeled c-myc CRD 
1705-1886 RNA. EMSA protocols were adopted from methods previously used by 
Sparanese and Lee (2007) and Prokipcak et al. (1994). Optimization of binding 
conditions was based on the in vitro interaction between CRD-BP and 5'-y P-
radiolabeled c-myc CRD 1705-1886 RNA. The optimal reaction conditions were 
identical to those previously outlined by Sparanese and Lee (2007). Optimum binding 
conditions were measured by the intensity of binding complexes. Figure 27, lanes 12 and 
13, illustrate an 'optimal' binding interaction between CRD-BP and 5'-y32P-radiolabeled 
c-myc CRD 1705-1886 RNA. Optimal binding conditions for CRD-BP/5'-y32P-
radiolabeled c-myc CRD 1705-1886 RNA were utilized for EMSA experiments using 5'-
y32P-radiolabeled c-myc CRD 1705-1886 RNA /HADHSC and APE1, respectively. 
Previous work by Sparanese and Lee (2007) demonstrated that recombinant forms of 
Rpp20, Rpp21 and Rpp40 do not bind 5'-y32P-radiolabeled c-myc CRD 1705-1886 RNA 
in vitro. As such, recombinant forms of Rpp20, Rpp21, and Rpp40 were utilized as 
negative controls in these experiments. Figure 27 (lanes 9, 10 and 11) and Figure 28 
(lanes 5, 6 and 7) demonstrate that at 500 nM Rpp 20, 21 and 40 do not bind 5'-y32P-
radiolabeled c-myc CRD 1705-1886 RNA. 
Figure 27 illustrates the binding of HADHSC to 5'- y 32P-radiolabeled c-myc CRD 
1705-1886 RNA. At lowest nanomolar concentrations (100 nM, lane 8), a lower binding 
complex is formed. As nanomolar concentrations of HADHSC are increased (200nM, 
300nM, 500nM; lanes 7, 6 and 5 respectively) a second binding complex is formed and 
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the intensity of the lower binding complex is greatly reduced. At highest nanomolar 
concentrations of HADHSC (750 nM, 1000 nM, 1500 nM; lanes 4, 3, and 2, 
respectively), the lower binding complex disappears whereas the larger binding complex 
is enhanced. It should be noted, however, that even at highest nanomolar concentrations 
of HADHSC (1500 nM, lane 2) the intensity of the larger complex is much lower when 
compared to that of the interaction between CRD-BP (2000 nM) and c-myc CRD RNA 
(lanes 12 and 13). 
c 
f_g_4Wf 
V ff$$#$$ / / 
Bound [ 
nM 
*M 
Unbound I , ...ittttt...,..^ „ , J 
' :»:;::.;':. i l X 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 
Figure 27: HADHSC is capable of binding to c-myc CRD RNA in vitro. Lanes 1 and 
14 contain c-myc CRD RNA alone. Lanes 13 and 14 contain 2000 nanomolar (nM) 
dialyzed CRD-BP as positive control. Lanes 9-11 contain 500 nM of non-RNA binding 
proteins Rpp 20, 21 and 40, respectively, as negative control. Lanes 2-8 contain varying 
nanomolar (nM) concentrations of HADHSC. 
As demonstrated in Figure 28, lane 4, 8 and 9, at 1000-2500 nM, recombinant 
APE1 binds 5'-y32P-radiolabeled c-myc CRD 1705-1886 RNA. Two binding complexes 
are observed for all micromolar concentrations utilized (1 uM, lanes 4; 2 uM, lane 8; 2.5 
uM, lane 9). Somewhat surprisingly, the intensity of the unbound substrate RNA in lanes 
containing recombinant APE1 (Figure 28, lanes 4, 8 and 9) is significantly diminished. 
The migration of most c-myc substrate RNA appears to have been retarded in the smallest 
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complex. By comparison, little substrate RNA appears in the larger complex. Given the 
relative uniformity in intensity of the larger complex across the range of micromolar 
concentrations utilized, the presence of the larger complex may represent non-specific 
protein/protein interaction, non-specific protein/RNA interaction or a combination of 
both. To determine if the c-myc CRD-1705-1886/HADHSC and c-myc CRD-1705-
1886/APE1 associations are specific, competition studies using unlabeled competitor 
RNA at various molar ratios, would be required. 
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Figure 28: Recombinant APE1 is capable of binding to c-myc CRD RNA in vitro. 
All lanes were incubated with 5'- y 32P-radiolabeled c-myc CRD 1705-1886 RNA (50,000 
cpm/lane). Lanes 1 and 10 contain c-myc CRD RNA alone. Lanes 2 and 3 contain 1.0 
uM (micromolar) and 1.5 uM of dialyzed CRD-BP, respectively, as positive control. 
Lanes 5-7 contain 500 nanomolar (nM) non-RNA binding proteins Rpp 20, 21 and 40, 
respectively, as negative control. Lane 4 contains 1.0 uM recombinant APE 1 (Hickson's 
lab, UK). Lane 8 and 9 contain 2.0 uM and 2.5 uM APE 1 (Sankar's lab, TX), 
respectively. Concentrations (uM) are shown above each lane. 
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3.2.7 Immunodepletion of Native 35 kDa Endoribonuclease Activity 
To further confirm the identity of the 35 kDa endoribonuclease, immunodepletion 
experiments of native 35 kDa endoribonuclease activity were performed with a PIERCE 
Seize X Protein A Immunoprecipitation kit. c-myc CRD RNA was the primary substrate 
RNA utilized for endoribonuclease assays of immunodepletion experiments. Of note, 
due to its availability, MDR1 RNA was utilized as a comparison RNA substrate in one 
endoribonuclease assay (see Figure 29). 
An autoradiograph of the results from the first immunodepletion experiment using 
the PIERCE Seize X Protein A Immunoprecipitation kit is shown in Figure 29. The spin 
column was constructed using anti-APEl monoclonal antibodies. 50 jag of anti-APEl 
antibody was cross-linked to the spin column matrix as previously described (section 
3.1.7). 
Spin column flow-through (FT, lane 3) and pooled wash fractions (Wash, lane 4) 
exhibit a significant decrease in endonuclease activity. A significant increase in 
endonuclease activity is once again observed in elution fractions 1 and 2 (lanes 5 and 6). 
These results suggest that the first attempted immunodepletion of native heparin-
sepharose extract, using monoclonal antibodies againt recombinant APE1, was 
successful. Moreover, an endoribonuclease present in post heparin-sepharose purified 
sample was bound to the matrix containing cross-linked anti-APEl monoclonal 
antibodies. 
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Figure 29: Autoradiograph depicting successful immunodepletion of native heparin-
sepharose purified extract using APE1 monoclonal antibodies. The endoribonuclease 
assay was performed using 5'- y 32P-radiolabeled MDR 1 RNA. Lanes 1 and 7 contain 
MDR 1 RNA alone. Lane 2 contains 2 uL (2U) post heparin-sepharose purified sample, 
prior to loading onto spin column. Lane 3 contains a 4 uL aliquot of flow through 
fraction 1. Lane 4 contains a 4 uL aliquot from spin column pooled wash (fractions 2 
and 3). Lanes 5 and 6 contain 4 uL aliquots from elution fractions 1 and 2 respectively. 
A second immunodepletion experiment also using a PIERCE Seize X Protein A 
Immunoprecipitation spin column was performed. An autoradiograph of the experiment 
is shown in Figure 30. Post heparin-sepharose purified sample pre-load (lanes 1 and 2) 
exhibited strong endonuclease activity. Pooled flow-through fraction 1 and wash flow #2 
and #3 is shown in 5. There was a clear reduction in observed endonuclease activity in 
the pooled flow through/wash sample (Figure 30; compare lane 5 to lanes 3 and 4). 
Elution fractions were hallmarked by the reappearance of strong endonuclease activity 
MDRU 
RNA 
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(lanes 6-8). Elution fraction 1 (Figure 30, lane 6) exhibited strongest activity. Elution 
fractions 2 and 3 (Figure 30, lanes 7 and 8, respectively) contained endonuclease activity; 
however, it was significantly diminished when compared to elution fraction 1 (Figure 30, 
lane 6). It should be noted that although endonuclease activity was diminished in pooled 
flow through/wash fractions (lane 4), activity remained readily apparent. 
There are two possible explanations for this observation. First, during loading of 
the heparin-sepharose sample, the antibodies present on the spin column matrix may have 
become saturated with protein present in the heparin-sepharose sample load. 
Consequently, unbound endoribonuclease would have passed directly through the 
column. Alternatively (bearing in mind that post heparin-sepharose sample contained 
two distinct (17 kDa and 35 kDa) endoribonuclease activities as previously shown in gel 
filtration chromatographic purification experiments; Chapter 2, Figure 6-A, 6-B and 
Figure 7-A), previous results suggested that the 17 kDa (RNase 1) and 35 kDa 
endoribonuclease (APE1) were distinct proteins. Considering that APE1 monoclonal 
antibodies were used to construct the immunoprecipitation spin column, it was expected 
that the 17 kDa RNase 1 protein in heparin-sepharose purified sample would not bind to 
the column matrix. Consequently, it is not surprising that endonuclease activity is 
present in pooled wash and flow through fractions (Figure 30; lane 5). 
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Figure 30: Autoradiograph depicting successful immunodepletion of native 
heparin-sepharose purified extract using APE1 monoclonal antibody. The standard 
endoribonuclease assay was performed using 5'-radiolabeled c-myc CRD RNA (A) 
Immunodepletion of native 35 kDa endoribonuclease activity. Lanes 1 contains 1 uL 
(1U) of post heparin sepharose purified sample (positive control). Lane 2 contains c-myc 
CRD RNA alone. Lanes 3 and 4 contain 2 ]xL (2U) and 3 uL (3U) aliquots of post 
heparin-sepharose purified sample (spin column pre-load). Lane 5 contains 4 uL of 
pooled flow through 1 and flow through 2 (wash). Lanes 6, 7 and 8 contain 4 ^L aliquots 
of elution fractions 1, 2 and 3, respectively. 
A third spin column (Figure 31-B) was constructed using syntaxin 18 polyclonal 
antibodies. Thirty |ig of syntaxin 18 polyclonal antibody was cross-linked to the protein 
A spin column matrix as previously outlined (Chapter 3, section 3.1.7). This column was 
constructed to function as a negative control. A Western blot of the third 
immunodepletion experiment was also performed (see Figure 32). 
Figure 31-A illustrates successful immunodepletion of post gel filtration (30-40 
kDa) purified native extract. This was perhaps the most clear-cut evidence supporting 
successful immunodepletion of post gel-filtration (30-40 kDa) purified native extract. 
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Flow-through/wash lanes (Figure 31-A, lanes 6 and 7) were marked by the absence of 
endonuclease activity. Elution fraction 1 (Figure 31-A, lane 8) illustrates the re-
appearance of endonuclease activity. Elution fraction 2 (Figure 31-A, lane 9) also 
exhibited strong activity; however, it was slightly diminished when compared to elution 
fraction 1 (compare lanes 8 and 9). 
The control column shown in Figure 31-B, demonstrated that heparin-sepharose 
sample activity was not immunodepleted with syntaxin 18 polyclonal antibody. The flow 
through (FT, Figure 31-B, lane 1) and pooled wash fraction two and three (Wash, Figure 
31-B, lane 3) displayed strong endonuclease activity with similar intensity to post 
heparin-sepharose column pre-load (Figure 31-B, compare lanes 1, 2 and 3). In contrast, 
elution fractions 1 and 2 (Figure 31-B, lanes 4 and 5, respectively) did not exhibit 
endonuclease activity. Results from the control column demonstrated that 
immunodepletion of endoribonuclease activity observed in previous immunodepletion 
columns (Figures 29, 30, 31-A) was produced specifically by the presence of anti-APEl 
monoclonal antibodies. 
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Figure 31: Successful immunodepletion of native 35 kDa endoribonuclease activity. 
(A) Lane 1 contains c-myc CRD RNA alone. Lanes 2 and 3 contain 2 uL (2U) and 3 uL 
(3U) of post heparin sepharose purified sample, respectively. Lanes 4 and 5 contain 4 uL 
(0.75U) and 5 uL (1U) aliquots of pooled gel filtration elution volumes 40-50 mL 
(protein sizes 30-40kDa), respectively. Lanes 6 and 7 contain 4 uL aliquots of flow 
through 1 and flow through 2 (Wash), respectively. Lanes 8 contains 4 uL from elution 
1. Lane 9 contains 4 uL from elution 2. Lane 10 contains 4 uL from elution 3. (B) 
Control column using syntaxin 18 polyclonal antibody. Lane 1 contains 2 uL (2U) of 
post heparin-sepharose purified sample. Lane 2 contains 4 uL of flow through 1. Lane 3 
contains 4 uL of pooled flow through fractions 2 and 3 (Wash). Lanes 4 and 5 contain 4 
uL of elution fractions 1 and 2, respectively. 
Figure 32 demonstrates Western blot analysis of the immunodepletion experiment 
shown in Figure 31-A. There was a striking similarity between endonuclease activity in 
post gel filtration (30-40 kDa) purified pre-load (Figure 31-A, lanes 4 and 5), elution 
fractions 1 and 2 (Figure 31-A, lanes 8 and 9, respectively) and the presence of APE1 in 
corresponding fractions (Figure 32, pre-load lane 2; Figure 32, elution fractions 1 and 2, 
lanes 6 and 7, respectively). In addition, the absence of endonuclease activity in wash 
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fractions (Figure 31-A, lanes 6 and 7) corresponded with the absence of APE 1 in flow 
through (FT) and wash fractions (Wash) on the Western blot shown in Figure 32. 
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Figure 32: Western blot result of APE 1 immunodepletion experiment. Molecular 
weight markers are shown to the left of blot. Lane 1 contains 0.5 \ig recombinant APE 1 
(Sankar's lab, TX). Lane 2 consists of a total volume of 2.0 mL from pooled fractions 
corresponding to elution volumes 40-50 mL (protein sizes of 30-40 kDa). Lane 3 
contains flow through fraction 1. Lanes 4 and 5 contain flow through fractions 2 and 3 
(wash). Lanes 6 and 7 contain elution fraction 1 and 2, respectively. 
A final experiment was done to test for the presence of annexin III and HADHSC 
in the immunodepleted native gel filtration (30-40 kDa) sample. The blot shown in 
Figure 32 was stripped and re-probed with anti-HADHSC and anti-annexin III antibodies, 
respectively. Figure 33 illustrates that annexin III is present in post gel filtration (30-40 
kDa) pre-load sample (lane 2); however, it is not present in flow through (FT, lane3), 
wash (lanes 4 and 5), or elution (lanes 6 and 7) samples. HADHSC did not appear on the 
blot (data not shown). These results led to the conclusion that annexin III and HADHSC 
do not contribute to native 35 kDa endoribonuclease activity. 
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Overall, this evidence strongly supports the notion that APE1 was the candidate 
protein responsible for the 35 kDa endoribonuclease activity observed throughout the 
purification of native rat liver extract. 
^ 
kDa 
if 
Anti-Annexin3 
1 2 3 4 5 6 7 
Figure 33: Annexin III is present in post-GF 30-40 kDa sample but does not 
contribute to endonuclease activity. Lane 1 contains 0.5 j^ g recombinant APE1 
(Sankar's lab, TX). Lane 2 consists of a total volume of 2.0 mL from pooled fractions 
corresponding to elution volumes 40-50 mL (protein sizes of 30-40 kDa). Lane 3 
contains flow through fraction 1. Lanes 4 and 5 contain flow through fractions 2 and 3 
(wash). Lanes 6 and 7 contain elution fraction 1 and 2, respectively. 
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CHAPTER 4 
General Discussion 
4.1 Introductory Overview-
Multifunctional Mammalian Proteins with Endoribonucleolytic Activity 
The role of endoribonucleases in mammalian gene expression has become 
increasingly evident; in particular, the role of these endoribonucleases in specialized 
mRNA decay pathways (Dodson and Shapiro 2002; Tourriere et al. 2001; 
Chernokalskaya et al. 1998; Hollien and Weissman 2006). However, much is still to be 
learned about the significance of mammalian endoribonucleases in controlling basal 
levels of gene expression. Of particular interest is the significance of the discovery that 
various mammalian proteins exhibit bifunctional or multifunctional capabilities, 
including endoribonucleolytic function. Often, the known function of a protein family, 
based largely on primary amino acid sequence, has not provided an adequate predictive 
measure of endonucleolytic function. Ras-GTPase activating protein SH3 domain 
binding protein (G3BP), Polysomal Ribonuclease 1 (PMR 1), Inositol-Requiring Enzyme 
1 (IRE 1), and Argonaute 2 (Ago 2) are but a few of the clear examples of 
endoribonucleases where such phenomena are observed. 
Recent studies would suggest that multifunctional mammalian proteins that 
exhibit endoribonucleolytic properties are of paramount importance for cell growth and 
differentiation (Bisbal et al. 2000). This is most clearly shown in current studies that 
have established a link between external stimuli and direct alteration of mRNA transcript 
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stability; most notably, the signal transduction pathways and hormonal based regulatory 
pathways. 
Hormonal regulation of mRNA transcripts represents an example of a well-
documented mechanism in which the availability of the target cleavage site is determined 
through trans-acting RNA-binding proteins. The effects of estrogen on vitelloginen and 
albumin mRNA stabilities in Xenopus laevis is one of the most extensively studied 
examples (Blume and Shapiro 1989; Chernokalskaya et al. 1998). Hormonal-based 
regulation of mammalian endoribonucleases has also been observed in the family of 
RNase A proteins. Studies designed to assess the extracellular distribution of this family 
of endoribonuclease proteins, performed in rat vaginal and uterine epithelial tissues, 
suggests that highly elevated levels of estradiol may alter the interaction between 
pancreatic type RNases and the inhibitory RNase proteins; however, the precise 
mechanism underlying the alteration is not yet known (Brockdorff and Knowler 1986; 
Schauer et al. 1991; Rao etal. 1994). 
Structural activation or suppression of proteins with endoribonuclease activity 
represents an alternate means for controlling their catalytic activity. Prime examples 
include RNase L and G3BP. It has been proposed that G3BP is targeted to the nucleus 
through phosphorylation of a serine 149 residue within an N-terminal fragment 2 (NTF-
2) like domain which functions as a signal for nuclear import and integration of G3BP 
into mRNP complexes with the eventual role of degrading c-myc mRNA via 
endonucleolytic cleavage (Tourriere et al. 2001). In fact, c-myc mRNA decay is delayed 
in RasGap-deficient mouse fibroblasts that lack the serine 149 phosphorylation site 
required for nuclear import, providing further support for this hypothesis (Tourriere et al. 
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2001). As such, it is quite plausible that a growth factor-induced change in mRNA decay 
may be modulated by the nuclear localization of a site-specific endoribonuclease such as 
G3BP (Irvine et al. 2004). The notion that a signal transduction mechanism is required 
for the activation of G3BPs endonucleolytic function is also supported by its localization 
in stress granules. Stress granule formation and the induction of heat-shock proteins and 
various stress-induced transcription factors upon exposure to UV light, elevated 
temperature and in the presence of oxidative reagents is a well documented pathway; 
however, the list of players involved in this response is incomplete (Tourriere et al. 2003, 
Tourriere et al. 2005). It is entirely possible that G3BP may function in controlling the 
fate of mRNAs during these cellular stress events. Further evidence of G3BP's role in 
vertebrate development has been generated through study of G3BP knockout mice. 
Absence of G3BP in mice during embryonic development has been shown to retard fetal 
growth and result in neuronal cell death (Zekri et al. 2005). Such findings lend support to 
the possibility that the endoribonucleolytic activity possessed by G3BP in vitro may play 
a significant role in posttranscriptional regulation of selected mRNAs in response to 
changing growth conditions and extracellular stimuli. 
As a testament to the diversity of endoribonuclease proteins, Canete-Soler and 
colleagues (2005) found that the aldolase A and C isozymes have a possible function as 
endoribonucleases within specific mRNP complexes, with an ability to cleave the NF 
transcript at UG sites. These studies suggest that a neuronal-specific mechanism, in 
response to an extracellular stimulus, functions to activate the endoribonucleolytic 
activity of aldolases A and C thus promoting cleavage of the NF-L mRNA transcript 
(Canete-Soler et al. 2005). This model of mRNA regulation is similar to the 
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aforementioned hormonal-type regulation of mRNA transcripts whereby access to the 
transcript is controlled by competing levels of endoribonuclease and the binding 
protein(s) that associate with select locations on the mRNA transcript. The neuronal-
expressed glycolytic enzymes aldolase A and aldolase C have also been shown to bind 
the light neurofilament (NF-L) in vitro and in vivo (Canete-Soler et al. 2005). 
Additionally, they have been shown to compete with poly (A)-binding protein (PABP) 
within NF mRNPs in vivo (Canete-Soler et al. 2005). The aldolase A and C isozymes 
were initially discovered and characterized as proteins functioning in glycolytic, 
gluconeogenic, and fructose metabolic pathways. Interestingly, cells coexpressing 
aldolases A and C have heterotetramers that bind to the NF-L mRNA and function 
differently than the homotetramers present in cells that express one distinctive form of 
the isozyme (Canete-Soler et al. 2005). Consequently, they have hypothesized that the 
differential expression may represent a mechanism that utilizes structural variation in the 
A and C isozymes to control gene expression in subsets of neurons, possibly in response 
to varying environmental stimuli. 
Given the wide-ranging implications of c-myc overexpression in carcinogenesis 
(Ioannidis et al. 2004), the link between signal transduction pathways/ endoribonuclease 
activation, and the numerous mammalian proteins that exhibit multiple functions 
including endoribonucleolytic activity, elucidating the identity of the native mammalian 
endoribonuclease(s) is of prime importance. In addition, it will provide insight into the 
mechanisms, players and pathways involved in mammalian mRNA decay. 
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Aims of this Investigation 
There were three aims of this investigation. The first aim was to re-purify the 
native enzyme(s) and the associated proteins from juvenile rat liver tissue that co-purified 
with endoribonucleolytic activity against c-myc CRD RNA. The second aim of this 
research was to confirm the identity of the protein(s) responsible for endoribonucleolytic 
activity against the CRD of c-myc mRNA and to immunodeplete native endonuclease 
activity using appropriate antibodies against the candidate endoribonuclease. The third 
aim of this research was to characterize recombinant form(s) of the native candidate for 
endonucleolytic activity. 
4.2 Purification and Identification of Candidate Endoribonucleases 
with LC/MS/Mass Spectrometry Analysis 
The primary objective of the first portion of this investigation was to re-purify and 
identify candidate proteins responsible for native endoribonuclease activity against c-myc 
CRD RNA. Results from the final column chromatography purification step (gel 
filtration) revealed two distinct endonuclease activities. The larger activity corresponded 
to a protein of 35 kDa, the smaller activity corresponded to a protein of 17 kDa (refer to 
section 2.2.1). Two sets of samples, post heparin-sepharose purified and gel filtration 
purified were sent for LC/MS/Mass Spectrometry analysis. Mass spectrometry results 
revealed several candidate proteins around 35 kDa and one candidate protein at 17 kDa 
(refer to section 2.2.1). The 35 kDa protein candidates investigated were HADHSC, 
annexin III, and APE1. The rationale for investigating these candidate proteins was their 
known or predicted ability to bind or interact with RNA. HADHSC contains a Rossmann 
fold motif known to facilitate binding of nucleotides, including RNA (Arnez and 
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Cavarelli 1997). The annexin family of proteins, namely annexin A2 as been shown to 
bind several RNA substrates, including human c-myc RNA (Filipenko et al. 2004). 
APE1 has multiple documented DNA-specific functionalities including both single-
stranded (Marenstein et al. 2004) and double-stranded DNA-specific endonulease 
activity. In addition, APE1 has been shown to bind RNA and to function by cleaving the 
RNA strand of RNA/DNA duplexes in a manner analogous to RNase H (Barzilay et al. 
1995). To our knowledge, none of the aforementioned proteins had been shown to 
possess endoribonucleolytic activity, so the possibility of uncovering a new function for 
one of these proteins was very exciting. In addition, it was determined that the likely 17 
kDa protein responsible for endoribonuclease acitivty was rat pancreatic RNase A 
(RNase 1). 
4.3 Confirming LC/MS/Mass Spectrometry Results and 
Characterizing Native 35 kDa and 17 kDa Endoribonucleases 
The primary objective of this section of the investigation was to test and confirm 
the identity of native 35 kDa and 17 kDa endoribonucleases. This was accomplished 
through a variety of Western blot and enzyme characterization experiments. It was 
determined that HADHSC, annexin III, APE1 and rat pancreatic RNase A (RNasel) were 
present in native extract (refer to section 3.2.1-3.2.3); however, at this point in the 
investigation it was not yet known which of these proteins contributed to native 35 kDa 
endonuclease activity. 17 kDa endonuclease activity was concluded to be the result of rat 
pancreatic RNasel as gel filtration data and Western blot data exhibited a high degree of 
correlation (refer to sections 3.2.1 and 3.2.2). Unexpectedly, anti-RNase 1 Western blots 
of post-gel filtration purified native sample (30-40 kDa protein sizes) identified a protein 
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band at approximately 37 kDa. Consequently, further tests were needed to conclusively 
identify the protein(s) responsible for the native 35 kDa endoribonuclease activity. 
To rule out the possibility that the native 35 kDa endonuclease activity was a 
result of a structural variant of an RNasel-like protein, native post heparin-sepharose and 
post-gel filtration (protein sizes 30-40 kDa) was treated (in separate experiments) with N-
glycosidase F and DTT (Figure 22 and Figure 23, respectively). It was determined that 
the native endonuclease activity corresponding to a molecular weight of 35 kDa was 
likely due to a monomeric protein which does not possess N-linked glycosylated 
residues. 
4.3.1 Testing Recombinant Proteins for Endoribonucleolytic Activity 
To determine if HADHSC, annexin III, APE1 or a combination thereof were 
responsible for the native 35 kDa endoribonuclease activity, recombinant forms of these 
proteins were obtained and tested using standard endoribonuclease assays (refer to 
section 3.2.4). Results showed that HADHSC and annexin III did not possess 
endonuclease activity under the conditions utilized. In contrast, recombinant APE1 did 
exhibit weak endoribonucleolytic activity. The endoribonuclease activity was similar but 
not identical to the native 35 kDa activity as recombinant APE1 cleaves c-myc CRD 
RNA at one predominant dinucleotide; UA 1751 (Figure 27). By comparison, the native 
35 kDa endoribonuclease cleaved c-myc CRD RNA at more locations, yet this enzyme 
exhibited a strong preference for the same UA dinucleotide 1751 (Figure 26-A and 26-B). 
While the observed pattern of endonucleolytic cleavage from the comparison of the 
native 35 kDa endoribonuclease and recombinant APE1 RNA was not identical, both 
exhibit a strong preference for UA dinucleotide 1751. 
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4.4 Electromobility Shift Assays 
Previous studies have in fact shown that APE1 can bind both single- and double-
stranded DNA (Mol et al. 2000) as well as single-stranded RNA (Barzilay et al. 1995). 
Results confirm that both HADHSC and APE1 bind to c-myc CRD RNA contruct (nts 
1705-1886). Both APE1 and HADHSC exhibit two binding complexes, respectively, 
however, at similar protein concentrations it appears as though APE1 binds c-myc CRD 
RNA (nts 1705-1886) more tightly than HADHSC (refer to section 3.2.5). 
To our knowledge, there are no previous studies that demonstrate HADHSC 
ability to bind single-stranded RNA. The presence of an RNA binding motif (Rossmann 
fold) within the predicted structure of HADHSC, and the multiple documented DNA-
/RNA-APE1 interactions led us to perform EMS A experiments to determine if these 
proteins could bind c-myc CRD RNA. In support of the dehydrogenase family of 
metabolic enzymes with RNA-binding capabilities, GAPDH, another known 
dehydrogenase contains a predicted Rossmann fold motif. Subsequent studies have 
revealed that the Rossmann fold of GAPDH provides the molecular basis for RNA 
recognition (Nagy et al. 2000). GAPDH has also been shown to bind single-stranded 
DNA containing a TAAAT motif. In fact, several dehydrogenase enzymes from multiple 
domains of life have been shown to possess RNA- and DNA-binding capabilities (Ciesla 
2006; Evguenieva-Hackenberg et al. 2002). In light of this it would be of interest to test 
HADHSC's ability to bind both double- and single-stranded DNA. It should be noted 
that although HADHSC can bind c-myc mRNA, it does not appear to affect c-myc mRNA 
in cells. Studies in our lab (Sellers and Lee, unpublished results) have shown that 
knocking down HADHSC in MCF-7 cells had no effect on levels of c-myc mRNA. 
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4.5 Immunodepletion of Endonuclease Activity in Native Rat Liver 
Extract 
Results of this investigation indicated that APE1 was the protein responsible for 
35 kDa endoribonucleolytic activity. To confirm previous data, an immunodepletion 
experiment was performed using anti-APEl monoclonal antibodies. Western blot data 
(Figure 32) indicated that APE1 is indeed present in post-gel filtration elution fractions 
(30-40 kDa protein sizes) correlating with endoribonuclease activity. Flow-through and 
wash fractions contained little endonuclease activity (Figure 31-A); however, elution 
fractions contained activity similar in intensity to pre-load sample (Figure 31-A). 
Similarly, Western blot analysis of this immunodepletion experiment confirmed that 
APE1 was present in pooled gel filtration (30-40 kDa protein sizes) pre-load sample 
(Figure 32), APE1 was absent in flow through and wash fractions and APE1 reappeared 
in elution fractions (Figure 32). 
Comparison of c-myc CRD RNA cleavage sites by the native 35 kDa 
endoribonuclease in immunodepletion pre-load (gel filtration sample, 30-40 kDa) and 
immunodepletion elution samples (refer to Figure 31-A), reveals an identical pattern; 
both exhibiting the characteristic preference for dinucleotide UA 1751. This is 
significant in two respects. Firstly, successful immunodepletion of native gel filtration 
(30-40 kDa) sample using APE1 monoclonal antibodies confirms that APE1 is likely 
responsible for native 35 kDa endoribonuclease activity. It should be mentioned that 
there are differences in the cleavage sites produced by native APE1 and recombinant 
APE1 against c-myc CRD RNA. Previous studies have shown that RNA cleavage 
specificities are often altered slightly when comparing recombinant and native 
endoribonucleases. For example, recombinant PMR1 has been shown to cleave a 
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substrate RNA transcript at identical sites to native PMR1, however, several sites of the 
RNA transcript that are cleaved by native PMR1 are not cleaved by recombinant PMR1 
(Chernokalskaya et al. 1998). Chernokalskaya and colleagues (1998) speculate that a 
specific protein fold achieved by native PMR1, but not by recombinant PMR1, accounts 
for the observed differences in RNA cleavage (Chernokalskaya et al. 1998). Similarly, a 
specific folding conformation may need to be adopted by native APE1 to achieve the 
entire set of observed cleavage products against c-myc CRD RNA. 
Secondly, it confirms that APE1 protein alone generates the observed cleavage 
pattern of cleavage against c-myc CRD RNA. The finding that APE1 is singularly 
responsible for endonuclease acitivity is important because HADHSC, which was shown 
to bind c-myc CRD RNA, is present in post-gel filtration (30-40 kDa). Binding of 
HADHSC to c-myc RNA during standard endoribonuclease assays may have altered the 
structure of c-myc RNA. Consequently, this may have limited or altered the accessibility 
of target cleavage sites along c-myc RNA. However, this hypothesis is not supported by 
evidence from endoribonuclease assays of immunodepletion experiments. 
Monoclonal anti-APEl antibodies were used in constructing the immunodepletion 
spin column, thus the only protein that would have bound to the anti-APEl antibodies 
(cross-linked to the column matrix) would have been APE1. Consequently, the cleavage 
pattern exhibited in spin column elution fractions would result from native APE1. Since 
the cleavage pattern against c-myc CRD RNA in the elution fractions is identical to the 
cleavage pattern in native pre-load sample from gel filtration elution fractions (protein 
sizes 30-40 kDa) (see Figure 32) and the fact that HADHSC is not present in the eluted 
fractions (as determined by Western blot), APE1 alone must be responsible. 
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4.6 Apurinic/Apyrimidinic Endonuclease-APEl 
Human Apurinic/Apyrimidinic Endonuclease (APE1) also named (APEX, 
HAP-1, Ref-1) is a multifunctional protein homologue of E. coli Exonuclease III. It has 
been characterized as having three principle functions in vivo; however, several other 
properties have been discovered such as 3'-5' exonuclease (Chou et al. 2000), 
phosphodiesterase activity (Izumi et al. 2002), and RNase H activity (Barzilay et al. 
1995). 
The first principle function in vivo is in repair of abasic sites in single-stranded 
breaks of DNA. APE1 recognizes damaged DNA and utilizes a hydrolytic Mg2+-
stimulated mechanism to execute phosphodiester backbone cleavage 5' to the lesion 
(Beernink et al. 2001; Mol et al. 2000). This generates a free 3'-OH terminus which is 
suitable for priming DNA polymerases (Friedberg et al. 1995). 
The second function of APE1 has been identified as a redox activator of DNA-
binding activity (Xanthoudakis et al. 1992). In vitro studies have confirmed that APE1 
converts the oxidized form (inactive state) of c-Jun into a reduced, active form, which can 
then bind DNA (Xanthoudakis et al. 1994). Recently, APE1 has been shown to function 
in mediating the activation of additional transcription factors including Pax 5, Pax 8 
(Evans et al. 2000). In addition, APE1 has been shown to activate the tumor suppressor 
p53 by redox and non-redox mechanisms, thereby facilitating p53 nuclear translocation 
and DNA binding (Jayaraman et al. 1997). 
The third and somewhat distinct function of APE1 is in Ca2+ dependent 
downregulation (repression) of parathyroid hormone (PTH) gene via binding to negative 
calcium response elements (nCaREs) within the PTH gene promoter (Okazaki et al. 
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1992; Okazaki et al. 1994). Experiments have shown that APE1 is a part of nuclear 
protein complex that binds to nCaRE-A and nCaRE-B (Okazaki et al. 1994). 
APE1 has been shown to play yet another major role in mammalian cells. APE1 
has been identified as a component of a 270-420 kDa endoplasmic reticulum-associated 
complex, termed SET complex (Fan et al. 2002; Fan et al. 2003; Lieberman and Fan 
2003). SET complex is a target in caspase-independent cell death mediated by the 
cytotoxic T-lymphocyte protease granzyme-A (Lieberman and Fan 2003). Granzyme-A 
cleaves Apel at a Lys31 residue, thereby destroying its known oxidative repair functions 
(Fan et al. 2003). It is believed by doing so, granzyme-A blocks cellular repair mediated 
by APE1 and forces apoptosis. In support of this finding, cells with RNAi-induced APE1 
knockdown are more sensitive to granzyme-A-induced death, whereas cells 
overexpressing a mutant non-cleavable form of APE 1 are more resistant to granzyme-A-
mediated death (Fan et al. 2003). 
It is hypothesized that APE1 possesses a single catalytic active site for DNA- and 
RNA-specific nuclease activities (Beernink et al. 2001). The active site of the Apel 
contains one Mg2+ metal ion which is coordinated predominantly by acidic residues 
Asp70 and Glu96 (Beernink et al. 2001). The coordination of a single Mg2+ metal ion is 
required for efficient phosphodiester bond hydrolysis (Beernink et al. 2001). However, 
structural data shows that Apel can bind two Mg2+metal ions in its active site at neutral 
pH but only one at acidic pH (Beernink et al. 2001). This phenomenon at neutral pH may 
indicate an additional two-metal catalytic functionality. 
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4.7 Concluding Remarks 
This study provides the first documented evidence that APE1 possesses the 
abililty to hydrolyze a specific site of single-stranded RNA. Furthermore, other DNA 
specific endonucleases, most notably the structure-specific human Flap Endonuclease 1 
(Fenl) which functions as a DNA-specific endonuclease required for cleavage of 
unannealed 5' arms of template-primer DNA substrates, a processor of Okazaki 
fragments during DNA synthesis, and a key player in DNA replication and DNA repair, 
has been shown to hydrolyze several single-stranded RNA substrates (Stevens 1998). 
Thus there is precedent to suspect that a DNA-specific endonuclease such as APE1 has 
the ability to hydrolyze single-stranded RNA substrates. Support for this type of dual 
functionality has been shown. Spinach CSP41 protein functions both as an mRNA-
binding protein and cellular ribonuclease (Yang et al. 1996). Mammalian GAPDH 
(isolated from rabbit muscle) has also been shown to bind and cleave RNA (Evguenieva-
Hackenberg et al. 2002). Interestingly, mammalian GAPDH was found to be sensitive to 
the ribonuclease inhibitor protein (RNasin) and was found to preferentially cleave 
between UA and CA dinucleotides, in a manner analogous to RNase A (Evguenieva-
Hackenberg et al. 2002). 
The question remains; however, of what significance, if any, is the finding that a 
DNA repair enzyme possesses the ability to cleave c-myc CRD RNA? Could 
APE1/RNA interactions result from 'relic' interactions of a primitive 'RNA world' prior 
to the existence of DNA? Under this scenario, DNA-specific activities may have been 
acquired as organisms evolved and developed DNA for the storage of genetic materials. 
Evidence would suggest that multifunctional proteins would be more efficient for 
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building complex gene regulatory mechanisms in mammalian cells possessing relatively 
low numbers of protein-encoding genes (Venter et al. 2001; Evguenieva-Hackenberg et 
al 2002). 
The preference of APE 1 for the dinucleotide 1751 UA may have some in vivo 
significance. AU-rich elements at 3' untranslated regions are well-characterized 
instability elements. Given the strong cleavage preference of native and recombinant 
APE1 for dinucleotide UA, it is tempting to speculate that it may function in vivo as a 
cellular endoribonuclease to destabilize particular mRNAs. Consequently, in vivo 
studies, aimed at manipulating cellular expresion of APE1 while monitoring the 
corresponding changes in levels of specific mRNAs including c-myc, is certainly 
warranted. 
Arguably less exciting is the finding that one of the mammalian 
endoribonucleases purified from rat liver, with the ability to degrade c-myc CRD RNA, is 
a member of the well-studied RNase A superfamily of proteins. Often overlooked, 
however, is the possible role of this family of proteins in controlling gene expression. 
Given the known structural capabilities of the RNase A superfamily of proteins such as 
the formation of higher order structures, one must consider the plausible functional 
implications of dimeric, trimeric or higher order associations within RNA metabolic 
processes. Equally intriguing is the discovery of RISBASES (RNases with Special 
Biological Actions) which have been implicated in tumor cell growth, neurological 
development, and biological differentiation and the discovery of potential therapeutic 
cytotoxicity of certain members of the RNase A superfamily such as onconase and 
Bovine Seminal RNase (BS-RNase). Unfortunately, the physiological role, particularly 
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the role of RNase A-type endoribonucleases in mammalian RNA decay pathways (if any) 
remains unclear. Further investigation of this superfamily of enzymes as related to their 
role in mRNA metabolism, is warranted. With regards to the RNase A superfamily of 
enzymes, one particular question clearly remain unanswered; Are there any members of 
the intercellular RNase A family of proteins that perform a physiological function in 
normal mRNA metabolism? 
As more information becomes available about the mechanisms that control the 
interaction between all endoribonuclease proteins, RNase inhibitory proteins, the 
elements that are required for activation of endonuclease-mediated pathways, and the 
RNA-binding proteins that protect RNA from endonucleolytic cleavage, we may uncover 
new structural features inherent in known and yet-to-be discovered families of 
endoribonuclease proteins. 
Future studies aimed at identifying the significance of multifunctional mammalian 
proteins with endoribonucleolytic activity should be a priority. In fact, the importance of 
other known mammalian proteins with endoribonucleolytic function for correct organism 
development has already been well established. For example, the ER stress response also 
participates in development of vertebrates. It contributes not only to the expression of ER 
proteins but of many genes that contribute to the phenotypic changes that characterize 
secretory cells, such as expansion of the ER and induction of chaperones (Reimold et al. 
2001). Zhang and colleagues (2005) utilized a gene inactivation approach to show that 
IRE 1 is required for the development of plasma cells. Given that IRE 1 lies upstream of 
XBP1, it is hypothesized that the developmental role of XBP1 is coupled to an ER-
signaling event which is regulated by the endoribonucleolytic activity of IRE 1. The 
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RNase L-mediated endoribonucleolytic activity in response to 2-5A activation, has been 
shown to influence muscle cell differentiation by lowering murine MyoD mRNA levels 
(Bisbal et al. 2000). In effect, Bisbal and colleagues (2000) demonstrated that RNase L 
functions to delay the onset of C2 mouse myoblast differentiation via regulation of MyoD 
mRNA stability. Mutations in the gene encoding RNase L have been recently implicated 
in the pathogenesis of prostate cancer (Silverman, 2003). In addition, RNase L is 
hypothesized to function in a role as tumor suppressor suggesting that mutations in the 
RNase L gene would prevent the necessary RNA cleavage responsible for the 
antiproliferative and apoptotic activities of the RNase L protein (Silverman 2003). 
The value of studying mammalian proteins that possess endoribonucleolytic 
function including domain identification, key catalytic residue identification and 
functional interactions required for ribonucleolytic activation, is clear. We can now 
utilize new and more robust bioinformatic tools to identify new proteins, protein families 
and to a lesser extent the secondary and tertiary structures required for their respective 
endoribonucleolytic activities. Additional research into the physiological significance of 
these proteins is absolutely necessary as it will facilitate our understanding of the 
mechanisms by which endoribonucleases are differentially and site-specifically activated 
in RNA processing pathways. 
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